<!DOCTYPE html>
<html class="no-js" lang="en">

<head>
  <!-- Google Tag Manager -->
  <script>
    (function (w, d, s, l, i) {
      w[l] = w[l] || []; w[l].push({
        'gtm.start':
          new Date().getTime(), event: 'gtm.js'
      }); var f = d.getElementsByTagName(s)[0],
        j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
          'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
    })(window, document, 'script', 'dataLayer', 'GTM-NXWD2J2');
  </script>
  <!-- End Google Tag Manager -->

  <meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
  <title>ASCVD Risk Estimator</title>
  <link rel="manifest" href="/manifest.json" />
  <meta name="msapplication-TileColor" content="#ffffff" />
  <meta name="msapplication-TileImage" content="/ms-icon-144x144.png" />
  <meta name="theme-color" content="#ffffff" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <link rel="shortcut icon" href="../ascvd_risk_estimator/assets/img/ASCVD_logo.png">

  <link rel="stylesheet" href="../ascvd_risk_estimator/assets/css/font-awesome.min.css">
  <link rel="stylesheet" href="../assets/css/splash.css">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,700,600,400,300|Roboto+Slab:400,700|Raleway:300" />
  <link rel="stylesheet" href="../ascvd_risk_estimator/assets/css/normalize.min.css">
  <link rel="stylesheet" href="../ascvd_risk_estimator/assets/css/foundation-sites.min.css">
  <link rel="stylesheet" href="../ascvd_risk_estimator/assets/css/ascvd.min.css">
  <link rel="stylesheet" href="../ascvd_risk_estimator/assets/css/custom.css">
</head>

<body style="position: static; background-color: white">
  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NXWD2J2" height="0" width="0"
      style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->
  <div class="splash-screen show-browser" data-bind="css:{'hide':appmodel.hideSplash()}">
    <div class="show-for-large-up">
        <img src="../assets/img/Xhdpi-landscape.png" alt="">
    </div>
    <div class="show-for-medium-only">
        <img src="../assets/img/Hdpi-landscape.png" alt="">
    </div>

    <div class="show-for-mobile-landscape">
        <img src="../assets/img/Hdpi-landscape.png" alt="">
    </div>
  
    <div class="show-for-mobile-potrait">
        <img src="../assets/img/Xhdpi-portrait.png" alt="">
    </div>
    <div class="splash-overlay">
        <h5><i class="fa fa-spinner fa-spin"> </i> Loading</h5>
    </div>
</div>   
  <div class="off-canvas-wrapper">
    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>
      <div class="off-canvas position-left" id="offCanvas" data-off-canvas style="height: 100%">
        <!-- Close button -->
        <button class="close-button" aria-label="Close menu" type="button" data-close></button>
        <!-- Menu -->
        <div class="row" id="test-eq">
          <nav class="nav-list small">
            <ul>
              <li>
                <a href="../index.html#!/content/manager/">
                  <img src="assets/img/headerlogo.svg" alt="ACC" width="100%" /></a>
              </li>

              <li>
                <div class="row group-section collapse">
                  <div class="column small-4 text-center">
                    <a href="../ldlc_lowering_therapy/index.html#!/content/calculator/"><img
                        src="assets/img/LDL_logo.png" alt="LDL-C Lowering Therapy" /></a>
                  </div>
                  <div class="column small-8 padding_left_top">
                    <a href="../ldlc_lowering_therapy/index.html#!/content/calculator/">
                      <h6 class="text-left">LDL-C Lowering Therapy</h6>
                    </a>
                  </div>
                </div>
              </li>
              <li>
                <div class="row group-section collapse">
                  <div class="column small-4 text-center">
                    <a href="../StatinIntolerance/index.html#!/"><img src="assets/img/Statin_Intolerance_logo.png"
                        alt="ACC Statin Intolerance" /></a>
                  </div>
                  <div class="column small-8 padding_left_top">
                    <a href="../StatinIntolerance/index.html#!/">
                      <h6 class="text-left">Statin Intolerance</h6>
                    </a>
                  </div>
                </div>
              </li>
              <li>
                <div class="row group-section collapse">
                  <div class="column small-4 text-center">
                    <a href="../hypertriglyceridemia/index.html#!/content/calculator/"><img
                        src="../assets/img/Hypertriglyceridemia_logo.png" alt="hyperT" /></a>
                  </div>
                  <div class="column small-8 padding_left_top">
                    <a href="../hypertriglyceridemia/index.html#!/content/calculator/">
                      <h6 class="text-left">Hypertriglyceridemia</h6>
                    </a>
                  </div>
                </div>
              </li>
              <li>
                <div class="row group-section collapse">
                  <div class="column small-4 text-center">
                    <a href="index.html#!/calulate/estimator/"><img src="assets/img/ASCVD_logo.png"
                        alt="ACC ASCVD" /></a>
                  </div>
                  <div class="column small-8 padding_left_top">
                    <a href="index.html#!/calulate/estimator/">
                      <h6 class="text-left">ASCVD Risk Estimator</h6>
                    </a>
                  </div>
                </div>
              </li>
            </ul>
          </nav>
        </div>
      </div>
      <div class="off-canvas-content" data-off-canvas-content>
        <div data-bind="page: {id:'calulate', role: 'start',beforeShow:remakeSticky()}" class="">
          <div data-bind="page: {id:'estimator', role: 'start',  afterShow:tabchange ,beforeShow:pageScrollTop}"
            class="page with-group-sections fill-page-height">
            <div class="data-display" id="scorebar">
              <div class="sticky-holder">
                <header class="header page">
                  <ul class="nav tabs tabs-primary show-for-medium hide-for-small-only float-left">
                    <li class="icon hide-for-small-only">
                      <a class="home" data-toggle="offCanvas">
                        <i class="fa fa-bars"></i>
                      </a>
                    </li>
                  </ul>
                  <a href="#!/calulate/estimator/" class="logo"><img src="assets/img/logo-header.svg" /></a>
                  <ul class="nav tabs tabs-primary swappable small">
                    <li class="icon hide-for-medium">
                      <a class="home" data-toggle="offCanvas">
                        <i class="fa fa-bars"></i>
                      </a>
                    </li>
                    <li class="estimator-Tab" class="selected">
                      <a class="btn-ga4" href="#!/calulate/estimator/">
                        Estimator
                      </a>
                    </li>
                    <li class="recommendation-Tab sucsess" style="display: none"
                      data-bind="visible:$root.recommendationUnlock()">
                      <a href="#!/calulate/recommendation/"><span class="ascvd-ce-ga4">Recommendation</span>
                        <i class="fa fa-arrow-circle-right"></i></a>
                    </li>
                    <li class="recommendationFail-Tab disabled"
                      data-bind="visible:!$root.recommendationUnlock(),click:function(){validate(true)}">
                      <a data-open="requiredModal" onclick="gaRecordMissingRecommendation()">Recommendation <i
                          class="fa fa-ban"></i></a>
                    </li>
                  </ul>
                </header>

                <div class="score-bar-holder">
                  <div class="score-bar row callout" style="margin-bottom: 0; display: none"
                    data-bind="visible:($root.allDataValidation().status == 'error' || $root.allDataValidation().status == 'warning') ,css:$root.allDataValidation().status">
                    <div class="column large-6 medium-8 small-12 small-centered">
                      <span class="small-fs-2x text-condensed"
                        data-bind="text:$root.allDataValidation().message"></span>
                    </div>
                  </div>
                  <div class="score-bar row"
                    data-bind="visible:$root.allDataValidation().status != 'error' && $root.allDataValidation().status != 'warning'">
                    <div class="column small-6 primary-color data-container">
                      <div class="data float-right">
                        <div class="text-bold data-header small-fs-2x large-fs-3x">
                          10-Year ASCVD Risk
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 2 ">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().TenYearRisk">
                            3%
                          </div>
                          <div class="text-condensed small-fs-2x large-fs-3x data-label">
                            calculated risk
                          </div>
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 2 ">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().TenYearOptimal">
                            3%
                          </div>
                          <div class="data-label text-condensed small-fs-2x large-fs-3x">
                            risk with optimal risk factors
                            <span data-tooltip aria-haspopup="true" class="tip-top" data-disable-hover="false"
                              tabindex="1" data-bind="attr:{title:$root.FormData.infotext.scorebar.text}">
                              <i class="fa fa-info-circle"></i>
                            </span>
                          </div>
                        </div>
                        <div class="data-group content-block" data-bind="visible: $root.ageValidation().id == 2">
                          <div class="text-condensed small-fs-1x medium-fs-2x medium-fs-3x"
                            data-bind="text:$root.FormData.notifications.age[2].message">
                            This calculator only provides 10-year risk
                            estimates for individuals 40 to 70 years of age.
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="column small-6 secondary-color data-container">
                      <div class="data float-left">
                        <div class="text-bold data-header small-fs-2x large-fs-3x">
                          Lifetime ASCVD Risk
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 3">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().yourLifeTimeRisk">
                            3%
                          </div>
                          <div class="text-condensed small-fs-2x large-fs-3x data-label">
                            calculated risk
                          </div>
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 3">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().lifeTimeRisk">
                            3%
                          </div>
                          <div class="data-label text-condensed small-fs-2x large-fs-3x">
                            risk with optimal risk factors
                            <span data-tooltip aria-haspopup="true" class="tip-top" data-disable-hover="false"
                              tabindex="1" data-bind="attr:{title:$root.FormData.infotext.scorebar.text}">
                              <i class="fa fa-info-circle"></i>
                            </span>
                          </div>
                        </div>
                        <div class="data-group content-block" data-bind="visible: $root.ageValidation().id == 3">
                          <div class="text-condensed small-fs-1x medium-fs-2x medium-fs-3x"
                            data-bind="text:$root.FormData.notifications.age[3].message">
                            Lifetime Risk Calculator only provides lifetime
                            risk estimates for individuals 20 to 59 years of
                            age.
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div class="page-wrapper">
              <div class="row relative-position">
                <h1>
                  ASCVD Risk Estimator
                  <div class="sub-line">
                    <p class="subtle text-left" style="color: #217289">
                      Intended for patients with LDL-C < 190 mg/dL (4.92 mmol/L), without ASCVD, not on LDL-C lowering
                        therapy </p>
                  </div>
                </h1>
                <a class="button secondary small reset-button expanded" data-bind="click:$root.resetAll"><i
                    class="fa fa-repeat"></i>&nbsp;Reset All</a>

                    <div class="large-12 medium-12 small-12" id="ToS" style="margin-bottom: 12px;">
                      <div class="medium-12">
                        <div id="estimate-callout" class="callout warning alert-box caution-box-style" data-closable="" data-bind="visible: $root.doNotShowAgainVisible">
                          <p>Click the <b>Terms</b> tab at the bottom of the app before using the LDL-C Lowering Therapy, Hypertriglyceridemia, Statin Intolerance, or ASCVD Risk Estimator tools in the Lipid Manager (“the Product”) to read the full Terms of Service and License Agreement (the “Agreement”) which governs the use of the Product. The Agreement includes, among other detailed terms and conditions, certain disclaimers of warranties by the American College of Cardiology Foundation (“ACCF”) and requires the user to agree to release ACCF from any and all liability arising in connection with your use of the Product. By using the Product, you accept and agree to be bound by all of the terms and conditions set forth in the Agreement, including such disclaimers and releases. If you do not accept the terms and conditions of the Agreement, you may not proceed to use the Product. The Agreement is subject to change from time to time, and your continued use of the Product constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement. </p>
                          <b>
                         <a id='close' onclick='this.parentNode.parentNode.parentNode.removeChild(this.parentNode.parentNode); return false;' class="close" id="appNotificationClose">x</a>
                       </b>
                     <br />
                     <p class="text-right bold not-show-again"> <a onclick="notShowAgain()">Do not show me this again</a> </p>
                        </div>
                      </div>
                    </div>
              </div>
              <div class="row group-section shrink-waypoint">
                <div class="column small-12">
                  <h2 class="with-underline">Demographics</h2>
                </div>
                <div class="question small-12 medium-4 column" data-bind="css: $root.sexValidation().status ">
                  <div class="label-holder">
                    <label>
                      <span class="text">Sex</span>
                      <span class="required-holder">
                        <i class="fa fa-holder-dynamic"></i>
                      </span>
                    </label>
                  </div>
                  <div class="input-holder">
                    <div class="input-spacer">
                      <div class="button-group selectable small radius" data-bind="foreach:$root.FormData.sex">
                        <a href="javascript:void(0);" style="white-space: nowrap" class="button small"
                          data-bind="click:function(){appmodel.Form().Sex(label)},css:{'selected':$root.Form().Sex() == label}"><i
                            class="fa fa-check"></i><span data-bind="text:label"></span></a>
                      </div>
                    </div>
                  </div>
                  <div class="message-holder">
                    <span data-bind="css: $root.sexValidation().status">
                      <i class="fa fa-holder"></i>
                      <span class="text" data-bind="text: $root.sexValidation().message"></span>
                    </span>
                  </div>
                  <div class="hint"></div>
                </div>
                <div class="question small-12 medium-3 column" data-bind="css: $root.ageValidation().status ">
                  <div class="label-holder">
                    <label>
                      <span class="text">Age</span>
                      <span class="required-holder">
                        <i class="fa fa-holder-dynamic"></i>
                      </span>
                    </label>
                  </div>
                  <div class="input-holder">
                    <div class="input-spacer">
                      <input type="number" data-bind="value:Form().Age, valueUpdate: 'blur'" />
                    </div>
                  </div>
                  <div class="message-holder">
                    <span data-bind="css: $root.ageValidation().status">
                      <i class="fa fa-holder"></i>
                      <span class="text" data-bind="text: $root.ageValidation().message"></span>
                    </span>
                  </div>
                  <div class="hint">Age must be between 20-79</div>
                </div>
                <div class="question small-12 medium-5 column" data-bind="css: $root.raceValidation().status ">
                  <div class="label-holder">
                    <label>
                      <span class="text">Race</span>
                      <span class="required-holder">
                        <i class="fa fa-holder-dynamic"></i>
                      </span>
                    </label>
                  </div>
                  <div class="input-holder">
                    <div class="button-group selectable small radius race--group-button"
                      data-bind="foreach:$root.FormData.race">
                      <a href="javascript:void(0);" class="button small"
                        data-bind="click:function(){appmodel.Form().Race(label)},css:{'selected':$root.Form().Race() == label}"><i
                          class="fa fa-check"></i><span data-bind="text:label"></span></a>
                    </div>
                  </div>
                  <div class="hint"></div>
                  <div class="message-holder">
                    <span data-bind="css: $root.raceValidation().status">
                      <i class="fa fa-holder"></i>
                      <span class="text" data-bind="text: $root.raceValidation().message"></span>
                    </span>
                  </div>
                </div>
                <div class="column small-12" data-bind=" visible:isRaceOther">
                  <div class="callout highlighted">
                    <span class="bold">Note:</span> These estimates may
                    underestimate the 10-year and lifetime risk for persons
                    from some race/ethnic groups, especially American Indians,
                    some Asian Americans (e.g., of south Asian ancestry), and
                    some Hispanics (e.g., Puerto Ricans), and may overestimate
                    the risk for others, including some Asian Americans (e.g.,
                    of east Asian ancestry) and some Hispanics (e.g., Mexican
                    Americans). Because the primary use of these risk
                    estimates is to facilitate the very important discussion
                    regarding risk reduction through lifestyle change, the
                    imprecision introduced is small enough to justify
                    proceeding with lifestyle change counseling informed by
                    these results.
                  </div>
                </div>
              </div>

              <div class="row group-section">
                <div class="small-12 column position-relative">
                  <h2 class="with-underline">Labs</h2>
                  <div class="unit-of-measure">
                    <div class="switch-input-space" style="width: 100%">
                      <label class="switch-value" for="check-unit-type">Unit Type</label>
                      <div class="switch radius small value-switch switch-2x">
                        <input class="switch-input" id="check-unit-type" type="checkbox" name="unit-type"
                          value="unit-type" data-bind="checked:Form().UnitOfMeasure, click:Form().UOMAction" />
                        <label class="switch-paddle" for="check-unit-type">
                          <span class="show-for-sr">Unit of Measure</span>
                          <span class="switch-active btn-ga4" aria-hidden="true">
                            US
                          </span>
                          <span class="switch-inactive btn-ga4" aria-hidden="true">
                            SI
                          </span>
                        </label>
                      </div>
                    </div>
                  </div>
                </div>

                <div class="row" style="padding: 1rem">
                  <div class="question medium-6 large-6 small-12 column end"
                    data-bind="css: $root.bloodPresureValidation().status ">
                    <div class="label-holder">
                      <label>
                        <span class="text">Systolic Blood Pressure
                          <small>(mm Hg)</small></span>
                        <span class="required-holder">
                          <i class="fa fa-holder-dynamic"></i>
                        </span>
                      </label>
                    </div>
                    <div class="input-holder">
                      <div class="input-spacer">
                        <input type="number" data-bind="value:Form().BloodPressure, valueUpdate: 'blur'" />
                      </div>
                    </div>
                    <div class="message-holder">
                      <span data-bind="css: $root.bloodPresureValidation().status">
                        <i class="fa fa-holder"></i>
                        <span class="text" data-bind="text: $root.bloodPresureValidation().message"></span>
                      </span>
                    </div>
                    <div class="hint">Value must be between 90-200</div>
                  </div>

                  <div class="question required small-12 medium-6 large-6 column end"
                    data-bind="css: $root.DBloodPressureValidation().status ">
                    <div class="label-holder">
                      <label>
                        <span class="text">
                          Diastolic Blood Pressure
                          <small class="pre">(mm Hg)</small>
                        </span>
                        <span class="required-holder">
                          <!-- <i class="fa fa-holder-dynamic"></i> -->
                        </span>
                      </label>
                    </div>
                    <div class="input-holder">
                      <div class="input-space">
                        <input type="number"
                          data-bind="value:Form().DBloodPressure, valueUpdate: 'blur', attr: { min: 60, max: 130, step: 1}" />
                      </div>
                    </div>
                    <div class="message-holder">
                      <span data-bind="css: $root.DBloodPressureValidation().status">
                        <i class="fa fa-holder"></i>
                        <span class="text" data-bind="text: $root.DBloodPressureValidation().message"></span>
                      </span>
                    </div>
                    <div class="hint">Value must be between 60-130</div>
                  </div>
                </div>

                <div class="row" style="padding: 1rem">
                  <div class="question medium-6 small-12 large-6 column"
                    data-bind="css: $root.totalCholesterolValidation().status ">
                    <div class="label-holder">
                      <label>
                        <span class="text">Total Cholesterol
                          <small data-bind="visible: !$root.Form().UnitOfMeasure() ">(mg/dL)</small>
                          <small data-bind="visible: $root.Form().UnitOfMeasure() ">(mmol/L)</small></span>
                        <span class="required-holder">
                          <i class="fa fa-holder-dynamic"></i>
                        </span>
                      </label>
                    </div>
                    <div class="input-holder">
                      <div class="input-spacer">
                        <input type="number" data-bind="value:Form().TotalCholesterolValue, valueUpdate: 'blur'" />
                      </div>
                    </div>
                    <div class="message-holder">
                      <span data-bind="css: $root.totalCholesterolValidation().status">
                        <i class="fa fa-holder"></i>
                        <span class="text" data-bind="text: $root.totalCholesterolValidation().message"></span>
                      </span>
                    </div>
                    <div class="hint" data-bind="visible: !$root.Form().UnitOfMeasure() ">
                      Value must be between 130 - 320
                    </div>
                    <div class="hint" data-bind="visible: $root.Form().UnitOfMeasure() ">
                      Value must be between 3.367 - 8.288
                    </div>
                  </div>
                  <div class="question medium-6 small-12 large-6 column" data-bind="css: $root.hdlValidation().status ">
                    <div class="label-holder">
                      <label>
                        <span class="text">HDL-Cholesterol
                          <small data-bind="visible: !$root.Form().UnitOfMeasure() ">(mg/dL)</small>
                          <small data-bind="visible: $root.Form().UnitOfMeasure() ">(mmol/L)</small>
                        </span>
                        <span class="required-holder">
                          <i class="fa fa-holder-dynamic"></i>
                        </span>
                      </label>
                    </div>
                    <div class="input-holder">
                      <div class="input-spacer">
                        <input type="number" data-bind="value:Form().HDLCholesterolValue, valueUpdate: 'blur'" />
                      </div>
                    </div>
                    <div class="message-holder">
                      <span data-bind="css: $root.hdlValidation().status">
                        <i class="fa fa-holder"></i>
                        <span class="text" data-bind="text: $root.hdlValidation().message"></span>
                      </span>
                    </div>
                    <div class="hint" data-bind="visible: !$root.Form().UnitOfMeasure() ">
                      Value must be between 20 - 100
                    </div>
                    <div class="hint" data-bind="visible: $root.Form().UnitOfMeasure() ">
                      Value must be between 0.518 - 2.59
                    </div>
                  </div>
                </div>
              </div>

              <div class="row group-section">
                <div class="column small-12">
                  <h2 class="with-underline">Personal History</h2>
                </div>
                <div class="question small-12 medium-6 large-4 column"
                  data-bind="css: $root.diabeticValidation().status ">
                  <div class="label-holder">
                    <label for="check-diabetic">
                      <span class="text">Diabetic</span>
                      <span class="required-holder">
                        <i class="fa fa-holder-dynamic"></i>
                      </span>
                    </label>
                  </div>
                  <div class="input-holder">
                    <div class="input-spacer">
                      <div class="button-group selectable expanded small radius"
                        data-bind="foreach:$root.FormData.diabetic">
                        <a href="javascript:void(0);" style="white-space: nowrap" class="button small"
                          data-bind="click:function(){appmodel.Form().Diabetic(label)},css:{'selected':$root.Form().Diabetic() == label}"><i
                            class="fa fa-check"></i><span data-bind="text:label"></span></a>
                      </div>
                    </div>
                  </div>
                  <div class="message-holder">
                    <span data-bind="css: $root.diabeticValidation().status">
                      <i class="fa fa-holder"></i>
                      <span class="text" data-bind="text: $root.diabeticValidation().message"></span>
                    </span>
                  </div>
                  <div class="hint"></div>
                </div>
                <div class="question small-12 medium-6 large-4 column"
                  data-bind="css: $root.smokerValidation().status ">
                  <div class="label-holder">
                    <label>
                      <span class="text">Smoker</span>
                      <span class="required-holder">
                        <i class="fa fa-holder-dynamic"></i>
                      </span>
                    </label>
                  </div>
                  <div class="input-holder">
                    <div class="input-spacer">
                      <div class="button-group selectable expanded small radius"
                        data-bind="foreach:$root.FormData.smoker">
                        <a href="javascript:void(0);" style="white-space: nowrap" class="button small"
                          data-bind="click:function(){appmodel.Form().Smoker(label)},css:{'selected':$root.Form().Smoker() == label}"><i
                            class="fa fa-check"></i><span data-bind="text:label"></span></a>
                      </div>
                    </div>
                  </div>
                  <div class="message-holder">
                    <span data-bind="css: $root.smokerValidation().status">
                      <i class="fa fa-holder"></i>
                      <span class="text" data-bind="text: $root.smokerValidation().message"></span>
                    </span>
                  </div>
                  <div class="hint"></div>
                </div>
                <div class="question small-12 medium-6 large-4 column end"
                  data-bind="css: $root.hypertensionValidation().status ">
                  <div class="label-holder">
                    <label>
                      <span class="text">Treatment for Hypertension</span>
                      <span class="required-holder">
                        <i class="fa fa-holder-dynamic"></i>
                      </span>
                    </label>
                  </div>
                  <div class="input-holder">
                    <div class="input-spacer">
                      <div class="button-group selectable expanded small radius"
                        data-bind="foreach:$root.FormData.hypertension">
                        <a href="javascript:void(0);" style="white-space: nowrap" class="button small"
                          data-bind="click:function(){appmodel.Form().Hypertension(label)},css:{'selected':$root.Form().Hypertension() == label}"><i
                            class="fa fa-check"></i><span data-bind="text:label"></span></a>
                      </div>
                    </div>
                  </div>
                  <div class="message-holder">
                    <span data-bind="css: $root.hypertensionValidation().status">
                      <i class="fa fa-holder"></i>
                      <span class="text" data-bind="text: $root.hypertensionValidation().message"></span>
                    </span>
                  </div>
                  <div class="hint"></div>
                </div>
              </div>

              <div class="row">
                <div class="column large-12 text-right">
                  <a class="button large-4 medium-4 small-12 ascvd-ce-ga4" href="#!/calulate/recommendation/"
                    data-bind="visible:$root.recommendationUnlock()">Recommendation</a>
                  <a class="button large-4 medium-4 small-12 disabled" data-open="requiredModal"
                    data-bind="visible:!$root.recommendationUnlock(),click:function(){validate(true)}"
                    onclick="gaRecordMissingRecommendation()">Calculate</a>
                </div>
              </div>
            </div>
          </div>

          <div data-bind="page: {id:'recommendation', afterShow:tabchange,beforeShow:pageScrollTop}"
            class="page with-group-sections fill-page-height">
            <div class="data-display" id="scorebar">
              <div class="shrink sticky-holder">
                <header class="header page">
                  <ul class="nav tabs tabs-primary show-for-medium hide-for-small-only float-left">
                    <li class="icon hide-for-small-only">
                      <a class="home" data-toggle="offCanvas">
                        <i class="fa fa-bars"></i>
                      </a>
                    </li>
                  </ul>
                  <a href="#!/calulate/estimator/" class="logo"><img src="assets/img/logo-header.svg" /></a>
                  <ul class="nav tabs tabs-primary swappable small">
                    <li class="icon hide-for-medium">
                      <a class="home" data-toggle="offCanvas">
                        <i class="fa fa-bars"></i>
                      </a>
                    </li>
                    <li class="estimator-Tab btn-ga4" class="selected">
                      <a class="btn-ga4" href="#!/calulate/estimator/">
                        <span class="btn-ga4">Estimator</span>
                      </a>
                    </li>
                    <li class="recommendation-Tab sucsess" style="display: none"
                      data-bind="visible:$root.recommendationUnlock()">
                      <a href="#!/calulate/recommendation/"><span class="ascvd-ce-ga4">Recommendation</span>
                        <i class="fa fa-arrow-circle-right"></i></a>
                    </li>
                    <li class="recommendationFail-Tab disabled"
                      data-bind="visible:!$root.recommendationUnlock(),click:function(){validate(true)}">
                      <a data-open="requiredModal">Recommendation <i class="fa fa-ban"></i></a>
                    </li>
                  </ul>
                </header>

                <div class="score-bar-holder">
                  <div class="score-bar row callout" style="margin-bottom: 0; display: none"
                    data-bind="visible:($root.allDataValidation().status == 'error' || $root.allDataValidation().status == 'warning') ,css:$root.allDataValidation().status">
                    <div class="column large-6 medium-8 small-12 small-centered">
                      <span class="small-fs-2x text-condensed"
                        data-bind="text:$root.allDataValidation().message"></span>
                    </div>
                  </div>
                  <div class="score-bar row"
                    data-bind="visible:$root.allDataValidation().status != 'error' && $root.allDataValidation().status != 'warning'">
                    <div class="column small-6 primary-color data-container">
                      <div class="data float-right">
                        <div class="text-bold data-header small-fs-2x large-fs-3x">
                          10-Year ASCVD Risk
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 2 ">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().TenYearRisk">
                            3%
                          </div>
                          <div class="text-condensed small-fs-2x large-fs-3x data-label">
                            calculated risk
                          </div>
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 2 ">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().TenYearOptimal">
                            3%
                          </div>
                          <div class="data-label text-condensed small-fs-2x large-fs-3x">
                            risk with optimal risk factors
                            <span data-tooltip aria-haspopup="true" class="tip-top" data-disable-hover="false"
                              tabindex="1" data-bind="attr:{title:$root.FormData.infotext.scorebar.text}">
                              <i class="fa fa-info-circle"></i>
                            </span>
                          </div>
                        </div>
                        <div class="data-group content-block" data-bind="visible: $root.ageValidation().id == 2">
                          <div class="text-condensed small-fs-1x medium-fs-2x medium-fs-3x"
                            data-bind="text:$root.FormData.notifications.age[2].message">
                            This calculator only provides 10-year risk
                            estimates for individuals 40 to 70 years of age.
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="column small-6 secondary-color data-container">
                      <div class="data float-left">
                        <div class="text-bold data-header small-fs-2x large-fs-3x">
                          Lifetime ASCVD Risk
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 3">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().yourLifeTimeRisk">
                            3%
                          </div>
                          <div class="text-condensed small-fs-2x large-fs-3x data-label">
                            calculated risk
                          </div>
                        </div>
                        <div class="data-group" data-bind="visible: $root.ageValidation().id != 3">
                          <div class="text-bold small-fs-4x medium-fs-6x large-fs-6x data-value"
                            data-bind="text:$root.Form().lifeTimeRisk">
                            3%
                          </div>
                          <div class="data-label text-condensed small-fs-2x large-fs-3x">
                            risk with optimal risk factors
                            <span data-tooltip aria-haspopup="true" class="tip-top" data-disable-hover="false"
                              tabindex="1" data-bind="attr:{title:$root.FormData.infotext.scorebar.text}">
                              <i class="fa fa-info-circle"></i>
                            </span>
                          </div>
                        </div>
                        <div class="data-group content-block" data-bind="visible: $root.ageValidation().id == 3">
                          <div class="text-condensed small-fs-1x medium-fs-2x medium-fs-3x"
                            data-bind="text:$root.FormData.notifications.age[3].message">
                            Lifetime Risk Calculator only provides lifetime
                            risk estimates for individuals 20 to 59 years of
                            age.
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div class="page-wrapper">
              <div class="row relative-position">
                <h1>
                  Recommendation
                  <span class="sub-line">
                    Based on the data entered (assuming LDL-C < 190 mg/dL (4.92 mmol/L), no ASCVD, not on LDL-C lowering
                      therapy) </span>
                </h1>
              </div>
              <div class="row group-section">
                <div class="column small-12 callout highlighted">
                  <h2 data-bind="html:$root.recommendationType().title"></h2>
                </div>
                <div class="column large-8 medium-7 small-12">
                  <div class="page-wrapper">
                    <div data-bind="html:$root.recommendationType().content"></div>
                    <h2>Lifestyle Recommendations</h2>
                    <p>
                      AHA/ACC guidelines stress the importance of lifestyle
                      modifications to lower cardiovascular disease risk. This
                      includes eating a heart-healthy diet, regular aerobic
                      exercises, maintenance of desirable body weight and
                      avoidance of tobacco products.
                    </p>
                    <div data-bind="html:$root.recommendationType().guidelines"></div>
                  </div>
                </div>
                <div class="column large-4 medium-5 small-12">
                  <br />
                  <div class="callout secondary">
                    <h4>Inputs</h4>
                    <ul class="no-bullet">
                      <li class="group-divide">
                        Sex:
                        <span class="strong" data-bind="text:Form().Sex()"></span>
                      </li>
                      <li>
                        Age:
                        <span class="strong" data-bind="text:Form().Age"></span>
                      </li>
                      <li>
                        Race:
                        <span class="strong" data-bind="text:Form().Race()"></span>
                      </li>
                      <li class="group-divide">
                        Total Cholesterol:
                        <span class="strong"
                          data-bind="text:numberTrim(Form().TotalCholesterolValue(),Form().UnitOfMeasure())"></span>
                        <small data-bind="visible: !$root.Form().UnitOfMeasure() ">mg/dL</small>
                        <small data-bind="visible: $root.Form().UnitOfMeasure() ">mmol/L</small>
                      </li>
                      <li>
                        HDL-Cholesterol:
                        <span class="strong"
                          data-bind="text: numberTrim(Form().HDLCholesterolValue(),Form().UnitOfMeasure())"></span>
                        <small data-bind="visible: !$root.Form().UnitOfMeasure() ">mg/dL</small>
                        <small data-bind="visible: $root.Form().UnitOfMeasure() ">mmol/L</small>
                      </li>
                      <li>
                        Systolic Blood Pressure:
                        <span class="strong" data-bind="text:Form().BloodPressure"></span>
                        <small>mm Hg</small>
                      </li>
                      <li class="group-divide">
                        Diabetes:
                        <span class="strong" data-bind="text: Form().isDiabetic() ? 'Yes':'No'  "></span>
                      </li>
                      <li>
                        Smoker:
                        <span class="strong" data-bind="text: Form().isSmoker()  ? 'Yes':'No' "></span>
                      </li>
                      <li>
                        Treatment for Hypertension:
                        <span class="strong" data-bind="text: Form().isHypertension()  ? 'Yes':'No'"></span>
                      </li>
                    </ul>
                  </div>
                  <a class="expanded button email_button btn-ga4" href="javascript:void(0);" id="email"
                    data-rel="external">Email</a>
                  <br />
                  <div class="callout highlighted" data-bind=" visible:isRaceOther">
                    <span class="bold">Note:</span> These estimates may
                    underestimate the 10-year and lifetime risk for persons
                    from some race/ethnic groups, especially American Indians,
                    some Asian Americans (e.g., of south Asian ancestry), and
                    some Hispanics (e.g., Puerto Ricans), and may overestimate
                    the risk for others, including some Asian Americans (e.g.,
                    of east Asian ancestry) and some Hispanics (e.g., Mexican
                    Americans).<br />
                    Because the primary use of these risk estimates is to
                    facilitate the very important discussion regarding risk
                    reduction through lifestyle change, the imprecision
                    introduced is small enough to justify proceeding with
                    lifestyle change counseling informed by these results.
                  </div>
                </div>
                <div class="column small-12">
                  <h4 class="italic">Disclaimer</h4>
                  <p class="italic">
                    The results and recommendations provided by this
                    application are intended to inform but do not replace
                    clinical judgment. Therapeutic options should be
                    individualized and determined after discussion between the
                    patient and their care provider.
                  </p>
                </div>
                <div class="clear-both"></div>
              </div>
            </div>
          </div>
        </div>
        <div data-bind="page: {id:'content'}">
          <header class="header page">
            <ul class="nav tabs tabs-primary show-for-medium hide-for-small-only float-left">
              <li class="icon hide-for-small-only">
                <a class="home" data-toggle="offCanvas">
                  <i class="fa fa-bars"></i>
                </a>
              </li>
            </ul>
            <a href="#!/calulate/estimator/" class="logo"><img src="assets/img/logo-header.svg" /></a>
            <ul class="nav tabs tabs-primary swappable small">
              <li class="icon hide-for-medium">
                <a class="home" data-toggle="offCanvas">
                  <i class="fa fa-bars"></i>
                </a>
              </li>
              <li class="estimator-Tab btn-ga4" class="selected">
                <a class="btn-ga4" href="#!/calulate/estimator/">
                  <span class="btn-ga4">Estimator</span>
                </a>
              </li>
              <li class="recommendation-Tab sucsess" style="display: none"
                data-bind="visible:$root.recommendationUnlock()">
                <a href="#!/calulate/recommendation/"><span class="ascvd-ce-ga4">Recommendation</span> <i
                    class="fa fa-arrow-circle-right"></i></a>
              </li>
              <li class="recommendationFail-Tab disabled"
                data-bind="visible:!$root.recommendationUnlock(),click:function(){validate(true)}">
                <a data-open="requiredModal">Recommendation <i class="fa fa-ban"></i></a>
              </li>
            </ul>
          </header>

          <div data-bind="page: {id:'about',  afterShow:tabchange ,beforeShow:pageScrollTop}"
            class="page with-group-sections">
            <div class="page-wrapper">
              <section class="section group-section">
                <div class="group-section-tab-holder">
                  <ul class="nav tabs">
                    <li class="selected about-index-Tab">
                      <a href="#!/content/about/about-index/">About</a>
                    </li>
                    <li class="credit-Tab">
                      <a href="#!/content/about/credit/">Credit</a>
                    </li>
                  </ul>
                </div>
                <div data-bind="page:{id:'about-index',  afterShow:subtabchange}" class="">
                  <h1 class="with-underline">About the Application</h1>

                  <h3>When was this app last updated?</h3>
                  <p>February 2024</p>
                  <h3>How can I provide feedback?</h3>
                  <p>
                    <a href="https://forms.gle/ktUBNqP6JEHUryME8" target="_blank" class="link">Click here to fill out our feedback
                      survey</a>
                  </p>

                  <h2>How is this app intended to be used?</h2>
                  <p>
                    This Risk Estimator is intended as a companion tool to
                    the <strong><a class="link" target="_blank"
                        href="http://circ.ahajournals.org/content/129/25_suppl_2/S49.full.pdf">2013 ACC/AHA Guideline on
                        the Assessment of
                        Cardiovascular Risk</a></strong> and the <strong><a class="link" target="_blank"
                        href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000625">2018 AHA/ACC Guideline
                        on the Management of Blood Cholesterol</a></strong>. This Risk Estimator enables health care
                    providers and
                    patients to estimate 10-year and lifetime risks for
                    atherosclerotic cardiovascular disease (ASCVD), defined as
                    coronary death or nonfatal myocardial infarction, or fatal
                    or nonfatal stroke, based on the Pooled Cohort Equations
                    and lifetime risk prediction tools.
                  </p>

                  <p>
                    The Risk Estimator is intended for use in those without
                    ASCVD with a LDL-cholesterol &lt;190 mg/dL.The information
                    required to estimate ASCVD risk includes age, sex, race,
                    total cholesterol, HDL cholesterol, systolic blood
                    pressure, blood pressure lowering medication use, diabetes
                    status, and smoking status.
                  </p>

                  <p>
                    The results and recommendations provided by this
                    application are intended to inform but do not replace
                    clinical judgment. Therapeutic options should be
                    individualized and determined after discussion between the
                    patient and their care provider.
                  </p>

                  <h2>How are the estimates in this app calculated?</h2>

                  <h3>10-Year ASCVD Risk Estimates</h3>
                  <p>
                    Estimates of 10-year risk for ASCVD are based on data from
                    multiple community-based populations and are applicable to
                    African-American and non-Hispanic white men and women 40
                    through 79 years of age.
                  </p>

                  <p>
                    For other ethnic groups, we recommend use of the equations
                    for non-Hispanic whites, though these estimates may under-
                    or overestimate risk for persons from some race/ethnic
                    groups.
                  </p>

                  <h3>Lifetime ASCVD Risk Estimates</h3>
                  <p>
                    Estimates of lifetime risk for ASCVD are provided for
                    adults 20 through 59 years of age and are shown as the
                    lifetime risk for ASCVD for a 50-year old without ASCVD
                    who has the risk factor values entered into the Estimator.
                    The estimates of lifetime risk are most directly
                    applicable to non-Hispanic whites. We recommend the use of
                    these values for other race/ethnic groups, though as
                    mentioned above, these estimates may represent under- and
                    over-estimates for persons of various ethnic groups.
                    Because the primary use of these lifetime risk estimates
                    is to facilitate the very important discussion regarding
                    risk reduction through lifestyle change, the imprecision
                    introduced is small enough to justify proceeding with
                    lifestyle change counseling informed by these results.
                  </p>

                  <h3>
                    10-Year Risk Estimates that Exceed Lifetime Risk Estimates
                  </h3>
                  <p>
                    In rare cases, 10-year risks may exceed lifetime risks
                    given that the estimates come from different approaches.
                    The reported estimate of lifetime risk is based on
                    assigning each person into one of 5 mutually exclusive
                    sex-specific groups, as per Lloyd-Jones et al.,
                    Circulation 2006; 113(6):791-8. Within each of the 5
                    groups, each person receives the same lifetime risk
                    estimate. In other words, using this approach, there are
                    only 5 possible lifetime risk estimates reported for men
                    and only 5 possible lifetime risk estimates reported for
                    women. In some cases, the average risk for the group will
                    underestimate the individual&rsquo;s true lifetime risk.
                    This feature of lifetime risk estimation will result in
                    the estimated lifetime risk being less than the estimated
                    10-year risk. In these cases, the 10-year risk should be
                    the primary focus for the risk discussion and risk
                    reduction efforts.
                  </p>
                </div>
                <div data-bind="page: {id:'credit',  afterShow:subtabchange}">
                  <h1 class="with-underline">Application Credits</h1>
                  <h2>
                    2013 ACC/AHA Guideline on the Assessment of Cardiovascular
                    Risk
                  </h2>
                  <div class="row">
                    <span class="no-word-wrap">David C. Goff, MD, PhD, FACP, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Donald M. Lloyd-Jones, MD, ScM,
                      FACC, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Glen Bennett, MPH</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Christopher J. O'Donnell, MD,
                      MPH</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Sean Coady, MS</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Jennifer Robinson, MD, MPH,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Ralph B. D'Agostino,Sr, PhD,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> J. Sanford Schwartz, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Raymond Gibbons, MD, FACC,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Susan T. Shero, MS, RN</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Philip Greenland, MD, FACC,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Sidney C. Smith, MD, FACC,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Daniel T. Lackland, DrPH,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Paul Sorlie, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Daniel Levy, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Neil J. Stone, MD, FACC,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Peter W.F. Wilson, MD,
                      FAHA</span>
                  </div>
                  <h2>
                    2013 ACC/AHA Guideline on the Treatment of Blood
                    Cholesterol to Reduce Atherosclerotic Cardiovascular Risk
                    in Adults
                  </h2>
                  <div class="row">
                    <span class="no-word-wrap">Neil J. Stone, MD, MACP, FAHA, FACC</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Jennifer Robinson, MD, MPH,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Alice H. Lichtenstein, DSc,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> C. Noel Bairey Merz, MD, FAHA,
                      FACC</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Donald M. Lloyd-Jones, MD, ScM,
                      FACC, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Conrad B. Blum, MD, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Patrick McBride, MD, MPH,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Robert H. Eckel, MD, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> J. Sanford Schwartz, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Anne C. Goldberg, MD, FACP,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Susan T. Shero, MS, RN</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> David Gordon, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Sidney C. Smith</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Daniel Levy, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Karol Watson, MD, PhD, FACC,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Peter W.F. Wilson, MD,
                      FAHA</span>
                  </div>
                  <h2>
                    2013 AHA/ACC/TOS Guideline for the Management of
                    Overweight and Obesity in Adults
                  </h2>
                  <div class="row">
                    <span class="no-word-wrap">Michael D. Jensen, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Donna H. Ryan, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Caroline M. Apovian, MD,
                      FACP</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Catherine M. Loria, PhD,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Jamy D. Ard, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Barbara E. Millen, DrPH,
                      RD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Anthony G. Comuzzie, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Cathy A. Nonas, MS, RD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Karen A. Donato, SM</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> F. Xavier Pi-Sunyer, MD,
                      MPH</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Frank B. Hu, MD, PhD,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> June Stevens, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Van S. Hubbard, MD, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Victor J. Stevens, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> John M. Jakicic, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Thomas A. Wadden, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Robert F. Kushner, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Bruce M. Wolfe, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Susan Z. Yanovski, MD</span>
                  </div>
                  <h2>
                    2013 AHA/ACC Guideline on Lifestyle Management to Reduce
                    Cardiovascular Risk
                  </h2>
                  <div class="row">
                    <span class="no-word-wrap">Robert H. Eckel, MD, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> John M. Jakicic, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Jamy D. Ard, MD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Nancy Houston</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Miller, RN, BSN, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Van S. Hubbard, MD, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Cathy A. Nonas, MS, RD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Janet M. de Jesus, MS, RD</span>

                    <span class="no-word-wrap"><strong>&bull;</strong> Frank M. Sacks, MD, FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> I-Min Lee, MD, ScD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Sidney C. Smith</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Alice H. Lichtenstein, DSc,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Laura P. Svetkey, MD, MHS</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Catherine M. Loria, PhD,
                      FAHA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Thomas W. Wadden, PhD</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Barbara E. Millen, DrPH, RD,
                      FADA</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Susan Z. Yanovski, MD</span>
                  </div>
                  <h2>
                    2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood
                    Cholesterol
                  </h2>
                  <div class="row">
                    <span class="no-word-wrap">Scott M. Grundy</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Neil J. Stone</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Alison L. Bailey</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Craig Beam</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Kim K. Birtcher</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Roger S. Blumenthal</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Lynne T. Braun</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Sarah de Ferranti</span>

                    <span class="no-word-wrap"><strong>&bull;</strong> Joseph Faiella-Tommasino</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Daniel E. Forman</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Ronald Goldberg</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Paul A. Heidenreich</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Mark A. Hlatky</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Daniel W. Jones</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Donald Lloyd-Jones</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Nuria Lopez-Pajares</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Chiadi E. Ndumele</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Carl E. Orringer</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Carmen A. Peralta</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Joseph J. Saseen</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Sidney C. Smith Jr</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Laurence Sperling</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Salim S. Virani</span>
                    <span class="no-word-wrap"><strong>&bull;</strong> Joseph Yeboah</span>
                  </div>
                  <h2>Application Development Credits</h2>
                  <div class="row">
                    <p>
                      Concepts for this application adapted from the Cardiac
                      Risk Assist App developed by Tin T.D. Nguyen, MD.
                    </p>
                    <p class="bold">
                      Special Thanks to the ACC Best Practice Quality
                      Improvement Subcommittee, whose members have provided
                      content development and review
                    </p>
                  </div>
                </div>
              </section>
            </div>
          </div>
          <div class="page with-group-sections fill-page-height"
            data-bind="page: {id:'disclaimer', afterShow:tabchange ,beforeShow:pageScrollTop}">
            <div class="page-wrapper">
              <section class="section group-section">
                <h3 class="highlighted">Terms of Service and License Agreement</h3>
	              <p>This Terms of Service and License Agreement constitutes a legal agreement (collectively, the "Agreement") between the American College of Cardiology Foundation ("ACCF") and You and your agents ("You") for the use of the LDL-C Lowering Therapy, Hypertriglyceridemia, Statin Intolerance, or ASCVD Risk Estimator tools in the Lipid Manager (“the Product”), whether You use the mobile application version of the Product or the web version of the Product. The Product allows You to access certain content included in the Product (“Content”).</p>
	              <p>By using the Product, You accept and agree to be bound by all of the terms and conditions set forth in this Agreement. If You do not wish to accept the terms and conditions of this Agreement, You may not proceed to use the Product. </p>
	              <p>ACCF may change the terms of this Agreement from time to time without further notice directly to You. When the terms are changed, ACCF will post a general conspicuous notice. If You do not agree with the revised terms, please discontinue use of the Product immediately. Your continued use of the Product following such notice constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement. This Agreement expressly incorporates by reference and includes rules or disclaimers that may be posted and updated within the Product or communicated to You from time to time. </p> 

	              <h3 class="highlighted">Term and Termination</h3>
	              <p>ACCF may terminate your access and/or the Product at any time. You agree that any termination of your access to the Product shall not result in any liability or other obligation of ACCF to You, or any third party in connection with such termination.</p>

	              <h3 class="highlighted">Intellectual Property Rights</h3>
	              <p>The Product, including the information, text, graphics, images, audio and video files, trademarks and other materials that may be contained therein (collectively "Content"), is owned by ACCF and/or its suppliers and is protected by patents, copyrights, trademarks, and other proprietary rights. Except as specifically provided in this Agreement, your use of the Product shall be governed and constrained by applicable patent, copyright, trademark and other intellectual property laws. ACCF grants You a limited, nonexclusive, nontransferable, revocable license to utilize and access the Product for your noncommercial, personal use according to the terms and conditions in this Agreement. You may not modify, publish, transmit, participate in the transfer or sale of, reproduce, create derivative works from, distribute, perform, display, incorporate into another website, or in any other way exploit the Service and/or any of the Content, in whole or in part. Except as expressly granted by this Agreement, You acquire no right, title or interest in the Product or the Content or other data or materials incorporated in the Product. ACCF, ACC or affiliates or licensors thereof shall retain all right, title and interest in the Product and Content.</p>

	              <h3 class="highlighted">Limitation of Liability</h3>
	              <p>TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW, ACCF HEREBY DISCLAIMS, AND IN NO EVENT SHALL ACCF OR ANY PARTY INVOLVED IN CREATING OR PRODUCING THE PRODUCT BE LIABLE FOR, ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA LOSS, OR OTHER LOSSES, WHETHER IN AN ACTION OF CONTRACT, NEGLIGENCE OR OTHER TORTIOUS ACTION, EVEN IF ACCF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, RESULTING FROM: (i) THE USE OR INABILITY TO USE THE PRODUCT, (ii) THE COST OF ANY SUBSTITUTE PRODUCTS AND/OR SERVICES RESULTING FROM ANY PRODUCTS, DATA, INFORMATION OR SERVICES OBTAINED OR WHICH YOU WERE UNABLE TO OBTAIN OR TRANSACTIONS EFFECTED OR FAILED TO BE EFFECTED, (iii) THE USE OR INABILITY TO USE ANY THIRD PARTY APPLICATIONS CONTAINED WITHIN THE PRODUCT, OR (iv) ANY MATTER OTHERWISE RELATED TO YOUR USE OF THE PRODUCT.</p>

	              <h3 class="highlighted">Release of Liability</h3>
	              <p>You assume all risks associated with use of the Product including, but not limited to any harm, injury or damages resulting directly or indirectly from the use of the Product, all such risks being known and understood by You. In consideration of your use of the Product, You, for yourself and anyone entitled to act on your behalf, waive and forever release ACCF, its officers, trustees, employees, representatives and successors from all claims and liabilities of any kind arising out of your use or misuse of the Product.</p>

	              <h3 class="highlighted">Indemnification</h3>
	              <p>You hereby agree to indemnify, save and hold ACCF, its directors, officers, shareholders, parents, subsidiaries, affiliates, agents and licensors harmless from and against any and all claims, liability, losses, damages and costs, including, without limitation, reasonable attorneys' fees and costs, arising out of your use or misuse of the Product or Content, or any violation of this Agreement. ACCF assumes the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify ACCF, and you agree to cooperate with ACCF’s defense of these claims. ACCF will use reasonable efforts to notify you of any such claim, action, or proceeding upon becoming aware of it.</p>

	              <h3 class="highlighted">Disclaimer of Warranties</h3>
	              <p>THE PRODUCT AND CONTENT ARE PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. ACCF AND ITS SUPPLIERS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT OR CONTENT, WHETHER EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT. ACCF MAKES NO WARRANTY THAT THE PRODUCT AND/OR ANY CONTENT THEREIN WILL MEET YOUR REQUIREMENTS, OR WILL BE UNINTERRUPTED, TIMELY, SECURE, CURRENT, ACCURATE, COMPLETE OR ERROR-FREE OR THE RESULTS THAT MAY BE OBTAINED BY USE OF THE PRODUCT OR ANY CONTENT THEREIN WILL BE ACCURATE OR RELIABLE. YOU UNDERSTAND AND ACKNOWLEDGE THAT YOUR SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO ANY DEFECT IN OR DISSATISFACTION WITH THE PRODUCT IS TO CEASE ITS USE.</p>
	              <p>The Content on the Product is presented as an educational service intended for licensed healthcare professionals. While the Content in the Product is about specific medical and healthcare issues, the Content is not a substitute for or replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.</p>
	              <p>The views and opinions expressed are those of the contributing authors and editors and do not necessarily represent the views of the ACCF. The material is not intended to present the only, or necessarily best, methods or procedures for the medical situations addressed, but rather is intended to represent an approach, view, statement or opinion.</p>
	              <p>Any reference to a specific therapy or commercial product in this Product does not constitute a guarantee or endorsement by ACCF of the quality or value of such therapy or product or any claims made by the manufacturer of such therapy or commercial product.</p>
	              <p>In addition, any statements about such therapy or commercial products are solely based on published clinical prediction rules and estimates of drug treatment effects from published clinical studies and do not represent an ACCF endorsement or evaluation of these products.</p> 

	              <h3 class="highlighted">Force Majeure</h3>
	              <p>ACCF will be excused from performance under this Agreement and will not be liable or considered in default under this Agreement in the event that the Product is unavailable for any period of time, or if ACCF is otherwise unable to perform its obligations hereunder, in whole or in part, as a result of a Force Majeure Event. For purposes of this Section, "Force Majeure Event" means an event or series of events caused by or resulting from any of the following: (1) weather conditions or other elements of nature or acts of God; (2) government regulation; (3) quarantines or embargoes; (4) telecommunications, network, computer, server or Internet downtime; (5) unauthorized access to ACCF's information technology systems by third parties; or (6) any other causes beyond the reasonable control of ACCF.</p>

	               <h3 class="highlighted">No Assignment</h3>
	               <p>This Agreement is personal to You, and You may not assign your rights or obligations to anyone.</p>

	              <h3 class="highlighted">No Waiver</h3>
	              <p>Neither failure nor delay on the part of any party to exercise any right, remedy, power or privilege hereunder nor course of dealing between the parties shall operate as a waiver thereof, or of the exercise of any other right, remedy, power or privilege. No term of this Agreement shall be deemed waived, and no breach consented to, unless such waiver or consent shall be in writing and signed by the party claimed to have waived or consented. No waiver of any rights or consent to any breaches shall constitute a waiver of any other rights or consent to any other breach.</p>

	              <h3 class="highlighted">Severability</h3>
	              <p>If any provision in this Agreement is held invalid or unenforceable under applicable law, the remaining provisions shall continue in full force and effect.</p>

	              <h3 class="highlighted">Governing Law</h3>
	              <p>This Agreement will be governed by and construed exclusively in accordance with the laws of the District of Columbia, USA, without regard to its conflicts of law principles and, to the extent applicable, the federal laws of the United States. If a dispute arises between ACCF and You, You hereby agree to submit such dispute to non-binding mediation, followed by binding arbitration, if necessary. Both the mediation and arbitration will be conducted by JAMS applying the laws of the District of Columbia without regard to its conflicts of laws principles and in the District of Columbia as venue.</p> 

	              <h3 class="highlighted">Certification</h3>
	              <p>I hereby certify that I understand and agree to the terms stated in this Agreement and that this Agreement applies to my initial use of the Product and all other subsequent uses of the Product. BY USING THIS PRODUCT, I HEREBY AFFIRM THAT I HAVE READ, FULLY UNDERSTAND, AND AGREE TO THE ABOVE STATEMENTS.</p> 
	
              </section>
            </div>
          </div>
          <div class="page with-group-sections fill-page-height"
            data-bind="page: {id:'resources',  afterShow:tabchange ,beforeShow:pageScrollTop}">
            <div class="page-wrapper">
              <section class="section group-section">
                <div class="row">
                  <div class="column medium-6 medium-push-6">
                    <h3>Patient Resources</h3>
                    <nav class="nav-list small">
                      <ul>
                        <li>
                          <a href="#!/content/patient-split-layout/patient_lifestyle">
                            <span class="text">
                              Diet and Physical Activity
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/patient-split-layout/patient_obesity">
                            <span class="text">
                              Weight Management Recommendations
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/patient-split-layout/patient_cholesterol">
                            <span class="text">
                              Blood Cholesterol Management Recommendations
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                      </ul>
                    </nav>
                  </div>
                  <div class="column medium-6 medium-pull-6">
                    <h3>Clinician Resources</h3>
                    <nav class="nav-list small">
                      <ul>
                        <li>
                          <a href="#!/content/clinician-split-layout/clinical_lifestyle">
                            <span class="text">
                              Lifestyle Recommendations
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                        <li>
                          <a href="#!/content/clinician-split-layout/risk_enhancing_factors">
                            <span class="text">
                              ASCVD Risk Enhancing Factors
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                        <li>
                          <a href="#!/content/clinician-split-layout/ethnicity_issues">
                            <span class="text">
                              Ethnicity Issues in Risk Evaluation
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                        <li>
                          <a href="#!/content/clinician-split-layout/summary_recommendations">
                            <span class="text">
                              General Populations Recommendation Summary
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/guideline_flowchart">
                            <span class="text">
                              Primary Prevention of ASCVD - Summary
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/secondary_prevention">
                            <span class="text">
                              Secondary Prevention - Patients with Clinical
                              ASCVD
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                        <li>
                          <a href="#!/content/clinician-split-layout/ldlc_treatment_younger_patients">
                            <span class="text">
                              LDL-C Treatment Suggestions for Younger Patients
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                        <li>
                          <a href="#!/content/clinician-split-layout/statin_dose_resource_section">
                            <span class="text">
                              Intensities of Statin Therapy
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/monitor_flowchart">
                            <span class="text">
                              Recommendations to Monitor Response to LDL-C
                              Lowering Therapy
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations">
                            <span class="text">
                              Statin Safety Recommendations
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/discussion_checklist">
                            <span class="text">
                              Discussion Checklist for Therapy Initiation
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/cac_score_inform_decisions">
                            <span class="text">
                              Using CAC Score to Inform Decisions
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/immunization_practice">
                            <span class="text">
                              Immunization Practice
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>

                        <li>
                          <a href="#!/content/clinician-split-layout/reference_external_links">
                            <span class="text">
                              External Links to Full Guidelines &amp; More
                              Information
                            </span>
                            <i class="fa fa-holder-dynamic"> </i>
                          </a>
                        </li>
                      </ul>
                    </nav>
                  </div>
                </div>
                <div class="row">
                  <div class="small-12 column">
                    <h3 class="">References</h3>
                    <ul class="patient-scenario">
                      <li>
                        <a target="_blank" href="https://www.acc.org/guidelines#doctype=Guidelines">Grundy SM, Stone NJ,
                          Bailey AL, Beam C, Birtcher
                          KK, Blumenthal RS, Braun LT, de Ferranti S,
                          Faiella-Tommasino J, Forman DE, Goldberg R,
                          Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D,
                          Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta
                          CA, Saseen JJ, Smith SC, Sperling L, Virani SS,
                          Yeboah J. 2018
                          ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
                          guideline on the management of blood cholesterol: a
                          report of the American College of Cardiology
                          Foundation/American Heart Association Task Force on
                          Clinical Practice Guidelines. J Am Coll Cardiol.
                          2018; xx:xxxx-xxxx.</a>
                      </li>
                    </ul>
                  </div>
                </div>
              </section>
            </div>
          </div>
          <div data-bind="page: {id:'clinician-split-layout'}">
            <div class="medium split-layout fill-page-height">
              <div class="split-sidebar">
                <div class="content-padding" style="padding-top: 1em">
                  <h4 class="">Clinician Resources</h4>
                </div>
                <nav class="nav-list small">
                  <ul>
                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_lifestyle">
                        <span class="text"> Lifestyle Recommendations </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/risk_enhancing_factors">
                        <span class="text">
                          ASCVD Risk Enhancing Factors
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/ethnicity_issues">
                        <span class="text">
                          Ethnicity Issues in Risk Evaluation
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/summary_recommendations">
                        <span class="text">
                          General Populations Recommendation Summary
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/guideline_flowchart">
                        <span class="text">
                          Primary Prevention of ASCVD - Summary
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/secondary_prevention">
                        <span class="text">
                          Secondary Prevention - Patients with Clinical ASCVD
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/ldlc_treatment_younger_patients">
                        <span class="text">
                          LDL-C Treatment Suggestions for Younger Patients
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/statin_dose_resource_section">
                        <span class="text">
                          Intensities of Statin Therapy
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/monitor_flowchart">
                        <span class="text">
                          Recommendations to Monitor Response to LDL-C
                          Lowering Therapy
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations">
                        <span class="text">
                          Statin Safety Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/discussion_checklist">
                        <span class="text">
                          Discussion Checklist for Therapy Initiation
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/cac_score_inform_decisions">
                        <span class="text">
                          Using CAC Score to Inform Decisions
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/immunization_practice">
                        <span class="text">
                          Immunization Practice
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/reference_external_links">
                        <span class="text">
                          External Links to Full Guidelines &amp; More
                          Information
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                  </ul>
                </nav>
                <div class="content-padding" style="padding-top: 1em">
                  <h4 class="">Patient Resources</h4>
                </div>
                <nav class="nav-list small">
                  <ul>
                    <li>
                      <a href="#!/content/patient-split-layout/patient_lifestyle">
                        <span class="text"> Diet and Physical Activity </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_obesity">
                        <span class="text">
                          Weight Management Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_cholesterol">
                        <span class="text">
                          Blood Cholesterol Management Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                  </ul>
                </nav>
                <div class="row">
                  <div class="small-12 column">
                    <h3 class="">References</h3>
                    <ul class="patient-scenario">
                      <li>
                        <a target="_blank" href="https://www.acc.org/guidelines#doctype=Guidelines">Grundy SM, Stone NJ,
                          Bailey AL, Beam C, Birtcher
                          KK, Blumenthal RS, Braun LT, de Ferranti S,
                          Faiella-Tommasino J, Forman DE, Goldberg R,
                          Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D,
                          Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta
                          CA, Saseen JJ, Smith SC, Sperling L, Virani SS,
                          Yeboah J. 2018
                          ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
                          guideline on the management of blood cholesterol: a
                          report of the American College of Cardiology
                          Foundation/American Heart Association Task Force on
                          Clinical Practice Guidelines. J Am Coll Cardiol.
                          2018; xx:xxxx-xxxx.</a>
                      </li>
                    </ul>
                  </div>
                </div>
              </div>
              <div class="split-content page with-group-sections">
                <div class="section-nav back hide-for-medium">
                  <a href="#!/content/resources/">
                    <div class="circle">
                      <i class="fa fa-holder-dynamic"> </i>
                    </div>
                    <div class="text">Back to Resources</div>
                  </a>
                </div>
                <div class="page-wrapper">
                  <div data-bind="page: {id:'clinical_understanding',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Understanding Cardiovascular Risk
                    </h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">10-Year ASCVD Risk</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                The 10-year calculated ASCVD risk is a
                                quantitative estimation of absolute risk based
                                upon data from representative population
                                samples.
                              </li>
                              <li>
                                The 10-year risk estimate for "optimal risk
                                factors" is represented by the following
                                specific risk factor numbers for an individual
                                of the same age, sex and race: Total
                                cholesterol of &le; 170 mg/dL, HDL-cholesterol
                                of &ge; 50 mg/dL, untreated systolic blood
                                pressure of &le; 110 mm Hg, no diabetes
                                history, and not a current smoker.
                              </li>
                              <li>
                                While the risk estimate is applied to
                                individuals, it is based on group averages.
                              </li>
                              <li>
                                Just because two individuals have the same
                                estimated risk does not mean that they will or
                                will not have the same event of interest.
                              </li>
                              <li>
                                Example: If the 10-year ASCVD risk estimate is
                                10%, this indicates that among 100 patients
                                with the entered risk factor profile, 10 would
                                be expected to have a heart attack or stroke
                                in the next 10 years.
                              </li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Lifetime ASCVD Risk</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                The lifetime calculated ASCVD risk represents
                                a quantitative estimation of absolute risk for
                                a 50 year old man or woman with the same risk
                                profile.
                              </li>
                              <li>
                                This estimation of risk is based on the
                                grouping of risk factor levels into 5 strata.
                                <ul>
                                  <li>All risk factors are optimal*</li>
                                  <li>
                                    &ge;1 risk factors are not optimal&dagger;
                                  </li>
                                  <li>
                                    &ge;1 risk factors are elevated&Dagger;
                                  </li>
                                  <li>1 major risk factor&sect;</li>
                                  <li>&ge;2 major risk factors&sect;</li>
                                </ul>
                              </li>
                              <li>
                                The division of lifetime risk by these 5
                                strata leads to thresholds in the data with
                                large apparent changes in lifetime risk
                                estimates.
                              </li>
                              <li>
                                Example: An individual that has all optimal
                                risk factors except for a systolic blood
                                pressure of 119 mm Hg has a lifetime ASCVD
                                risk of 5%. In contrast, a similar individual
                                that has all optimal risk factors except for a
                                systolic blood pressure of 120 mm Hg has a
                                lifetime ASCVD risk of 36%. This substantial
                                difference in lifetime risk is due to the fact
                                that they are in different stratum.
                              </li>
                            </ul>
                            <p class="quiet">
                              *Optimal risk levels for lifetime risk are
                              represented by the simultaneous presence of all
                              of the following: Untreated total cholesterol
                              &lt;180 mg/dL, untreated blood pressure
                              &lt;120/&lt;80 mm Hg, no diabetes history, and
                              not a current smoker
                            </p>
                            <p class="quiet">
                              &dagger;Nonoptimal risk levels for lifetime risk
                              are represented by 1 or more of the following:
                              Untreated total cholesterol of 180 to 199 mg/dL,
                              untreated systolic blood pressure of 120 to 139
                              mm Hg or diastolic&nbsp;blood pressure of 80 to
                              89 mm Hg, and no diabetes history and not a
                              current smoker
                            </p>
                            <p class="quiet">
                              &Dagger;Elevated risk levels for lifetime risk
                              are represented by 1 or more of the following:
                              Untreated total cholesterol of 200 to 239 mg/dL,
                              untreated systolic blood pressure of 140 to 159
                              mm Hg or diastolic&nbsp;blood pressure of 90 to
                              99 mm Hg, and no diabetes history and not a
                              current smoker
                            </p>
                            <p class="quiet">
                              &sect;Major risk levels for lifetime risk are
                              represented by any of the following: Total
                              cholesterol &ge;240 mg/dL or treated, systolic
                              blood pressure &ge;160 mm Hg or
                              diastolic&nbsp;blood pressure &ge;100 mm Hg or
                              treated, or diabetes, or current smoker
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'clinical_lifestyle',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">Lifestyle Recommendations</h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Diet recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>Diet recommendations for LDL-C lowering</h3>
                            <ol>
                              <li>
                                Consume a dietary pattern that emphasizes
                                intake of vegetables, fruits, and whole
                                grains; includes low-fat dairy products,
                                poultry, fish, legumes, non-tropical vegetable
                                oils and nuts; and limits intake of sweets,
                                sugar-sweetened beverages, and red meats. (I
                                A)
                                <ul>
                                  <li>
                                    Adapt this dietary pattern to appropriate
                                    calorie requirements, personal and
                                    cultural food preferences, and nutrition
                                    therapy for other medical conditions
                                    (including diabetes mellitus).
                                  </li>
                                  <li>
                                    Achieve this pattern by following plans
                                    such as the DASH dietary pattern, the USDA
                                    Food Pattern, or the AHA Diet.
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Aim for a dietary pattern that achieves 5-6%
                                of calories from saturated fat. (I A)
                              </li>
                              <li>
                                Reduce percent of calories from saturated fat.
                                (I A)
                              </li>
                              <li>
                                Reduce percent of calories from trans fat. (I
                                A)
                              </li>
                            </ol>
                            <h3>
                              Diet recommendations for blood pressure lowering
                            </h3>
                            <ol>
                              <li>
                                Consume a dietary pattern that emphasizes
                                intake of vegetables, fruits, and whole
                                grains; includes low-fat dairy products,
                                poultry, fish, legumes, non-tropical vegetable
                                oils and nuts; and limits intake of sweets,
                                sugar-sweetened beverages, and red meats. (I
                                A)
                                <ul>
                                  <li>
                                    Adapt this dietary pattern to appropriate
                                    calorie requirements, personal and
                                    cultural food preferences, and nutrition
                                    therapy for other medical conditions
                                    (including diabetes mellitus).
                                  </li>
                                  <li>
                                    Achieve this pattern by following plans
                                    such as the DASH dietary pattern, the USDA
                                    Food Pattern, or the AHA Diet.
                                  </li>
                                </ul>
                              </li>
                              <li>Lower sodium intake. (I A)</li>
                              <li>
                                Consume no more than 2400 mg of sodium per
                                day. (I B)
                              </li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Weight Management Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>Diets for weight loss</h3>
                            <ol>
                              <li>
                                Prescribe a diet to achieve reduced calorie
                                intake for obese or overweight individuals who
                                would benefit from weight loss, as part of a
                                comprehensive lifestyle intervention with 1 of
                                the following (I A):
                                <ul>
                                  <li>
                                    1200-1500 kcal/day for women and 1500-1800
                                    kcal/day for men.
                                  </li>
                                  <li>500-750 kcal/day energy deficit.</li>
                                  <li>
                                    Use one of the evidence-based diets that
                                    restricts certain food types (e.g.,
                                    high-carbohydrate foods, low-fiber foods,
                                    or high-fat foods) in order to create an
                                    energy deficit by reduced food intake.
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Prescribe a calorie-restricted diet for obese
                                or overweight individuals who would benefit
                                from weight loss, based on the patient's
                                preferences and health status, and preferably
                                refer to a nutrition professional for
                                counseling. (I A)
                              </li>
                            </ol>
                            <h3>
                              Lifestyle interventions and counseling for
                              weight loss
                            </h3>
                            <ol>
                              <li>
                                Advise participation in a comprehensive
                                lifestyle program that assists participants in
                                adhering to a lower calorie diet and
                                increasing physical activity through the use
                                of behavioral strategies. (I A)
                              </li>
                              <li>
                                Prescribe on site, high-intensity (i.e.,
                                &gt;14 sessions in 6 months) comprehensive
                                weight loss interventions provided in
                                individual or group sessions by a trained
                                interventionist. (I A)
                              </li>
                              <li>
                                Consider prescription of electronically
                                delivered weight loss programs (including by
                                telephone) that includes personalized feedback
                                from a trained interventionist, recognizing
                                that it may result in smaller weight loss than
                                face-to-face interventions. (IIa A)
                              </li>
                              <li>
                                Consider some commercial-based programs that
                                provide comprehensive lifestyle interventions,
                                provided there is peer-reviewed published
                                evidence of their safety and efficacy. (IIa A)
                              </li>
                              <li>
                                Consider a very low calorie diet (&lt;800
                                kcal/day) only in limited circumstances and
                                only when provided by trained practitioners in
                                a medical care setting where medical
                                monitoring and high intensity lifestyle
                                intervention can be provided. (IIa A)
                              </li>
                              <li>
                                Advise individuals who have lost weight to
                                participate long term (&gt;1 year) in a
                                comprehensive weight loss maintenance program.
                                (I A)
                              </li>
                              <li>
                                Prescribe face-to-face or telephone-delivered
                                weight loss maintenance programs that provide
                                regular contact (&gt; monthly) with a trained
                                interventionist who helps participants engage
                                in high levels of physical activity (i.e.,
                                200-300 minutes/week), monitor body weight
                                regularly (&gt; weekly), and consume a
                                reduced-calorie diet (need to lower body
                                weight). (I A)
                              </li>
                            </ol>
                            <h3>
                              Selection criteria for bariatric surgical
                              treatment of obesity
                            </h3>
                            <ol>
                              <li>
                                Advise adults with a BMI &ge;40 kg/m² or BMI
                                &ge;35 kg/m² with obesity-related co-morbid
                                conditions who are motivated to lose weight
                                and who have not responded to behavioral
                                treatment with or without pharmacotherapy with
                                sufficient weight loss to achieve targeted
                                health outcome goals that bariatric surgery
                                may be an appropriate option to improve health
                                and offer referral to an experienced bariatric
                                surgeon for consultation and evaluation. (IIa
                                A)
                              </li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Physical Activity Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>
                              Physical activity recommendations for modifying
                              lipids and blood pressure lowering
                            </h3>
                            <ol>
                              <li>
                                Advise adults to engage in aerobic physical
                                activity to reduce LDL-cholesterol,
                                non-HDL-cholesterol, and blood pressure. (IIa
                                A)
                                <ul>
                                  <li>Frequency: 3-4 sessions a week</li>
                                  <li>Intensity: Moderate to vigorous</li>
                                  <li>Duration: 40 minutes on average</li>
                                </ul>
                              </li>
                            </ol>
                            <h3>
                              Physical activity recommendations for secondary
                              prevention*
                            </h3>
                            <ol>
                              <li>
                                Aerobic exercise
                                <ul>
                                  <li>Frequency: 3-5 days/week</li>
                                  <li>
                                    Intensity: 50-80% of exercise capacity
                                  </li>
                                  <li>Duration: 20-60 minutes</li>
                                  <li>
                                    Modalities: Examples include walking,
                                    treadmill, cycling, rowing, stair
                                    climbing, and arm/leg ergometry
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Resistance exercise
                                <ul>
                                  <li>Frequency: 2-3 days/week</li>
                                  <li>
                                    Intensity: 10-15 repetitions/set to
                                    moderate fatigue
                                  </li>
                                  <li>
                                    Duration: 1-3 sets of 8-10 upper and lower
                                    body exercises
                                  </li>
                                  <li>
                                    Modalities: Examples include calisthenics,
                                    elastic bands, cuff/hand weights,
                                    dumbbells, free weights, wall pulleys, and
                                    weight machines
                                  </li>
                                </ul>
                              </li>
                            </ol>
                            <cite class="quiet">*Balady GJ et al. Core components of cardiac
                              rehabilitation/secondary prevention programs:
                              2007 update: a Scientific Statement of the
                              American Heart Association Exercise, Cardiac
                              Rehabilitation, and Prevention Committee, the
                              Council on Clinical Cardiology; the Councils on
                              Cardiovascular Nursing, Epidemiology and
                              Prevention, and Nutrition, Physical Activity and
                              Metabolism; and the American Association of
                              Cardiovascular and Pulmonary Rehabilitation.
                              Circulation 2007;115:2675-2682</cite>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Tobacco Cessation Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>5 R's for patients not ready to quit</h3>
                            <ol>
                              <li>
                                Relevance&mdash;Encourage the patient to
                                indicate why quitting is personally relevant.
                              </li>
                              <li>
                                Risks&mdash;Ask the patient to identify
                                potential negative consequences of tobacco
                                use.
                              </li>
                              <li>
                                Rewards&mdash;Ask the patient to identify
                                potential benefits of stopping tobacco use.
                              </li>
                              <li>
                                Roadblocks&mdash;Ask the patient to identify
                                barriers or impediments to quitting.
                              </li>
                              <li>
                                Repetition&mdash;The motivational intervention
                                should be repeated every time an unmotivated
                                patient has an interaction with a clinician.
                                Tobacco users who have failed in previous quit
                                attempts should be told that most people make
                                repeated quit attempts before they are
                                successful.
                              </li>
                            </ol>
                            <h3>5 A's for patients that are ready to quit</h3>
                            <ol>
                              <li>
                                Ask&mdash;Systematically identify all tobacco
                                users at every visit.
                              </li>
                              <li>
                                Advise&mdash;Strongly urge all smokers to
                                quit.
                              </li>
                              <li>
                                Assess&mdash;Identify smokers willing to make
                                a quit attempt.
                              </li>
                              <li>
                                Assist&mdash;Aid the patient in quitting.
                              </li>
                              <li>
                                Arrange&mdash;Schedule follow-up contact.
                              </li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>

                  <div data-bind="page: {id: 'risk_enhancing_factors', afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      ASCVD Risk Enhancing Factors
                    </h1>
                    <table class="table">
                      <thead>
                        <th>ASCVD Risk Enhancing Factors</th>
                      </thead>
                      <tbody>
                        <td>
                          <div class="row">
                            <ul>
                              <li>
                                <b>Family history of premature ASCVD;</b>
                                (males <55 years; females <65 years) </li>
                              <li>
                                <b>Primary hypercholesterolemia </b>(LDL-C
                                160-189 mg/dL (4.1- 4.8 mmol/L); non-HDL-C
                                190-219 mg/dL (4.9-5.6 mmol/L).<sup>*</sup>
                              </li>
                              <li>
                                <b>Metabolic syndrome </b>(increased waist
                                circumference, elevated TG (>175 mg/dL (>2
                                mmol/L ), BP, glucose, low HDL-C<br />(<40 in men, <50 in women) are factors; tally of 3
                                  makes the diagnosis) </li>
                              <li>
                                <b>Chronic kidney disease </b> (eGFR 15- 59
                                ml/min per1.73 m<sup>2</sup> with or without
                                albuminuria) not treated with dialysis or
                                kidney transplantation)
                              </li>
                              <li>
                                <b>Chronic inflammatory conditions </b>such as
                                psoriasis, rheumatoid arthritis (RA) or human
                                immunodeficiency virus (HIV)/ acquired
                                immunodeficiency syndrome (AIDS)
                              </li>
                              <li>
                                <b>History of premature menopause (before age
                                  40) and history of pregnancy-associated
                                  conditions that increase later ASCVD risk
                                  such as pre-eclampsia</b>
                              </li>
                              <li>
                                <b>High-risk ethnicities </b>(e.g. South Asian
                                ancestry)
                              </li>
                              <li>
                                <b>Lipid/Biomarkers: </b>Associated with
                                increased ASCVD risk
                                <ul>
                                  <li>
                                    Persistently* elevated, primary
                                    hypertriglyceridemia;( ≥ 175-500 mg/dl);
                                  </li>
                                  <li>
                                    If measured:
                                    <ul>
                                      <li>
                                        <b>High-sensitivity C-reactive protein
                                          - </b>(≥2.0 mg/L)
                                      </li>
                                      <li>
                                        <b>Elevated lipoprotein (a) </b>- ≥50
                                        mg/dl or ≥125 nmol/L, but especially
                                        in those with higher Lp(a) values and
                                        if used in women, only in the presence
                                        of hypercholesterolemia
                                      </li>
                                      <li>
                                        <b>Elevated apolipoprotein B (apo B) </b>≥130 mg/dl
                                      </li>
                                    </ul>
                                  </li>
                                </ul>
                              </li>
                            </ul>
                          </div>
                        </td>
                      </tbody>
                    </table>
                    <p class="text">
                      <sup>*</sup> Optimally, three determinations
                    </p>
                  </div>

                  <div data-bind="page: {id: 'ethnicity_issues', afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Ethnicity Issues in Risk Evaluation
                    </h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">EVALUATION</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <div data-bind="" class="nested-accordion">
                              <div class="ascvd-issues">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.ascvd-issues')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    ASCVD Issues informed by ethnicity
                                  </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <!--
                                                        <div class="bar close">
                                                            <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                                        </div>
-->
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> South Asian
                                        and East Asian ASCVD risk varies by
                                        country of origin; Individuals from
                                        South Asia have increased ASCVD risk.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b> Race
                                        and country of origin together with
                                        socio-economic status and
                                        acculturation level may explain risk
                                        factor burden more precisely. e.g.
                                        ASCVD risk is higher among individuals
                                        from Puerto Rico than from Mexico.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> ASCVD risk
                                        assessment in African American women
                                        shows increased ASCVD risk compared to
                                        their otherwise similar white
                                        counterparts.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>Heterogeneity in risk
                                        according to ethnic groups and within
                                        ethnic groups.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="lipid-issues">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.lipid-issues')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    Lipid issues informed by ethnicity
                                  </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> Lower levels
                                        of HDL-C compared to whites. Higher
                                        prevalence of LDL-C among Asian
                                        Indians, Filipinos, Japanese, and
                                        Vietnamese compared to whites. An
                                        increased prevalence of high TGs was
                                        seen in all Asian American subgroups.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b>
                                        Hispanic/Latino women have higher
                                        prevalence of low HDL-C compared to
                                        Hispanic/Latino men.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> Higher
                                        levels of HDL-C and lower levels of
                                        triglycerides (TG) than in
                                        Non-Hispanic whites or
                                        Mexican-Americans.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>All ethnic groups
                                        appear to be at greater risk for
                                        dyslipidemia, but important to
                                        identify those with more sedentary
                                        behavior and less favorable diet.
                                        Cultural and racial differences
                                        between Asians and Hispanic/Latinos
                                        subgroups make generalizations
                                        unreliable.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="metabolic-issues">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.metabolic-issues')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    Metabolic issues informed by ethnicity
                                  </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> Increased
                                        Metabolic Syndrome (MetS) seen with
                                        lower waist circumference than in
                                        whites. Type 2 diabetes (DM) develops
                                        at a lower lean body mass and at
                                        earlier age (17- 19). Majority of risk
                                        in South Asians explained by known
                                        risk factors, especially those related
                                        to insulin resistance.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b> DM
                                        disproportionately present compared to
                                        whites and blacks. Increased
                                        prevalence MetS, DM in Mexican
                                        Americans compared to whites & Puerto
                                        Ricans.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> Increased DM
                                        and hypertension.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>Increased prevalence
                                        of DM. Features of MetS vary by
                                        ethnicity. Waist circumference, not
                                        weight, should be used to determine
                                        abdominal adiposity when possible.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">RISK DECISIONS</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <div data-bind="" class="nested-accordion">
                              <div class="pooled-cohort">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.pooled-cohort')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    Pooled Cohort Equations (PCE)
                                  </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> No separate
                                        PCE available; use PCE for whites. PCE
                                        may underestimate ASCVD risk in South
                                        Asians. PCE may overestimate risk in
                                        East Asians.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b> No
                                        separate PCE available; use PCE for
                                        non-Hispanic whites. If African
                                        American ancestry also, then use PCE
                                        for African Americans.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> Use PCE for
                                        African Americans.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>Country specific
                                        ethnicity, along with socio-economic
                                        status, may affect estimation of risk
                                        of PCE.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="coronary-artery">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.coronary-artery')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    Coronary Artery Calcium (CAC) Score
                                  </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> In terms of
                                        CAC burden, South Asian men were
                                        similar to non-Hispanic white men, but
                                        higher CAC when compared to African
                                        Americans, Latinos and Chinese
                                        Americans. South Asian women had
                                        similar CAC to whites and other ethnic
                                        women, although CAC burden higher in
                                        older age.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b> CAC
                                        predicts similarly in whites and those
                                        who identify as Hispanic/Latino.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> In MESA
                                        (Multi-Ethnic Study of
                                        Atherosclerosis), CAC score was
                                        highest in Caucasian and Hispanic men,
                                        with African-Americans having
                                        significantly lower prevalence and
                                        severity of CAC.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>Risk factor
                                        differences in MESA between
                                        ethnicities didn’t fully explain
                                        variability in CAC However, CAC
                                        predicted ASCVD events over and above
                                        traditional risk factors in all
                                        ethnicities.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">TREATMENT </span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <div data-bind="" class="nested-accordion">
                              <div class="lifestyle-counseling">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.lifestyle-counseling')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    Lifestyle counseling (Utilize principles
                                    of Mediterranean & DASH diets)</span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> Utilize
                                        lifestyle counseling to recommend a
                                        heart healthy diet consistent with
                                        ethnic preferences to avoid weight
                                        gain, address BP and lipids.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b>
                                        Utilize lifestyle counseling to
                                        recommend a heart healthy diet
                                        consistent with ethnic preferences to
                                        avoid weight gain, address BP and
                                        lipids.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> Utilize
                                        lifestyle counseling to recommend a
                                        heart healthy diet consistent with
                                        ethnic preferences to avoid weight
                                        gain, address BP and lipids.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b> Need to disaggregate
                                        Asian and Hispanic/Latino groups due
                                        to regional differences in lifestyle
                                        preferences. Challenge is to avoid
                                        increased sodium, sugar and calories
                                        as groups acculturate.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="intensity-of-statin-therapy">
                                <h2 class="nested-toggle with-underline"
                                  onclick="nestedPanelVisibleToggle('.intensity-of-statin-therapy')">
                                  <i class="fa fa-holder"></i><span class="text">
                                    Intensity of statin therapy and response
                                    to LDL-C lowering
                                  </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> Japanese
                                        patients may be sensitive to statin
                                        dosing. In an open-label, randomized
                                        primary prevention trial, Japanese
                                        participants had a reduction in CVD
                                        events with low-intensity doses of
                                        pravastatin as compared to placebo. In
                                        a secondary prevention trial, Japanese
                                        participants with CAD benefitted from
                                        a moderate-intensity doses of
                                        pitavastatin.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b> No
                                        sensitivity to statin dosage compared
                                        to non-Hispanic white or black
                                        individuals.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> No
                                        sensitivity to statin dosage compared
                                        to non-Hispanic white individuals.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>Using a lower statin
                                        intensity in Japanese patients may
                                        give results similar to those seen
                                        with higher intensities in
                                        non-Japanese patients.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="safety">
                                <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.safety')">
                                  <i class="fa fa-holder"></i><span class="text"> Safety </span>
                                </h2>
                                <div class="nested-collapsable-panel" style="display: none">
                                  <div class="content">
                                    <div class="row">
                                      <p class="text">
                                        <b>Asian-Americans:</b> Higher
                                        rosuvastatin plasma levels in
                                        Japanese, Chinese, Malay, and Asian-
                                        Indians compared to white. FDA
                                        recommends a lower starting dose (5 mg
                                        of rosuvastatin in Asians vs. 10 mg in
                                        whites). Caution urged as dose
                                        uptitrated.
                                      </p>
                                      <p class="text">
                                        <b>Hispanic/Latino-Americans:</b> No
                                        specific safety issues with statins
                                        related to Hispanic/Latino status.
                                      </p>
                                      <p class="text">
                                        <b>African-Americans:</b> Baseline
                                        serum CK values are higher in AA than
                                        in whites. The 95th percentile
                                        race/ethnic specific and sex-specific
                                        serum CK normal levels are available
                                        for assessing changes in serum CK.
                                      </p>
                                      <p class="text">
                                        <b>Comments: </b>Clinicians should
                                        take Asian ethnicity into account when
                                        prescribing dose of rosuvastatin (see
                                        package insert). In adults of East
                                        Asian descent, other statins should be
                                        used preferentially over simvastatin.
                                      </p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="row">
                      <p class="text">
                        <sup>*</sup>The term Asian characterizes a diverse
                        population group. Individuals from Bangladesh, India,
                        Nepal, Pakistan and Sri Lanka make up the majority of
                        the South Asian group. Individuals from Japan, Korea,
                        and China make up the majority of the East Asian
                        group.
                      </p>
                      <p class="text">
                        <sup>†</sup>The term Hispanics/Latinos in the United
                        States characterizes a diverse population group. This
                        includes white, black, and Native American races.
                        Their ancestry goes from Europe to America, including
                        among these, individuals from the Caribbean, Mexico,
                        Central and South America
                      </p>
                    </div>
                  </div>

                  <div data-bind="page: {id: 'secondary_prevention', afterShow: listchange, beforeShow: panzoom}"
                    class="group-section">
                    <h1 class="with-underline">
                      Secondary Prevention - Patients with Clinical ASCVD
                    </h1>
                    <div class="holder">
                      <div class="button-group small panzoom-buttons expanded panzoom-buttons-custom">
                        <button class="zoom-in button icon-only secondary" formnovalidate>
                          <i class="fa fa-plus-circle"></i>
                          <span class="text">Zoom In</span>
                        </button>
                        <button class="zoom-out button icon-only secondary" formnovalidate>
                          <i class="fa fa-minus-circle"></i>
                          <span class="text">Zoom Out</span>
                        </button>
                        <button class="reset ui-btn button icon-only secondary" formnovalidate>
                          <i class="fa fa-refresh"></i>
                          <span class="text">Reset</span>
                        </button>
                      </div>
                      <div class="parent panzoom" style="margin: 0">
                        <div class="panzoom-element">
                          
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id: 'ldlc_treatment_younger_patients', afterShow: listchange}"
                    class="group-section">
                    <h1 class="with-underline">
                      LDL-C Treatment Suggestions for Younger Patients
                    </h1>
                    <p>
                      The following is a summary of some of the key
                      suggestions for primary prevention in patients age 20-39
                      provided by the 2018 ACC/AHA Cholesterol Guideline.
                    </p>
                    <ul>
                      <li>
                        In patients without phenotypically severe
                        hypercholesterolemia:<br />
                        - Expert consensus discussion suggests beginning risk
                        assessment by estimating lifetime risk. Multiple risk
                        factors indicate lifestyle intervention.
                      </li>
                      <li>
                        In patients with persistent, moderate
                        hypercholesterolemia (LDL-C 160-189 mg/dL (4.1-4.8
                        mmol/L)):<br />
                        - Expert consensus discussion suggests that lifestyle
                        intervention is indicated, and long-term statin
                        therapy would be beneficial, especially for those with
                        other risk enhancing factors.
                      </li>
                      <li>
                        In patients with severe hypercholesterolemia (LDL-C
                        >190 mg/dL (≥4.9 mmol/L)):<br />
                        - Expert consensus discussion suggests lifestyle
                        intervention is indicated.<br />
                        - Guideline also recommends maximally tolerated
                        therapy statin therapy. (I, B)<br />
                        - If recommended LDL-C reduction of > 50% is not
                        achieved, then possible addition of non-statin
                        therapies is also recommended.
                      </li>
                      <li>
                        In patients with diabetes either of long duration (≥10
                        years of T2D, ≥20 years of T1D), and/or albuminuria
                        (≥30 mcg albumin/mg creatinine), eGFR &lt;60
                        ml/min/m², retinopathy, neuropathy:<br />
                        - Expert consensus discussion suggests lifestyle
                        intervention is indicated.<br />
                        - Guideline recommends that it may be reasonable to
                        initiate statin therapy. (IIb, C)
                      </li>
                    </ul>
                  </div>

                  <div data-bind="page: {id: 'discussion_checklist', afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Discussion Checklist for Therapy Initiation
                    </h1>
                    <table class="table checklist-therapy">
                      <thead>
                        <tr>
                          <th class="small-4">Checklist Item</th>
                          <th class="small-8">Recommendation</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>ASCVD Risk Assessment</td>
                          <td>
                            <ul>
                              <li>
                                Assign to statin treatment group; use ASCVD
                                risk estimator plus
                                <ul>
                                  <li>
                                    In lower risk primary prevention adults
                                    40-75 years with LDL-C ≥70 mg/dL(≥1.8
                                    mmol/L) . Not needed in secondary
                                    prevention, LDL-C ≥190 mg/dL (≥4.9 mmol/L)
                                    and those 40-75 years with diabetes.
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Assess other patient characteristics which
                                influence risk. See Risk Enhancing Factors
                              </li>
                              <li>
                                Assess calcium artery calcium if risk decision
                                uncertain and additional information is needed
                                to clarify ASCVD risk
                                <ul>
                                  <li>
                                    Use decision tools to explain risk (such
                                    as this app, Mayo Clinic Statin Choice
                                    Decision Aid)
                                  </li>
                                </ul>
                              </li>
                            </ul>
                          </td>
                        </tr>
                        <tr>
                          <td>Lifestyle Modifications</td>
                          <td>
                            <ul>
                              <li>
                                Review lifestyle habits (diet, physical
                                activity, weight/BMI, tobacco use)
                              </li>
                              <li>
                                Endorse a healthy lifestyle and provide
                                relevant advice/materials/referrals
                                (CardioSmart, AHA Life's Simple 7, NLA Patient
                                Tear Sheets, PCNA Clinicians' Lifestyle
                                Modification Toolbox, cardiac rehab,
                                dietitian, smoking cessation program)
                              </li>
                            </ul>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            Potential Net-Clinical Benefit of Pharmacotherapy
                          </td>
                          <td>
                            <ul>
                              <li>Recommend statins as first-line therapy</li>
                              <li>
                                Consider the combination of statin and
                                non-statin therapy in select patients
                              </li>
                              <li>
                                Discuss potential risk reduction from
                                lipid-lowering therapy
                              </li>
                              <li>
                                Discuss the potential for adverse
                                effects/drug-drug interactions
                              </li>
                            </ul>
                          </td>
                        </tr>
                        <tr>
                          <td>Cost Considerations</td>
                          <td>
                            <ul>
                              <li>
                                Discuss potential out-of-pocket cost of
                                therapy to the patient (e.g., insurance plan
                                coverage, tier level, copayment)
                              </li>
                            </ul>
                          </td>
                        </tr>
                        <tr>
                          <td>Shared Decision Making</td>
                          <td>
                            <ul>
                              <li>
                                Encourage patient to verbalize what was heard
                                (personal ASCVD risk, available options and
                                their risk/benefit)
                              </li>
                              <li>
                                Invite the patient to ask questions, express
                                values/preferences, state ability to adhere to
                                lifestyle changes and medications
                              </li>
                              <li>
                                Refer patients to trustworthy materials to aid in their understanding of issues
                                regarding risk decisions.
                              </li>
                              <li>
                                Collaborate with the patient to determine
                                therapy and follow-up plan
                              </li>
                            </ul>
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </div>

                  <div data-bind="page: {id: 'cac_score_inform_decisions', afterShow: listchange}"
                    class="group-section">
                    <h1 class="with-underline">
                      Using CAC Score to Inform Decisions
                    </h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Specific CAC Guideline Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <table class="recommendationTable table">
                              <tbody>
                                <tr>
                                  <td><b>COR</b></td>
                                  <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                                  <td class="text-center">
                                    <b>Recommendations</b>
                                  </td>
                                </tr>
                                <tr>
                                  <td class="CORIIa">IIa</td>
                                  <td class="LOE-B">B-NR</td>
                                  <td>
                                    In intermediate-risk or selected
                                    borderline-risk adults, if the decision
                                    about statin usage remains uncertain, it
                                    is reasonable to use a coronary artery
                                    calcium (CAC) score in the decision to
                                    withhold, postpone or initiate statin
                                    therapy.
                                  </td>
                                </tr>
                                <tr>
                                  <td class="CORIIa">IIa</td>
                                  <td class="LOE-B">B-NR</td>
                                  <td>
                                    In intermediate-risk adults or selected
                                    borderline-risk adults in whom a CAC score
                                    is measured for the purpose of making a
                                    treatment decision, AND
                                    <ul>
                                      <li>
                                        If CAC=0, it is reasonable to withhold
                                        statin therapy and reassess CAC score
                                        in 5-10 years, as long as higher risk
                                        conditions are absent (diabetes
                                        mellitus, family history of premature
                                        CHD, cigarette smoking)
                                      </li>
                                      <li>
                                        If CAC= 1 to 99, it is reasonable to
                                        initiate statin therapy for patients ≥
                                        55 years of age;
                                      </li>
                                      <li>
                                        If CAC≥ 100 or CAC ≥ 75<sup>th</sup>
                                        percentile, it is reasonable to
                                        initiate statin therapy.
                                      </li>
                                    </ul>
                                  </td>
                                </tr>
                                <tr>
                                  <td class="CORIIb">IIb</td>
                                  <td class="LOE-B">B-R</td>
                                  <td>
                                    In adults 76-80 years of age with LDL-C of
                                    70 to 189 mg/dL (1.7 to 4.8 mmol/L), it
                                    may be reasonable to measure coronary
                                    artery calcium (CAC) to reclassify those
                                    with CAC = 0 to avoid statin therapy.
                                  </td>
                                </tr>
                              </tbody>
                            </table>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Specific CAC Score Ethnicity
                            Considerations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <div class="table-scroll">
                              <table class="table">
                                <thead>
                                  <tr>
                                    <th>&nbsp;</th>
                                    <th colspan="4" class="text-center">
                                      Ethnic/racial groupings
                                    </th>
                                  </tr>
                                </thead>
                                <tbody>
                                  <tr>
                                    <td>&nbsp;</td>
                                    <td>
                                      <b>Asian-Americans<sup>*</sup></b>
                                    </td>
                                    <td>
                                      <b>Hispanic/Latino-Americans<sup>†</sup></b>
                                    </td>
                                    <td><b>African-Americans </b></td>
                                    <td><b>Comments:</b></td>
                                  </tr>
                                  <tr>
                                    <td>
                                      <b>Coronary Artery Calcium (CAC) Score
                                      </b>
                                    </td>
                                    <td>
                                      In terms of CAC burden, South Asian men
                                      were similar to non-Hispanic white men,
                                      but higher CAC when compared to African
                                      Americans, Latinos and Chinese
                                      Americans. South Asian women had similar
                                      CAC to whites and other ethnic women,
                                      although CAC burden higher in older age.
                                    </td>
                                    <td>
                                      CAC predicts similarly in whites and
                                      those who identify as Hispanic/Latino.
                                    </td>
                                    <td>
                                      In MESA (Multi-Ethnic Study of
                                      Atherosclerosis), CAC score was highest
                                      in Caucasian and Hispanic men, with
                                      African-Americans having significantly
                                      lower prevalence and severity of CAC.
                                    </td>
                                    <td>
                                      Risk factor differences in MESA between
                                      ethnicities didn’t fully explain
                                      variability in CAC However, CAC
                                      predicted ASCVD events over and above
                                      traditional risk factors in all
                                      ethnicities.
                                    </td>
                                  </tr>
                                </tbody>
                              </table>
                            </div>
                            <div class="row">
                              <p class="text">
                                <sup>*</sup>The term Asian characterizes a
                                diverse population group. Individuals from
                                Bangladesh, India, Nepal, Pakistan and Sri
                                Lanka make up the majority of the South Asian
                                group. Individuals from Japan, Korea, and
                                China make up the majority of the East Asian
                                group.
                              </p>
                              <p class="text">
                                <sup>†</sup> The term Hispanics/Latinos in the
                                United States characterizes a diverse
                                population group. This includes white, black,
                                and Native American races. Their ancestry goes
                                from Europe to America, including among these,
                                individuals from the Caribbean, Mexico,
                                Central and South America
                              </p>
                            </div>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>

                  <div data-bind="page: {id:'immunization_practice',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">Standards for Adult Immunization Practice</h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Why Focus on Adult Immunizations? </span></h2>
                        <div class="collapsable-panel ">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>ACC is part of a consortium of medical specialty societies - <a href="https://cmss.org/improving-adult-immunization-rates/" target="_blank" title="Specialty Societies Advancing Adult Immunization - A Cooperative Agreement with the CDC - CMSS"><i><u>Specialty Societies Advancing Adult Immunization</u></i></a> - funded through CDC and supported by CMSS to provide vaccination resources to cardiovascular clinicians, including education and learning opportunities, clinical practice guidance, and quality improvement initiatives.</p>
                            <p><b><i>Why focus on adult immunizations?</i></b></p>
                            <ul>
                              <li>Adult vaccination rates are extremely low.</li>
                              <li>Most adults are NOT aware that they need vaccines.</li>
                              <li>Recommendation from their healthcare professional is the strongest predictor of whether patients get vaccinated.</li>
                              <li>There are many missed opportunities for vaccination because many healthcare professionals are not routinely assessing vaccination status.</li>
                            </ul>

                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Standard Steps for All Healthcare Professionals</span></h2>
                        <div class="collapsable-panel ">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">

                            <p>The National Vaccine Advisory Committee (NVAC) revised the a Standards for Adult Immunization Practice in 2013. View the most recent <a href="https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html" title="Standards for Adult Immunization Practices | CDC" target="_blank"><u>Standards for Adult Immunization Practice</u></a> on the CDC website. These updated standards call on ALL healthcare professionals — whether they provide vaccinations or not — to take steps to help ensure that their adult patients are fully immunized. These steps are as follows:</p>

                            <div data-bind="" class="nested-accordion">
                              <div class="assess-immunization">
                                <h4 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.assess-immunization')"><i class="fa fa-holder"></i><span class="text">Assess <small>immunization status of all your patients at every clinical encounter.</small></span></h4>
                                <div class="nested-collapsable-panel " style="display:none;">
                                  <div class="content">
                                    <div class="row">
                                      <p>All healthcare providers are called upon to help ensure that their adult patients are fully immunized:</p>
                                      <ul>
                                        <li>Stay informed. Get the latest CDC recommendations for immunization of adults.</li>
                                        <li>Implement protocols and policies. Ensure that patients’ vaccine needs are routinely reviewed, and patients get reminders about vaccines they need.</li>
                                      </ul>

                                      <p>Assessment is the critical first step in ensuring that your adult patients get the vaccines they need for protection against serious vaccine-preventable diseases.<br><br>

                                        Your patients’ vaccination needs will change over time based on factors such as:</p>
                                      <ul>
                                        <li>Age</li>
                                        <li>health conditions</li>
                                        <li>lifestyle</li>
                                        <li>travel</li>
                                        <li>occupation</li>
                                      </ul>

                                      <p>Adults think immunization is important, but most are not aware of all the vaccines they need. They rely on you to tell them which vaccines are recommended for them.​</p>

                                      <p><b>Whether you provide vaccines or not, assess immunization status at every clinical encounter.​</b></p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="recommend-vaccines">
                                <h4 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.recommend-vaccines')"><i class="fa fa-holder"></i><span class="text">Recommend <small>(strongly) the vaccines that patients need.</small></span></h4>
                                <div class="nested-collapsable-panel " style="display:none;">
                                  <div class="content">
                                    <div class="row">
                                      <p>For some patients, a recommendation might not be enough. <b>SHARE</b> important information to help patients make informed decisions about vaccinations:</p>
                                      <ul class="list-type-none">
                                        <li><b>S</b>HARE the tailored reasons why the recommended vaccine is right for the patient given his or her age, health status, lifestyle, occupation, or other risk factors.</li>
                                        <li><b>H</b>IGHLIGHT positive experiences with vaccines (personal or in your practice), as appropriate, to reinforce the benefits and strengthen confidence in vaccination.</li>
                                        <li><b>A</b>DDRESS patient questions and any concerns about the vaccine, including side effects, safety, and vaccine effectiveness in plain and understandable language.</li>
                                        <li><b>R</b>EMIND patients that vaccines protect them and their loved ones from many common and serious diseases.</li>
                                        <li><b>E</b>XPLAIN the potential costs of getting the disease, including serious health effects, time lost (such as missing work or family obligations), and financial costs.</li>
                                      </ul>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="vaccination-provider">
                                <h4 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.vaccination-provider')"><i class="fa fa-holder"></i><span class="text">Administer or Refer <small>your patients to a vaccination provider.</small></span></h4>
                                <div class="nested-collapsable-panel " style="display:none;">
                                  <div class="content">
                                    <div class="row">
                                      <p>Download the <a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-admin.pdf" target="_blank">Vaccine Administration</a> factsheet.</p>
                                      <p><b>There are a number of steps you can take to improve vaccine administration in your office and better protect your patients from vaccine-preventable diseases.</b></p>

                                      <ol>
                                        <li>
                                          <b>Recommend and offer vaccines at the same visit</b>. Research shows that when patients receive a vaccine recommendation and are offered the vaccine at the same time, they are more likely to get vaccinated.
                                          <ul>
                                            <li>For vaccines you don't stock, REFER patients to a local immunization provider that can vaccinate.</li>
                                            <li>There is an expanding network of immunization providers. For details, download this <b><a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-referral.pdf" target="_blank" title="Vaccine Referral: A Series on Standards for Adult Immunization Practice. (cdc.gov)">Vaccine Referral</a></b> factsheet.</li>
                                          </ul>
                                        </li>
                                        <li>
                                          <b><a href="https://www.cdc.gov/vaccines/ed/courses.html" title="Vaccine Courses, Broadcasts, Webcasts and Self Study Training | CDC" target="_blank">Train </a>and educate your staff on vaccine administration</b>. Help improve vaccine delivery and ensure patient safety.​
                                        </li>
                                        <li><b>Use <a href="https://www.immunize.org/standing-orders/" title="Vaccine Standing Orders for Healthcare Providers (immunize.org)" target="_blank">standing orders</a> or protocols (where allowed by state law) for vaccine administration</b>. Authorizing nurses, pharmacists, and other healthcare professionals to assess patient vaccine status and administer needed vaccinations without examination or direct order from the attending provider can save time and reduce missed opportunities for vaccination.</li>

                                        <li><b>Properly store and handle vaccines</b>. This critical step can reduce wastage. Review <a href="https://www.cdc.gov/vaccines/hcp/admin/storage/index.html" title="Vaccine Storage and Handling Resources | CDC" target="_blank">CDC recommendations and guidelines on vaccine storage and handling practices.</a></li>

                                        <li><b>Distribute <a href="https://www.cdc.gov/vaccines/hcp/vis/index.html" title="Vaccine Information Statements (VISs) | CDC" target="_blank">Vaccine Information Statements (VIS)</a> to patients</b>. Help your patients make informed decisions about vaccinations.</li>

                                        <li><b>Ensure proper care for patients</b>. Minimize potential risks to your patients by following safety protocols.</li>

                                        <li><b>Follow standard precautions to control infection</b>. Minimize the risks of spreading disease when administering vaccines. Review the <a target="_blank" title="Guide to Infection Prevention for Outpatient Settings: Minimum Expectations for Safe Care | HAI | CDC" href="https://www.cdc.gov/HAI/settings/outpatient/outpatient-care-guidelines.html">CDC Guide to Infection Prevention for Outpatient Care</a>.</li>
                                        <li>
                                          <b>Be aware of and prepared for potential adverse reactions</b>. All vaccines have the potential to cause adverse reactions. Most are minor (e.g., itching, soreness) but severe reactions (e.g., anaphylaxis), while rare, can occur. Make sure you and your staff are prepared to handle severe reactions.​
                                          <ul>
                                            <li><a href="https://www.immunize.org/catg.d/p3082.pdf" target="_blank" title="Medical Management of Vaccine Reactions in Adults in a Community Setting (immunize.org)">Review IAC's Chart of Medical Management of Vaccine Reactions in Adult Patients Procedures.</a></li>
                                            <li>Report any adverse events that occur following vaccination to the <a href="https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html" title="VAERS | Vaccine Safety | CDC​" target="_blank">Vaccine Adverse Events Reporting System (VAERS)</a>.</li>
                                          </ul>
                                        </li>
                                      </ol>
                                    </div>
                                  </div>
                                </div>
                              </div>
                              <div class="document-vaccines">
                                <h4 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.document-vaccines')"><i class="fa fa-holder"></i><span class="text">Document <small>vaccines received by your patients.</small></span></h4>
                                <div class="nested-collapsable-panel " style="display:none;">
                                  <div class="content">
                                    <div class="row">
                                      <ul>
                                        <li>Participate in your state's immunization registry. Help your office, your patients, and your patients' other providers know which vaccines your patients have had.</li>
                                        <li>Follow up. Confirm that patients received recommended vaccines that you referred them to get from other immunization providers.</li>
                                      </ul>

                                      <p>Keep an up-to-date record of the vaccines your patients have received to make sure they have the best protection against vaccine-preventable diseases. <br><br>

                                        To ensure patients get the vaccines they need and to prevent unnecessary vaccination, you should:</p>

                                      <ul>
                                        <li>Record vaccination in patients' medical records</li>
                                        <li>Provide documentation of vaccines received to patients for their personal records.</li>
                                        <li>Document vaccinations in immunization information systems (IIS)</li>
                                      </ul>

                                      <p><b>Immunization Information Systems (IIS)</b> <br><br>

                                        IIS are confidential, community-wide, computerized databases that record vaccines administered by participating healthcare professionals. <br><br>

                                        Documenting vaccines into IIS can benefit your practice by:</p>

                                      <ul>
                                        <li>Consolidating vaccination records for your patients.</li>
                                        <li>Helping you assess your patients' immunization status.</li>
                                        <li>Reducing chances for unnecessary doses of vaccine or missed opportunities to provide vaccines.</li>
                                        <li>Facilitating use of reminder and recall notifications to send to patients.</li>
                                        <li>Making calculation of your office's immunization coverage rates easier.</li>
                                      </ul>

                                      <p>Learn more about <a href="https://www.cdc.gov/vaccines/programs/iis/training.html" title="Training for Immunization Information System (IIS) | CDC" target="_blank">Immunization Information Systems (IIS)</a> or reach out to your <a href="https://www.cdc.gov/vaccines/programs/iis/contacts-locate-records.html" title="Contacts for Immunization Records | CDC​" target="_blank">state's main contact</a> regarding questions about your state or local registry.</p>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>

                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">External Resource Links</span></h2>
                        <div class="collapsable-panel ">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li><a href="https://www.acc.org/ClinicalSolutionsImmunization" target="_blank" title="">Advancing Adult Immunization - American College of Cardiology (acc.org)</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/hcp/adults/for-patients/index.html" target="_blank" title="">Resources for Educating Adult Patients about Vaccines | CDC</a></li>

                              <li><a href="https://www.izsummitpartners.org/adult-immunization-standards/" target="_blank" title="">Standards for Adult Immunization Practice - National Adult and Influenza Immunization Summit (izsummitpartners.org) </a></li>

                              <li><a href="https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html#notes" target="_blank" title="">Vaccines Indicated for Adults Based on Medical Indications | CDC</a></li>

                              <li><a href="https://journals.sagepub.com/doi/pdf/10.1177/003335491412900203" target="_blank" title="">Recommendations from the National Vaccine Advisory Committee: Standards for Adult Immunization Practice (sagepub.com)</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html" target="_blank" title="">Adult Immunization Schedule by Vaccine and Age Group | CDC</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-adults.pdf" target="_blank" title="">Immunizing Adult Patients: Standards for Practice. (cdc.gov)</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice.pdf" target="_blank" title="">Overview: A Series on Standards for Adult Immunization Practice. (cdc.gov)</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-assessment.pdf" target="_blank" title="">Vaccine Needs Assessment: A Series on Standards for Adult Immunization Practice. (cdc.gov)</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-recommendation.pdf" target="_blank" title="">Vaccine Recommendation (cdc.gov)</a></li>

                              <li><a href="https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-admin.pdf" target="_blank" title="">Vaccine Administration: A Series on Standards for Adult Immunization Practice. (cdc.gov)</a></li>

                              <li><a href="https://cmss.org/improving-adult-immunization-rates/" target="_blank" title="">Specialty Societies Advancing Adult Immunization - A Cooperative Agreement with the CDC - CMSS</a></li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>

                  <div data-bind="page: {id:'statin',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Groups that Benefit from Statin Therapy
                    </h1>

                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">1. Secondary Prevention:</span>
                          <span class="sub-line">Clinical ASCVD</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Clinical ASCVD includes acute coronary
                              syndromes, history of MI, stable or unstable
                              angina, coronary or other arterial
                              revascularization, stroke, TIA, or peripheral
                              arterial disease presumed to be of
                              atherosclerotic origin.
                            </p>

                            <p>
                              High-intensity statin therapy should be
                              initiated or continued as first-line therapy in
                              women and men &le;75 years of age who have
                              clinical ASCVD, unless contraindicated. (I A)
                            </p>

                            <p>
                              In individuals with clinical ASCVD in whom
                              high-intensity statin therapy would otherwise be
                              used, when high-intensity statin therapy is
                              contraindicated or when characteristics
                              predisposing to statin-associated adverse
                              effects are present, moderate-intensity statin
                              should be used as the second option if
                              tolerated. (I A)
                            </p>

                            <p>
                              In individuals with clinical ASCVD &gt;75 years
                              of age, it is reasonable to evaluate the
                              potential for ASCVD risk-reduction benefits and
                              for adverse effects, drug-drug interactions and
                              to consider patient preferences, when initiating
                              a moderate- or high-intensity statin. It is
                              reasonable to continue statin therapy in those
                              who are tolerating it. (IIa B)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">2. Primary Prevention: </span>
                          <span class="sub-line">LDL-C &ge;190 mg/dL</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Individuals with LDL-C &ge;190 mg/dL or
                              triglycerides &ge;500 mg/dL should be evaluated
                              for secondary causes of hyperlipidemia. (I B)
                            </p>

                            <p>
                              Adults &ge;21 years of age with primary LDL-C
                              &ge;190 mg/dL should be treated with
                              high-intensity statin therapy unless
                              contraindicated. For individuals unable to
                              tolerate high-intensity statin therapy, use the
                              maximum tolerated statin intensity. (I B)
                            </p>

                            <p>
                              For individuals &ge;21 years of age with an
                              untreated primary LDL-C &ge;190 mg/dL, it is
                              reasonable to intensify statin therapy to
                              achieve at least a 50% LDL-C reduction. (IIa B)
                            </p>

                            <p>
                              For individuals &ge;21 years of age with an
                              untreated primary LDL-C &ge;190 mg/dL, after the
                              maximum intensity of statin therapy has been
                              achieved, addition of a nonstatin drug may be
                              considered to further lower LDL-C. Evaluate the
                              potential for ASCVD risk reduction benefits,
                              adverse effects, drug-drug interactions, and
                              consider patient preferences. (IIb C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">3. Primary Prevention:</span><span
                            class="sub-line">
                            Diabetes and aged 40 to 75 years with LDL-C
                            between 70 - 189 mg/dL</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Moderate-intensity statin therapy should be
                              initiated or continued for adults 40 to 75 years
                              of age with diabetes mellitus. (I A)
                            </p>

                            <p>
                              High-intensity statin therapy is reasonable for
                              adults 40 to 75 years of age with diabetes
                              mellitus with a &ge;7.5% estimated 10-year ASCVD
                              risk unless contraindicated. (IIa B)
                            </p>

                            <p>
                              In adults with diabetes mellitus, who are &lt;40
                              or &gt;75 years of age, it is reasonable to
                              evaluate the potential for ASCVD benefits and
                              for adverse effects, for drug-drug interactions,
                              and to consider patient preferences when
                              deciding to initiate, continue, or intensify
                              statin therapy. (IIa C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">4. Primary Prevention: </span><span
                            class="sub-line">No diabetes and estimated 10-year ASCVD risk of
                            &ge;7.5% who are between 40 to 75 years of age
                            with LDL-C between 70 - 189 mg/dL</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              The Pooled Cohort Equations should be used to
                              estimate 10-year ASCVD risk for individuals with
                              LDL-C 70 to 189 mg/dL without clinical ASCVD to
                              guide initiation of statin therapy for the
                              primary prevention of ASCVD. (I B)
                            </p>

                            <p>
                              Before initiating statin therapy for the primary
                              prevention of ASCVD in adults with LDL-C 70 -
                              189 mg/dL without clinical ASCVD or diabetes it
                              is reasonable for clinicians and patients to
                              engage in a discussion which considers the
                              potential for ASCVD risk reduction benefits and
                              for adverse effects, for drug-drug interactions,
                              and patient preferences for treatment. (IIa C)
                            </p>

                            <p>
                              Adults 40 to 75 years of age with LDL-C 70 to
                              189 mg/dL, without clinical ASCVD or diabetes
                              and an estimated 10-year ASCVD risk &ge;7.5%
                              should be treated with moderate- to
                              high-intensity statin therapy. (I A)
                            </p>

                            <p>
                              It is reasonable to offer treatment with a
                              moderate-intensity statin to adults 40 to 75
                              years of age, with LDL-C 70 to 189 mg/dL,
                              without clinical ASCVD or diabetes and an
                              estimated 10-year ASCVD risk of 5% to &lt;7.5%.
                              (IIa B)
                            </p>

                            <p>
                              In adults with LDL-C &lt;190 mg/dL who are not
                              otherwise identified in a statin benefit group,
                              or for whom after quantitative risk assessment a
                              risk-based treatment decision is uncertain,
                              additional factors may be considered to inform
                              treatment decision making. In these individuals,
                              statin therapy for primary prevention may be
                              considered after evaluating the potential for
                              ASCVD risk reduction benefits, adverse effects,
                              drug-drug interactions, and discussion of
                              patient preferences. (IIb C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Additional Factors</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p><strong>These factors may include:</strong></p>
                            <p>
                              Statin benefit may be less clear in other
                              groups; additional factors may be considered to
                              inform treatment decision making.
                            </p>
                            <ol>
                              <li>5 to &lt;7.5% 10-year ASCVD risk</li>
                              <li>
                                Primary LDL-C &ge;160 mg/dL or other evidence
                                of genetic hyperlipidemias
                              </li>
                              <li>Family history of premature ASCVD</li>
                              <li>
                                High sensitivity C-reactive protein &ge;2 mg/L
                              </li>
                              <li>
                                Coronary artery calcium score &ge;300 Agatston
                                units or &ge;75th percentile for age, sex, and
                                ethnicity
                              </li>
                              <li>Ankle-brachial index &lt;0.9</li>
                              <li>Lifetime risk of ASCVD</li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'summary_recommendations',afterShow: listchange}" class="group-section">
                    <h1>General Populations Recommendation Summary</h1>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Primary Prevention Recommendations for Adults
                            40-75 Years LDL 70-189 mg/dL (1.7 - 4.8 mmol/L)
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. In adults at intermediate-risk, statin therapy
                            reduces risk of ASCVD and in the context of a risk
                            discussion, if a decision is made for statin
                            therapy, a moderate- intensity statin should be
                            recommended.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            2. In intermediate risk patients, LDL-C levels
                            should be reduced by ≥ 30%, and for optimal ASCVD
                            risk reduction, especially in high-risk patients,
                            achieve LDL-C reductions of ≥ 50%.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            3. For the primary prevention of clinical ASCVD*
                            in adults 40 to 75 years of age without diabetes
                            and with LDL-C 70 to 189 mg/dL (1.7 to 4.8
                            mmol/L), the 10-year ASCVD risk of a first "hard"
                            ASCVD event (fatal and non-fatal MI or stroke)
                            should be estimated using the race and
                            sex-specific Pooled Cohort Equations (PCE) and
                            adults should be categorized as low risk (<5%), borderline risk (5 to <7.5%),
                              intermediate-risk (≥7.5 to <20%), and high-risk (≥20%). </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            4. Clinicians and patients should engage in a risk
                            discussion that considers risk factors, adherence
                            to healthy lifestyle, the potential for ASCVD
                            risk-reduction benefits and the potential for
                            adverse effects and drug–drug interactions, as
                            well as patient preferences for an individualized
                            treatment decision.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            5. In intermediate-risk adults, risk-enhancing
                            factors favor initiation or intensification of
                            statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            6. In intermediate-risk or selected
                            borderline-risk adults, if the decision about
                            statin usage remains uncertain, it is reasonable
                            to use a coronary artery calcium (CAC) score in
                            the decision to withhold, postpone or initiate
                            statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            7. In intermediate-risk adults or selected
                            borderline-risk adults in whom a CAC score is
                            measured for the purpose of making a treatment
                            decision, AND
                            <ul>
                              <li>
                                If CAC=0, it is reasonable to withhold statin
                                therapy and reassess CAC score in 5-10 years,
                                as long as higher risk conditions are absent
                                (diabetes mellitus, family history of
                                premature CHD, cigarette smoking)
                              </li>
                              <li>
                                If CAC= 1 to 99, it is reasonable to initiate
                                statin therapy for patients ≥ 55 years of age;
                              </li>
                              <li>
                                If CAC≥ 100 or CAC ≥ 75<sup>th</sup>
                                percentile, it is reasonable to initiate
                                statin therapy.
                              </li>
                            </ul>
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            8. In intermediate-risk adults who would benefit
                            from more aggressive LDL-C lowering and in whom
                            high-intensity statins are advisable, but not
                            acceptable or tolerated, it may be reasonable to
                            add a non-statin drug (ezetimibe or bile acid
                            sequestrant) to a moderate-intensity statin.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            9. In patients at borderline risk, in risk
                            discussion, the presence of risk-enhancing factors
                            may justify initiation of moderate-intensity
                            statin therapy.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommendations for Older Adults
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            1. In adults > 75 years of age with LDL-C of 70 to
                            189 mg/dL (1.7 to 4.8 mmol/L), initiating a
                            moderate- intensity statin may be reasonable.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            2. In adults > 75 years of age, it may be
                            reasonable to stop statin therapy when functional
                            decline (physical or cognitive), multimorbidity,
                            frailty or reduced life expectancy limit the
                            potential benefits of statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In adults 76-80 years of age with LDL-C of 70
                            to 189 mg/dL (1.7 to 4.8 mmol/L), it may be
                            reasonable to measure coronary artery calcium
                            (CAC) to reclassify those with CAC = 0 to avoid
                            statin therapy.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommendations for Patients with Diabetes
                            Mellitus
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. In adults 40 to 75 years of age with diabetes,
                            regardless of estimated 10-year ASCVD risk,
                            moderate-intensity statin therapy is indicated.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            2. In adults with diabetes who are 40 to 75 years
                            of age and have LDL-C 70 to 189 mg/dL (1.7 to 4.8
                            mmol/L), it is reasonable to assess the 10-year
                            risk of a first ASCVD event using the race and
                            sex-specific Pooled Cohort Equations (PCE) to help
                            stratify ASCVD risk.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In adults with diabetes who have multiple ASCVD
                            risk factors, it is reasonable to prescribe
                            high-intensity statin therapy with the aim to
                            reduce LDL-C by ≥50%.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            4. In adults with diabetes older than 75 years of
                            age who are already on statin therapy, it is
                            reasonable to continue statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            5. In adults with diabetes and 10-year ASCVD risk
                            ≥20%, it may be reasonable to add ezetimibe to
                            maximum tolerated statin therapy to reduce LDL-C
                            by ≥50%.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            6. In adults with diabetes older than 75 years,
                            after a patient discussion of potential benefits
                            and risks, it may be reasonable to initiate statin
                            therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            7. In adults 20 to 39 years of age with diabetes
                            either of long duration (≥10 years of Type 2
                            diabetes, ≥20 years of Type 1), and/or albuminuria
                            (≥30 mcg albumin/mg creatinine), eGFR <60 ml/min/m², retinopathy, neuropathy, it may be
                              reasonable to initiate statin therapy. </td>
                        </tr>
                      </tbody>
                    </table>

                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommendations for Primary Severe
                            Hypercholesterolemia (LDL-C ≥ 190 mg/dL (≥ 4.9
                            mmol/L))
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            1. In patients 20 to 75 years of age with LDL-C
                            ≥190 mg/dL (≥4.9 mmol/L), maximally-tolerated
                            statin therapy is recommended.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            2. In patients 20 to 75 years of age with LDL-C ≥
                            190 mg/dL (≥4.9 mmol/L), who achieve less than 50%
                            reduction in LDL-C while receiving
                            maximally-tolerated statin therapy, and/or have an
                            LDL-C-≥100 mg/dL (≥2.6 mmol/L), ezetimibe therapy
                            is reasonable.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In patients 20 to 75 years of age with a
                            baseline LDL-C ≥190 mg/dL (≥4.9 mmol/L), who
                            achieve less than 50% reduction in LDL-C and have
                            fasting triglycerides >300 mg/dL (>3.4 mmol/L)
                            while taking maximally-tolerated statin and
                            ezetimibe therapy, the addition of a bile acid
                            sequestrant may be considered.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            4. In heterozygous familial hypercholesterolemia
                            patients 30 to 75 years of age with LDL-C ≥100
                            mg/dL (≥2.6 mmol/L) while taking
                            maximally-tolerated statin and ezetimibe therapy,
                            the addition of a PCSK9 inhibitor may be
                            considered.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            5. In patients 40 to 75 years of age with a
                            baseline LDL-C ≥220 mg/dL (≥5.7 mmol/L) who
                            achieve on treatment LDL-C ≥130 mg/dL (≥3.4
                            mmol/L), while receiving maximally-tolerated
                            statin and ezetimibe therapy, the addition of a
                            PCSK9 inhibitor may be considered.
                          </td>
                        </tr>
                        <tr>
                          <td colspan="2" class="text-center">
                            Value Statement: Uncertain Value (B-NR)
                          </td>
                          <td>
                            6. Among patients with familial
                            hypercholesterolemia without evidence of clinical
                            ASCVD taking maximally-tolerated statin and
                            ezetimibe therapy, PCSK9 inhibitors provide
                            uncertain value at 2018 US list prices.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommendations for Statin Therapy Use in Patients
                            with ASCVD
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. In patients ≤75 years of age with clinical
                            ASCVD*, high-intensity statin therapy should be
                            initiated or continued with the aim of achieving a
                            ≥50% reduction in LDL-C.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            2. In patients with clinical ASCVD in whom
                            high-intensity statin therapy is contraindicated
                            or who experience statin-associated side effects,
                            moderate-intensity statin therapy should be
                            initiated or continued with the aim of achieving a
                            30-49% reduction in LDL-C.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            3. In patients with clinical ASCVD, who are judged
                            to be very high-risk and considered for PCSK9
                            therapy, maximally tolerated LDL-C lowering
                            therapy should include maximally tolerated statin
                            therapy and ezetimibe
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">A <sup>SR</sup></td>
                          <td>
                            4. In patients with clinical ASCVD, who are judged
                            to be very high-risk and who are on maximally
                            tolerated LDL-C lowering therapy with LDL-C ≥70
                            mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg/dL (≥2.6
                            mmol/L), it is reasonable to add a PCSK9 inhibitor
                            following a clinician-patient discussion about the
                            net benefit, safety, and cost.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            5. In patients with clinical ASCVD who are on
                            maximally tolerated statin therapy and are judged
                            to be at very high-risk, and have LDL-C ≥70 mg/dL
                            (≥1.8 mmol/L), it is reasonable to add ezetimibe
                            therapy.
                          </td>
                        </tr>

                        <tr>
                          <td colspan="2" class="text-center">
                            Value Statement: Low Value (LOE: B-NR)
                          </td>
                          <td>
                            6. At mid-2018 list prices, PCSK9 inhibitors have
                            a low-cost value (>$150,000 per QALY) compared to
                            good cost value (&lt;$50,000 per QALY) (Section 7
                            of the Guideline provides a full discussion of the
                            dynamic interaction of different prices and
                            clinical benefit)
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            7. In patients with clinical ASCVD older than 75
                            years, it is reasonable to initiate moderate or
                            high-intensity statin therapy after evaluating the
                            potential for ASCVD risk-reduction, adverse
                            effects, drug-drug interactions, frailty, and
                            patient preferences.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            8. In patients with clinical ASCVD older than 75
                            years of age who are tolerating high-intensity
                            statin therapy, it is reasonable to continue
                            high-intensity statin therapy after evaluating the
                            potential for ASCVD risk-reduction, adverse
                            effects, drug-drug interactions, frailty, and
                            patient preferences.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            9. In patients with clinical ASCVD who are
                            receiving maximally tolerated statin therapy and
                            LDL-C remains ≥70 mg/dL (≥1.8 mmol/L), it may be
                            reasonable to add ezetimibe.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            10. In patients with heart failure with reduced
                            ejection fraction due to ischemic heart disease
                            who have a reasonable life expectancy (3-5 years)
                            and are not already on a statin due to ASCVD,
                            clinicians may consider initiation of
                            moderate-intensity statin therapy to reduce the
                            occurrence of ASCVD events.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <div data-bind="page: {id:'guideline_flowchart',afterShow: listchange, beforeShow: panzoom}"
                    class="group-section flow-chart">
                    <h1>Primary Prevention of ASCVD - Summary</h1>
                    <div class="button-group small panzoom-buttons expanded">
                      <button class="zoom-in button icon-only secondary" formnovalidate>
                        <i class="fa fa-plus-circle"></i>
                        <span class="text">Zoom In</span>
                      </button>
                      <button class="zoom-out button icon-only secondary" formnovalidate>
                        <i class="fa fa-minus-circle"></i>
                        <span class="text">Zoom Out</span>
                      </button>
                      <button class="reset ui-btn button icon-only secondary" formnovalidate>
                        <i class="fa fa-refresh"></i>
                        <span class="text">Reset</span>
                      </button>
                    </div>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <img src="img/primary_prevention.PNG" alt="primary prevention" style="width: 100%" />
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'statin_dose_resource_section',afterShow: listchange}"
                    class="group-section">
                    <h1 class="with-underline">
                      Intensities of Statin Therapy
                    </h1>
                    <div class="row">
                      <p>
                        <b>High-, Moderate-, and Low-Intensity Statin
                          Therapy</b>
                      </p>
                      <table class="table checklist-therapy">
                        <thead>
                          <tr>
                            <th>&nbsp;</th>
                            <th><b>High-Intensity</b></th>
                            <th><b>Moderate-Intensity</b></th>
                            <th><b>Low-Intensity</b></th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td><b>LDL-C </b> <br /><b>Lowering </b>§</td>
                            <td>≥ 50%</td>
                            <td>30% to 49%</td>
                            <td>&lt; 30%</td>
                          </tr>
                          <tr>
                            <td><b>Primary </b> <br /><b>Statins</b></td>
                            <td>
                              <b>Atorvastatin (40†)-80 mg</b> <br /><b>Rosuvastatin 20 </b><i>(40)</i><b> mg</b>
                            </td>
                            <td>
                              <b>Atorvastatin 10 </b><i>(20)</i><b> mg</b><br /><b>Rosuvastatin</b> <i>(5)</i><b> 10
                                mg</b> <br /><b>Simvastatin 20-40 mg‡</b>
                            </td>
                            <td><i>Simvastatin 10 mg</i></td>
                          </tr>
                          <tr>
                            <td><b>Other</b><br /><b>Statins</b></td>
                            <td>-</td>
                            <td>
                              <b>Pravastatin 40 </b><i>(80)</i><b> mg</b><br /><b>Lovastatin 40 </b><i>(80)</i><b>
                                mg</b><br /><i>Fluvastatin XL 80 mg</i><br /><b>Fluvastatin 40 mg
                                BID</b><br /><i>Pitavastatin 1-4 mg</i>
                            </td>
                            <td>
                              <b>Pravastatin 10-20 mg</b><br /><b>Lovastatin 20 mg</b><br /><i>Fluvastatin 20-40 mg</i>
                            </td>
                          </tr>
                        </tbody>
                      </table>
                    </div>
                    <div class="row">
                      <p class="text">
                        Percent LDL-C reductions with the primary statin
                        medications used in clinical practice (atorvastatin,
                        rosuvastatin, simvastatin) were estimated using the
                        median reduction in LDL-C from the VOYAGER database.
                        Reductions in LDL-C for other statin medications
                        (fluvastatin, lovastatin, pitavastatin, pravastatin)
                        were identified according to FDA approved product
                        labeling in adults with hyperlipidemia, primary
                        hypercholesterolemia and mixed dyslipidemia.
                      </p>
                    </div>
                    <div class="row">
                      <p class="text">
                        <b>Boldface</b> type indicates specific statins and
                        doses that were evaluated in RCTs, and the Cholesterol
                        Treatment Trialists 2010 meta-analysis. All these RCTs
                        demonstrated a reduction in major cardiovascular
                        events.
                      </p>
                    </div>
                    <div class="row">
                      <p class="text">
                        <i>Italic</i> type indicates statins and doses that
                        have been approved by the FDA but were not tested in
                        the RCTs reviewed.
                      </p>
                      <p class="text">
                        § LDL-C lowering that should occur with the dosage
                        listed below each intensity
                      </p>
                      <p class="text">
                        ‡ Although simvastatin 80 mg was evaluated in RCTs,
                        initiation of simvastatin 80 mg or titration to 80 mg
                        is not recommended by the FDA because of the increased
                        risk of myopathy, including rhabdomyolysis
                      </p>
                      <p class="text">
                        * Percent reductions are estimates from data across
                        large populations. Individual responses to statin
                        therapy varied in the RCTs and should be expected to
                        vary in clinical practice.
                      </p>
                      <p class="text">
                        † Evidence from 1 RCT only: down-titration if unable
                        to tolerate atorvastatin 80 mg in the IDEAL
                        (Incremental Decrease through Aggressive Lipid
                        Lowering) study.
                      </p>
                      <p class="text">
                        BID indicates twice daily; FDA, Food and Drug
                        Administration; LDL-C, low-density lipoprotein
                        cholesterol; and RCTs, randomized controlled trials.
                      </p>
                    </div>
                  </div>
                  <div data-bind="page: {id:'statin_dose',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Intensities of Statin Therapy
                    </h1>

                    <div class="row">
                      <div class="column large-4">
                        <h3>Low-Intensity</h3>
                        <p>
                          Daily dose lowers LDL-C, on average by approximately
                          &lt;30%
                        </p>
                        <table class="table">
                          <thead>
                            <tr>
                              <th></th>
                              <th>
                                <small> dose </small>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <!-- ko foreach: Statins() -->
                            <tr>
                              <!-- ko foreach: dose -->
                              <!-- ko if: type == 'doselow' -->
                              <!-- ko if: htmlText != '--' -->
                              <td data-bind="html:$parent.name"></td>
                              <td data-bind="html: htmlText" class="text-right"></td>
                              <!-- /ko -->
                              <!-- /ko -->
                              <!-- /ko -->
                            </tr>
                            <!-- /ko -->
                          </tbody>
                        </table>
                      </div>
                      <div class="column large-4">
                        <h3>Moderate-Intensity</h3>
                        <p>
                          Daily dose lowers LDL-C, on average by approximately
                          30% to &lt;50%
                        </p>
                        <table class="table">
                          <thead>
                            <tr>
                              <th></th>
                              <th>
                                <small> dose </small>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <!-- ko foreach: Statins() -->
                            <tr>
                              <!-- ko foreach: dose -->
                              <!-- ko if: type == 'dosemedium' -->
                              <!-- ko if: htmlText != '--' -->
                              <td data-bind="html:$parent.name"></td>
                              <td data-bind="html: htmlText" class="text-right"></td>
                              <!-- /ko -->
                              <!-- /ko -->
                              <!-- /ko -->
                            </tr>
                            <!-- /ko -->
                          </tbody>
                        </table>
                      </div>
                      <div class="column large-4">
                        <h3>High-Intensity</h3>
                        <p>
                          Daily dose lowers LDL-C, on average by approximately
                          &ge;50%
                        </p>
                        <table class="table">
                          <thead>
                            <tr>
                              <th></th>
                              <th>
                                <small> dose </small>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <!-- ko foreach: Statins() -->
                            <tr>
                              <!-- ko foreach: dose -->
                              <!-- ko if: type == 'dosehigh' -->
                              <!-- ko if: htmlText != '--' -->
                              <td data-bind="html:$parent.name"></td>
                              <td data-bind="html: htmlText" class="text-right"></td>
                              <!-- /ko -->
                              <!-- /ko -->
                              <!-- /ko -->
                            </tr>
                            <!-- /ko -->
                          </tbody>
                        </table>
                      </div>
                    </div>
                    <div class="row">
                      <p class="quiet">
                        Statins and doses that are approved by the U.S. FDA
                        but were not tested in the RCTs reviewed are listed in
                        parentheses
                      </p>
                      <p class="quiet">
                        <strong> * </strong>
                        Evidence from 1 RCT (down-titration if unable to
                        tolerate atorvastatin 80 mg)
                      </p>
                      <p class="quiet">
                        <strong> ** </strong>
                        Initiation of or titration to simvastatin 80 mg is not
                        recommended by the FDA due to increased risk of
                        myopathy, including rhabdomyolysis
                      </p>
                    </div>
                  </div>
                  <div data-bind="page: {id:'monitor_flowchart',afterShow: listchange, beforeShow: panzoom}"
                    class="group-section flow-chart">
                    <h1>
                      Recommendations to Monitor Response to LDL-C Lowering
                      Therapy
                    </h1>

                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommendations to Monitor Response to LDL-C
                            Lowering Therapy
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            Adherence to changes in lifestyle and effects of
                            LDL-C lowering medication should be assessed by
                            measurement of fasting lipids and appropriate
                            safety indicators, 4 to 12 weeks after statin
                            initiation or dose adjustment, and every 3-12
                            months thereafter based on need to assess
                            adherence and/or safety.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <div data-bind="page: {id:'clinical_reference_safety_recomendations',afterShow: listchange}"
                    class="group-section">
                    <h1 class="with-underline">
                      Statin Safety Recommendations
                    </h1>

                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommendations for Statin Safety and Statin
                            Associated Side Effects
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><b>COR</b></td>
                          <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                          <td class="text-center"><b>Recommendations</b></td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. A clinician patient risk discussion is
                            recommended before initiating statin therapy to
                            review net clinical benefit, weighing the
                            potential for ASCVD risk reduction against the
                            potential for statin-associated side effects,
                            statin-drug interactions and safety, yet
                            emphasizing that side effects can be addressed
                            successfully.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            2. In patients with statin-associated muscle
                            symptoms, a thorough assessment of symptoms and an
                            evaluation for non-statin causes and predisposing
                            factors are recommended.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In patients with indication for statin therapy
                            identification of potential predisposing factors
                            for statin associated side effects including new
                            onset diabetes and statin-associated muscle
                            symptoms is recommended prior to initiation of
                            treatment.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            4. In patients with statin-associated side effects
                            that are not severe, it is recommended to reassess
                            and to rechallenge to achieve a maximal LDL-C
                            lowering by modified dosing regimen, an alternate
                            statin or in combination with non-statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            5. In patients with increased diabetes risk or new
                            onset diabetes, it is recommended to continue
                            statin therapy with added emphasis on adherence,
                            net clinical benefit, and the core principles of
                            regular moderate-intensity physical activity,
                            maintaining a healthy dietary pattern, and
                            sustaining modest weight loss.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            6. In patients treated with statins, it is
                            recommended to measure creatine kinase levels in
                            individuals with severe statin-associated muscle
                            symptoms, objective muscle weakness, and to
                            measure liver transaminases (aspartate
                            aminotransferase, alanine aminotransferase) as
                            well as total bilirubin and alkaline phosphatase
                            (hepatic panel) if there are symptoms suggesting
                            hepatotoxicity.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            7. In patients at increased ASCVD risk with
                            chronic, stable liver disease (including
                            non-alcoholic fatty liver disease) when
                            appropriately indicated, it is reasonable to use
                            statins after obtaining baseline measurements and
                            determining a schedule of monitoring and safety
                            checks.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            8. In patients at increased ASCVD risk with severe
                            statin-associated muscle symptoms or recurrent
                            statin-associated muscle symptoms despite
                            appropriate statin rechallenge, it is reasonable
                            to use RCT proven non-statin therapy that is
                            likely to provide net clinical benefit.
                          </td>
                        </tr>
                        <tr>
                          <td class="No-Benifit">III: No Benefit</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            9. Coenzyme Q10 is not recommended for the routine
                            use in patients treated with statins or for the
                            treatment of statin-associated muscle symptoms.
                          </td>
                        </tr>
                        <tr>
                          <td class="No-Benifit">III: No Benefit</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            10. In patients treated with statins, routine
                            measurements of creatine kinase and transaminase
                            levels are not useful.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <div data-bind="page: {id:'reference_external_links',afterShow: listchange}" class="group-section">
                    <h1>External Links &amp; References</h1>
                    <nav class="nav nav-list small">
                      <ul>
                        <li>
                          <a target="blank" href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000678">
                            <span class="text">2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular
                              Disease</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000625">
                            <span class="text">2018 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce
                              Atherosclerotic Cardiovascular Risk in Adults</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S49.full.pdf">
                            <span class="text">2013 ACC/AHA Guideline on the Assessment of
                              Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S1.full.pdf">
                            <span class="text">2013 ACC/AHA Guideline on the Treatment of
                              Blood Cholesterol to Reduce Atherosclerotic
                              Cardiovascular Risk in Adults</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S102.full.pdf">
                            <span class="text">2013 AHA/ACC/TOS Guideline for the Management
                              of Overweight and Obesity in Adults</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S76.full.pdf">
                            <span class="text">2013 AHA/ACC Guideline on Lifestyle Management
                              to Reduce Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://www.ncbi.nlm.nih.gov/books/NBK63952/">
                            <span class="text">2008 AHRQ Guideline on Treating Tobacco Use and
                              Dependence</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <!-- <li>
                            <a
                              target="blank"
                              href="http://ldl.cardiosource.org/"
                            >
                              <span class="text"
                                >ACC Dyslipidemia Clinical Community</span
                              ><i class="fa fa-holder-dynamic"></i>
                            </a>
                          </li>
                          <li>
                            <a
                              target="blank"
                              href="http://cardiometabolic.cardiosource.org/"
                            >
                              <span class="text"
                                >ACC Cardiometabolic Clinical Community</span
                              ><i class="fa fa-holder-dynamic"></i>
                            </a>
                          </li>
                          <li>
                            <a
                              target="blank"
                              href="http://www.cardiosource.org/~/media/Files/Science%20and%20Quality/Guidelines/Clinical_Documents/Prevention%20Guidelines%20Clinical%20Vignettes.pdf"
                            >
                              <span class="text">Clinical Vignettes</span
                              ><i class="fa fa-holder-dynamic"></i>
                            </a>
                          </li> -->
                      </ul>
                    </nav>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div data-bind="page: {id:'patient-split-layout'}">
            <div class="medium split-layout fill-page-height">
              <div class="split-sidebar">
                <h4 class="content-padding">Clinician Resources</h4>
                <nav class="nav-list small">
                  <ul>


                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_lifestyle">
                        <span class="text"> Lifestyle Recommendations </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/risk_enhancing_factors">
                        <span class="text">
                          ASCVD Risk Enhancing Factors
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/ethnicity_issues">
                        <span class="text">
                          Ethnicity Issues in Risk Evaluation
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/summary_recommendations">
                        <span class="text">
                          General Populations Recommendation Summary
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/guideline_flowchart">
                        <span class="text">
                          Primary Prevention of ASCVD - Summary
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/secondary_prevention">
                        <span class="text">
                          Secondary Prevention - Patients with Clinical ASCVD
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/ldlc_treatment_younger_patients">
                        <span class="text">
                          LDL-C Treatment Suggestions for Younger Patients
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/statin_dose_resource_section">
                        <span class="text">
                          Intensities of Statin Therapy
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/monitor_flowchart">
                        <span class="text">
                          Recommendations to Monitor Response to LDL-C
                          Lowering Therapy
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations">
                        <span class="text">
                          Statin Safety Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/discussion_checklist">
                        <span class="text">
                          Discussion Checklist for Therapy Initiation
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/cac_score_inform_decisions">
                        <span class="text">
                          Using CAC Score to Inform Decisions
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/immunization_practice">
                        <span class="text">
                          Immunization Practice
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/reference_external_links">
                        <span class="text">
                          External Links to Full Guidelines &amp; More
                          Information
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                  </ul>
                </nav>
                <h4 class="content-padding">Patient Resources</h4>
                <nav class="nav-list small">
                  <ul>
                    <li>
                      <a href="#!/content/patient-split-layout/patient_lifestyle">
                        <span class="text"> Diet and Physical Activity </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_obesity">
                        <span class="text">
                          Weight Management Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_cholesterol">
                        <span class="text">
                          Blood Cholesterol Management Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                  </ul>
                </nav>
                <div class="row">
                  <div class="small-12 column">
                    <h3 class="">References</h3>
                    <ul class="patient-scenario">
                      <li>
                        <a target="_blank" href="https://www.acc.org/guidelines#doctype=Guidelines">Grundy SM, Stone NJ,
                          Bailey AL, Beam C, Birtcher
                          KK, Blumenthal RS, Braun LT, de Ferranti S,
                          Faiella-Tommasino J, Forman DE, Goldberg R,
                          Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D,
                          Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta
                          CA, Saseen JJ, Smith SC, Sperling L, Virani SS,
                          Yeboah J. 2018
                          ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
                          guideline on the management of blood cholesterol: a
                          report of the American College of Cardiology
                          Foundation/American Heart Association Task Force on
                          Clinical Practice Guidelines. J Am Coll Cardiol.
                          2018; xx:xxxx-xxxx.</a>
                      </li>
                    </ul>
                  </div>
                </div>
              </div>
              <div class="split-content page with-group-sections">
                <div class="section-nav back hide-for-medium">
                  <a href="#!/content/resources/">
                    <div class="circle">
                      <i class="fa fa-holder-dynamic"> </i>
                    </div>
                    <div class="text">Back to Guidelines &amp; Resources</div>
                  </a>
                </div>
                <div class="page-wrapper">
                  <div data-bind="page: {id:'patient_risk',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Understanding My Cardiovascular Risk
                    </h1>
                    <p>
                      The "2013 ACC/AHA Guideline on the Assessment of
                      Cardiovascular Risk" provides clear recommendations for
                      estimating cardiovascular disease risk. Risk assessments
                      are extremely useful when it comes to reducing risk for
                      cardiovascular disease because they help determine
                      whether a patient is at high risk for cardiovascular
                      disease, and if so, what can be done to address any
                      cardiovascular risk factors a patient may have. Here are
                      the highlights of the guideline:
                    </p>
                    <ul>
                      <li>
                        <p>
                          Risk assessments are used to determine the
                          likelihood of a patient developing cardiovascular
                          disease, heart attack or stroke in the future. In
                          general, patients at higher risk for cardiovascular
                          disease require more intensive treatment to help
                          prevent the development of cardiovascular disease.
                        </p>
                      </li>
                      <li>
                        <p>
                          Risk assessments are calculated using a number of
                          factors including age, gender, race, cholesterol and
                          blood pressure levels, diabetes and smoking status,
                          and the use of blood pressure-lowering medications.
                          Typically, these factors are used to estimate a
                          patient's risk of developing cardiovascular disease
                          in the next 10 years. For example, someone who is
                          young with no risk factors for cardiovascular
                          disease would have a very low 10-year risk for
                          developing cardiovascular disease. However, someone
                          who is older with risk factors like diabetes and
                          high blood pressure will have a much higher risk of
                          developing cardiovascular disease in the next 10
                          years.
                        </p>
                      </li>
                      <li>
                        <p>
                          If a preventive treatment plan is unclear based on
                          the calculation of risk outlined above, care
                          providers should take into account other factors
                          such as family history and level of C-reactive
                          protein. Taking this additional information into
                          account should help inform a treatment plan to
                          reduce a patient's 10-year risk of developing
                          cardiovascular disease.
                        </p>
                      </li>
                      <li>
                        <p>
                          Calculating the 10-year risk for cardiovascular
                          disease using traditional risk factors is
                          recommended every 4-6 years in patients 20-79 years
                          old who are free from cardiovascular disease.
                          However, conducting a more detailed 10-year risk
                          assessment every 4-6 years is reasonable in adults
                          ages 40-79 who are free of cardiovascular disease.
                          Assessing a patient's 30-year risk of developing
                          cardiovascular disease can also be useful for
                          patients 20-59 years of age who are free of
                          cardiovascular disease and are not at high
                          short-term risk for cardiovascular disease.
                        </p>
                      </li>
                      <li>
                        <p>
                          Risk estimations vary drastically by gender and
                          race. Patients with the same traditional risk
                          factors for cardiovascular disease such as high
                          blood pressure can have a different 10-year risk for
                          cardiovascular disease as a result of their sex and
                          race.
                        </p>
                      </li>
                      <li>
                        <p>
                          After care providers and patients work together to
                          conduct a risk assessment, it's important that they
                          discuss the implications of their findings.
                          Together, patients and their care providers should
                          weigh the risks and benefits of various treatments
                          and lifestyle changes to help reduce the risk of
                          developing cardiovascular disease.
                        </p>
                      </li>
                    </ul>
                    <p class="quiet">
                      Source:
                      <a class="link" href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Risk-Assessment">
                        www.cardiosmart.org
                      </a>
                    </p>
                  </div>
                  <div data-bind="page: {id:'patient_lifestyle',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Diet and Physical Activity Recommendations
                    </h1>
                    <h3>Diet</h3>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <!-- <img
                              src="assets/img/Diet.png" 
                              data-src="assets/graphics/Benifit-Group-Infographic.svg"
                              alt="Groups that benifit from Statins"
                              style="width: 100%"
                            /> -->
                          <img src="assets/img/Diet.png" data-src="assets/graphics/Diet_Physical_first.svg"
                            style="width: 100%" />
                        </div>
                      </div>
                      <!-- <div
                          class="button-group small panzoom-buttons expanded"
                        >
                          <button
                            class="zoom-in button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-plus-circle"></i>
                            <span class="text">Zoom In</span>
                          </button>
                          <button
                            class="zoom-out button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-minus-circle"></i>
                            <span class="text">Zoom Out</span>
                          </button>
                          <button
                            class="reset ui-btn button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-refresh"></i>
                            <span class="text">Reset</span>
                          </button>
                        </div> -->
                      <p class="quiet">
                        Additional Resources available at:
                        <a target="_blank" class="link"
                          href="https://www.cardiosmart.org/topics/healthy-living/eat-better">
                          CardioSmart.org/EatBetter
                        </a>
                      </p>
                    </div>
                    <h3>Physical Activity</h3>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <!-- <img
                              src="assets/img/Diet.png" 
                              data-src="assets/graphics/Benifit-Group-Infographic.svg"
                              alt="Groups that benifit from Statins"
                              style="width: 100%"
                            /> -->
                          <img src="assets/img/Physical.png" style="width: 100%">
                        </div>
                      </div>
                      <!-- <div
                          class="button-group small panzoom-buttons expanded"
                        >
                          <button
                            class="zoom-in button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-plus-circle"></i>
                            <span class="text">Zoom In</span>
                          </button>
                          <button
                            class="zoom-out button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-minus-circle"></i>
                            <span class="text">Zoom Out</span>
                          </button>
                          <button
                            class="reset ui-btn button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-refresh"></i>
                            <span class="text">Reset</span>
                          </button>
                        </div> -->
                      <p class="quiet">
                        Additional Resources available at:
                        <a target="_blank" class="link"
                          href="https://www.cardiosmart.org/topics/healthy-living/move-more">
                          CardioSmart.org/MoveMore
                        </a>
                      </p>
                    </div>
                    <!-- <p class="quiet">
                        Source:
                        <a
                          class="link"
                          href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Lifestyle"
                        >
                          www.cardiosmart.org
                        </a>
                      </p> -->
                  </div>
                  <div data-bind="page: {id:'patient_obesity',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Weight Management Recommendations
                    </h1>
                    <p class="quiet">
                      Additional Resources available at:
                      <a target="_blank" class="link" href="https://www.cardiosmart.org/loseweight">
                        CardioSmart.org/LoseWeight
                      </a>
                    </p>
                  </div>
                  <div data-bind="page: {id:'patient_cholesterol',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Blood Cholesterol Management Recommendations
                    </h1>
                    <h3>Lower Your 'Bad' Cholesterol to Protect Your Heart</h3>
                    </ul>
                    <p class="quiet">
                      Patient Voices on Managing High Cholesterol can be found at :
                      <a target="_blank" class="link"
                        href="https://www.cardiosmart.org/topics/high-cholesterol/patient-voices-managing-high-cholesterol">
                        CardioSmart.org/PatientVoicesLDL
                      </a>
                    </p>

                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <!-- <img
                              src="assets/img/Diet.png" 
                              data-src="assets/graphics/Benifit-Group-Infographic.svg"
                              alt="Groups that benifit from Statins"
                              style="width: 100%"
                            /> -->
                          <img src="assets/img/Cholesterol_first.png" style="width: 100%">
                        </div>
                      </div>
                      <!-- <div
                          class="button-group small panzoom-buttons expanded"
                        >
                          <button
                            class="zoom-in button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-plus-circle"></i>
                            <span class="text">Zoom In</span>
                          </button>
                          <button
                            class="zoom-out button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-minus-circle"></i>
                            <span class="text">Zoom Out</span>
                          </button>
                          <button
                            class="reset ui-btn button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-refresh"></i>
                            <span class="text">Reset</span>
                          </button>
                        </div> -->
                      <p class="quiet">
                        Additional resources available at :
                        <a target="_blank" class="link" href="https://www.cardiosmart.org/topics/high-cholesterol">
                          CardioSmart.org/Cholesterol
                        </a>
                      </p>
                    </div>
                    <h3>Managing High Cholesterol</h3>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <!-- <img
                              src="assets/img/Diet.png" 
                              data-src="assets/graphics/Benifit-Group-Infographic.svg"
                              alt="Groups that benifit from Statins"
                              style="width: 100%"
                            /> -->
                          <img src="assets/img/Cholesterol_second.png" style="width: 100%">
                        </div>
                      </div>
                      <!-- <div
                          class="button-group small panzoom-buttons expanded"
                        >
                          <button
                            class="zoom-in button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-plus-circle"></i>
                            <span class="text">Zoom In</span>
                          </button>
                          <button
                            class="zoom-out button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-minus-circle"></i>
                            <span class="text">Zoom Out</span>
                          </button>
                          <button
                            class="reset ui-btn button icon-only secondary"
                            formnovalidate
                          >
                            <i class="fa fa-refresh"></i>
                            <span class="text">Reset</span>
                          </button>
                        </div> -->
                      <p class="quiet">
                        <!-- Additional Resources available at: -->
                        <a target="_blank" class="link"
                          href="https://www.cardiosmart.org/topics/healthy-living/move-more">
                          <!-- CardioSmart.org/MoveMore -->
                        </a>
                      </p>
                    </div>
                  </div>
                  <div data-bind="page: {id:'statin_infographic',afterShow: listchange,beforeShow:panzoom}"
                    class="group-section">
                    <div class="row">
                      <h1>
                        Groups that Benefit from Statin Therapy Infographic
                      </h1>
                    </div>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <img src="assets/img/squared_metal_@2X.png"
                            data-src="assets/graphics/Benifit-Group-Infographic.svg"
                            alt="Groups that benifit from Statins" style="width: 100%" />
                        </div>
                      </div>
                      <div class="button-group small panzoom-buttons expanded">
                        <button class="zoom-in button icon-only secondary" formnovalidate>
                          <i class="fa fa-plus-circle"></i>
                          <span class="text">Zoom In</span>
                        </button>
                        <button class="zoom-out button icon-only secondary" formnovalidate>
                          <i class="fa fa-minus-circle"></i>
                          <span class="text">Zoom Out</span>
                        </button>
                        <button class="reset ui-btn button icon-only secondary" formnovalidate>
                          <i class="fa fa-refresh"></i>
                          <span class="text">Reset</span>
                        </button>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'patient_reference_definition',afterShow: listchange}"
                    class="group-section">
                    <div class="content-padding">
                      <h1 class="with-underline">
                        Common Cardiovascular Terms
                        <span class="sub-line">Alphabetical Glossary</span>
                      </h1>
                      <input placeholder="Search" type="search"
                        data-bind="value: glossaryQuery, valueUpdate: 'keyup'" />
                      <ul class="no-bullet" data-bind="template: {name:'glossaryItem', foreach:$root.glossaryItems}">
                      </ul>
                      <script type="text/html" id="glossaryItem">
                          <li class="group-divide-auto">
                            <h4 data-bind="html: label"></h4>
                            <p data-bind="html: definition"></p>
                          </li>
                        </script>

                      <p class="quiet">
                        <a class="link" href="https://www.cardiosmart.org/AZ-Topics">For additional cardiovascular terms
                          visit
                          www.cardiosmart.org</a>
                      </p>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>

          <div class="page with-group-sections fill-page-height"
            data-bind="page: {id:'clinician',  afterShow:tabchange ,beforeShow:pageScrollTop}">
            <div class="page-wrapper">
              <section class="section group-section">
                <h1>Clinician Resources</h1>
                <nav class="nav-list">
                  <ul>


                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_lifestyle"><span class="text">Lifestyle
                          Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/summary_recommendations"><span class="text">General
                          Populations Recommendation Summary</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/guideline_flowchart"><span class="text">Recommendations
                          for Initiation of Statin
                          Therapy</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/statin_dose"><span class="text">Intensities of Statin
                          Therapy</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/monitor_flowchart"><span class="text">Recommendations
                          to Monitor Response to Statin
                          Therapy</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations"><span
                          class="text">Statin Safety Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/reference_external_links"><span class="text">External
                          Links to Full Guidelines &amp; More
                          Information</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>
                  </ul>
                </nav>
              </section>
            </div>
          </div>
          <div data-bind="page: {id:'clinician-split-layout'}">
            <div class="medium split-layout fill-page-height">
              <div class="split-sidebar">
                <h3 class="content-padding">Clinician Resources</h3>
                <nav class="nav-list small">
                  <ul>


                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_lifestyle"><span class="text">Lifestyle
                          Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/summary_recommendations"><span class="text">General
                          Populations Recommendation Summary</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/guideline_flowchart"><span class="text">Recommendations
                          for Initiation of Statin
                          Therapy</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/statin_dose"><span class="text">Intensities of Statin
                          Therapy</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/monitor_flowchart"><span class="text">Recommendations
                          to Monitor Response to Statin
                          Therapy</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations"><span
                          class="text">Statin Safety Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/clinician-split-layout/reference_external_links"><span class="text">External
                          Links to Full Guidelines &amp; More
                          Information</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>
                  </ul>
                </nav>
              </div>
              <div class="split-content page with-group-sections">
                <div class="section-nav back hide-for-medium">
                  <a data-bind="page-href: '../clinician'">
                    <div class="circle">
                      <i class="fa fa-holder-dynamic"></i>
                    </div>
                    <div class="text">Back to Guidelines &amp; Resources</div>
                  </a>
                </div>
                <div class="page-wrapper">
                  <div data-bind="page: {id:'clinical_understanding',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Understanding Cardiovascular Risk
                    </h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">10-Year ASCVD Risk</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                The 10-year calculated ASCVD risk is a
                                quantitative estimation of absolute risk based
                                upon data from representative population
                                samples.
                              </li>
                              <li>
                                The 10-year risk estimate for "optimal risk
                                factors" is represented by the following
                                specific risk factor numbers for an individual
                                of the same age, sex and race: Total
                                cholesterol of &le; 170 mg/dL, HDL-cholesterol
                                of &ge; 50 mg/dL, untreated systolic blood
                                pressure of &le; 110 mm Hg, no diabetes
                                history, and not a current smoker.
                              </li>
                              <li>
                                While the risk estimate is applied to
                                individuals, it is based on group averages.
                              </li>
                              <li>
                                Just because two individuals have the same
                                estimated risk does not mean that they will or
                                will not have the same event of interest.
                              </li>
                              <li>
                                Example: If the 10-year ASCVD risk estimate is
                                10%, this indicates that among 100 patients
                                with the entered risk factor profile, 10 would
                                be expected to have a heart attack or stroke
                                in the next 10 years.
                              </li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Lifetime ASCVD Risk</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                The lifetime calculated ASCVD risk represents
                                a quantitative estimation of absolute risk for
                                a 50 year old man or woman with the same risk
                                profile.
                              </li>
                              <li>
                                This estimation of risk is based on the
                                grouping of risk factor levels into 5 strata.
                                <ul>
                                  <li>All risk factors are optimal*</li>
                                  <li>
                                    &ge;1 risk factors are not optimal&dagger;
                                  </li>
                                  <li>
                                    &ge;1 risk factors are elevated&Dagger;
                                  </li>
                                  <li>1 major risk factor&sect;</li>
                                  <li>&ge;2 major risk factors&sect;</li>
                                </ul>
                              </li>
                              <li>
                                The division of lifetime risk by these 5
                                strata leads to thresholds in the data with
                                large apparent changes in lifetime risk
                                estimates.
                              </li>
                              <li>
                                Example: An individual that has all optimal
                                risk factors except for a systolic blood
                                pressure of 119 mm Hg has a lifetime ASCVD
                                risk of 5%. In contrast, a similar individual
                                that has all optimal risk factors except for a
                                systolic blood pressure of 120 mm Hg has a
                                lifetime ASCVD risk of 36%. This substantial
                                difference in lifetime risk is due to the fact
                                that they are in different stratum.
                              </li>
                            </ul>
                            <p class="quiet">
                              *Optimal risk levels for lifetime risk are
                              represented by the simultaneous presence of all
                              of the following: Untreated total cholesterol
                              &lt;180 mg/dL, untreated blood pressure
                              &lt;120/&lt;80 mm Hg, no diabetes history, and
                              not a current smoker
                            </p>
                            <p class="quiet">
                              &dagger;Nonoptimal risk levels for lifetime risk
                              are represented by 1 or more of the following:
                              Untreated total cholesterol of 180 to 199 mg/dL,
                              untreated systolic blood pressure of 120 to 139
                              mm Hg or diastolic&nbsp;blood pressure of 80 to
                              89 mm Hg, and no diabetes history and not a
                              current smoker
                            </p>
                            <p class="quiet">
                              &Dagger;Elevated risk levels for lifetime risk
                              are represented by 1 or more of the following:
                              Untreated total cholesterol of 200 to 239 mg/dL,
                              untreated systolic blood pressure of 140 to 159
                              mm Hg or diastolic&nbsp;blood pressure of 90 to
                              99 mm Hg, and no diabetes history and not a
                              current smoker
                            </p>
                            <p class="quiet">
                              &sect;Major risk levels for lifetime risk are
                              represented by any of the following: Total
                              cholesterol &ge;240 mg/dL or treated, systolic
                              blood pressure &ge;160 mm Hg or
                              diastolic&nbsp;blood pressure &ge;100 mm Hg or
                              treated, or diabetes, or current smoker
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'clinical_lifestyle',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">Lifestyle Recommendations</h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Diet recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>Diet recommendations for LDL-C lowering</h3>
                            <ol>
                              <li>
                                Consume a dietary pattern that emphasizes
                                intake of vegetables, fruits, and whole
                                grains; includes low-fat dairy products,
                                poultry, fish, legumes, non-tropical vegetable
                                oils and nuts; and limits intake of sweets,
                                sugar-sweetened beverages, and red meats. (I
                                A)
                                <ul>
                                  <li>
                                    Adapt this dietary pattern to appropriate
                                    calorie requirements, personal and
                                    cultural food preferences, and nutrition
                                    therapy for other medical conditions
                                    (including diabetes mellitus).
                                  </li>
                                  <li>
                                    Achieve this pattern by following plans
                                    such as the DASH dietary pattern, the USDA
                                    Food Pattern, or the AHA Diet.
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Aim for a dietary pattern that achieves 5-6%
                                of calories from saturated fat. (I A)
                              </li>
                              <li>
                                Reduce percent of calories from saturated fat.
                                (I A)
                              </li>
                              <li>
                                Reduce percent of calories from trans fat. (I
                                A)
                              </li>
                            </ol>
                            <h3>
                              Diet recommendations for blood pressure lowering
                            </h3>
                            <ol>
                              <li>
                                Consume a dietary pattern that emphasizes
                                intake of vegetables, fruits, and whole
                                grains; includes low-fat dairy products,
                                poultry, fish, legumes, non-tropical vegetable
                                oils and nuts; and limits intake of sweets,
                                sugar-sweetened beverages, and red meats. (I
                                A)
                                <ul>
                                  <li>
                                    Adapt this dietary pattern to appropriate
                                    calorie requirements, personal and
                                    cultural food preferences, and nutrition
                                    therapy for other medical conditions
                                    (including diabetes mellitus).
                                  </li>
                                  <li>
                                    Achieve this pattern by following plans
                                    such as the DASH dietary pattern, the USDA
                                    Food Pattern, or the AHA Diet.
                                  </li>
                                </ul>
                              </li>
                              <li>Lower sodium intake. (I A)</li>
                              <li>
                                Consume no more than 2400 mg of sodium per
                                day. (I B)
                              </li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Weight Management Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>Diets for weight loss</h3>
                            <ol>
                              <li>
                                Prescribe a diet to achieve reduced calorie
                                intake for obese or overweight individuals who
                                would benefit from weight loss, as part of a
                                comprehensive lifestyle intervention with 1 of
                                the following (I A):
                                <ul>
                                  <li>
                                    1200-1500 kcal/day for women and 1500-1800
                                    kcal/day for men.
                                  </li>
                                  <li>500-750 kcal/day energy deficit.</li>
                                  <li>
                                    Use one of the evidence-based diets that
                                    restricts certain food types (e.g.,
                                    high-carbohydrate foods, low-fiber foods,
                                    or high-fat foods) in order to create an
                                    energy deficit by reduced food intake.
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Prescribe a calorie-restricted diet for obese
                                or overweight individuals who would benefit
                                from weight loss, based on the patient's
                                preferences and health status, and preferably
                                refer to a nutrition professional for
                                counseling. (I A)
                              </li>
                            </ol>
                            <h3>
                              Lifestyle interventions and counseling for
                              weight loss
                            </h3>
                            <ol>
                              <li>
                                Advise participation in a comprehensive
                                lifestyle program that assists participants in
                                adhering to a lower calorie diet and
                                increasing physical activity through the use
                                of behavioral strategies. (I A)
                              </li>
                              <li>
                                Prescribe on site, high-intensity (i.e.,
                                &gt;14 sessions in 6 months) comprehensive
                                weight loss interventions provided in
                                individual or group sessions by a trained
                                interventionist. (I A)
                              </li>
                              <li>
                                Consider prescription of electronically
                                delivered weight loss programs (including by
                                telephone) that includes personalized feedback
                                from a trained interventionist, recognizing
                                that it may result in smaller weight loss than
                                face-to-face interventions. (IIa A)
                              </li>
                              <li>
                                Consider some commercial-based programs that
                                provide comprehensive lifestyle interventions,
                                provided there is peer-reviewed published
                                evidence of their safety and efficacy. (IIa A)
                              </li>
                              <li>
                                Consider a very low calorie diet (&lt;800
                                kcal/day) only in limited circumstances and
                                only when provided by trained practitioners in
                                a medical care setting where medical
                                monitoring and high intensity lifestyle
                                intervention can be provided. (IIa A)
                              </li>
                              <li>
                                Advise individuals who have lost weight to
                                participate long term (&gt;1 year) in a
                                comprehensive weight loss maintenance program.
                                (I A)
                              </li>
                              <li>
                                Prescribe face-to-face or telephone-delivered
                                weight loss maintenance programs that provide
                                regular contact (&gt; monthly) with a trained
                                interventionist who helps participants engage
                                in high levels of physical activity (i.e.,
                                200-300 minutes/week), monitor body weight
                                regularly (&gt; weekly), and consume a
                                reduced-calorie diet (need to lower body
                                weight). (I A)
                              </li>
                            </ol>
                            <h3>
                              Selection criteria for bariatric surgical
                              treatment of obesity
                            </h3>
                            <ol>
                              <li>
                                Advise adults with a BMI &ge;40 kg/m² or BMI
                                &ge;35 kg/m² with obesity-related co-morbid
                                conditions who are motivated to lose weight
                                and who have not responded to behavioral
                                treatment with or without pharmacotherapy with
                                sufficient weight loss to achieve targeted
                                health outcome goals that bariatric surgery
                                may be an appropriate option to improve health
                                and offer referral to an experienced bariatric
                                surgeon for consultation and evaluation. (IIa
                                A)
                              </li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Physical Activity Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>
                              Physical activity recommendations for modifying
                              lipids and blood pressure lowering
                            </h3>
                            <ol>
                              <li>
                                Advise adults to engage in aerobic physical
                                activity to reduce LDL-cholesterol,
                                non-HDL-cholesterol, and blood pressure. (IIa
                                A)
                                <ul>
                                  <li>Frequency: 3-4 sessions a week</li>
                                  <li>Intensity: Moderate to vigorous</li>
                                  <li>Duration: 40 minutes on average</li>
                                </ul>
                              </li>
                            </ol>
                            <h3>
                              Physical activity recommendations for secondary
                              prevention*
                            </h3>
                            <ol>
                              <li>
                                Aerobic exercise
                                <ul>
                                  <li>Frequency: 3-5 days/week</li>
                                  <li>
                                    Intensity: 50-80% of exercise capacity
                                  </li>
                                  <li>Duration: 20-60 minutes</li>
                                  <li>
                                    Modalities: Examples include walking,
                                    treadmill, cycling, rowing, stair
                                    climbing, and arm/leg ergometry
                                  </li>
                                </ul>
                              </li>
                              <li>
                                Resistance exercise
                                <ul>
                                  <li>Frequency: 2-3 days/week</li>
                                  <li>
                                    Intensity: 10-15 repetitions/set to
                                    moderate fatigue
                                  </li>
                                  <li>
                                    Duration: 1-3 sets of 8-10 upper and lower
                                    body exercises
                                  </li>
                                  <li>
                                    Modalities: Examples include calisthenics,
                                    elastic bands, cuff/hand weights,
                                    dumbbells, free weights, wall pulleys, and
                                    weight machines
                                  </li>
                                </ul>
                              </li>
                            </ol>
                            <cite class="quiet">*Balady GJ et al. Core components of cardiac
                              rehabilitation/secondary prevention programs:
                              2007 update: a Scientific Statement of the
                              American Heart Association Exercise, Cardiac
                              Rehabilitation, and Prevention Committee, the
                              Council on Clinical Cardiology; the Councils on
                              Cardiovascular Nursing, Epidemiology and
                              Prevention, and Nutrition, Physical Activity and
                              Metabolism; and the American Association of
                              Cardiovascular and Pulmonary Rehabilitation.
                              Circulation 2007;115:2675-2682</cite>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Tobacco Cessation Recommendations</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <h3>5 R's for patients not ready to quit</h3>
                            <ol>
                              <li>
                                Relevance&mdash;Encourage the patient to
                                indicate why quitting is personally relevant.
                              </li>
                              <li>
                                Risks&mdash;Ask the patient to identify
                                potential negative consequences of tobacco
                                use.
                              </li>
                              <li>
                                Rewards&mdash;Ask the patient to identify
                                potential benefits of stopping tobacco use.
                              </li>
                              <li>
                                Roadblocks&mdash;Ask the patient to identify
                                barriers or impediments to quitting.
                              </li>
                              <li>
                                Repetition&mdash;The motivational intervention
                                should be repeated every time an unmotivated
                                patient has an interaction with a clinician.
                                Tobacco users who have failed in previous quit
                                attempts should be told that most people make
                                repeated quit attempts before they are
                                successful.
                              </li>
                            </ol>
                            <h3>5 A's for patients that are ready to quit</h3>
                            <ol>
                              <li>
                                Ask&mdash;Systematically identify all tobacco
                                users at every visit.
                              </li>
                              <li>
                                Advise&mdash;Strongly urge all smokers to
                                quit.
                              </li>
                              <li>
                                Assess&mdash;Identify smokers willing to make
                                a quit attempt.
                              </li>
                              <li>
                                Assist&mdash;Aid the patient in quitting.
                              </li>
                              <li>
                                Arrange&mdash;Schedule follow-up contact.
                              </li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'statin',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Groups that Benefit from Statin Therapy
                    </h1>

                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">1. Secondary Prevention:</span>
                          <span class="sub-line">Clinical ASCVD</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Clinical ASCVD includes acute coronary
                              syndromes, history of MI, stable or unstable
                              angina, coronary or other arterial
                              revascularization, stroke, TIA, or peripheral
                              arterial disease presumed to be of
                              atherosclerotic origin.
                            </p>

                            <p>
                              High-intensity statin therapy should be
                              initiated or continued as first-line therapy in
                              women and men &le;75 years of age who have
                              clinical ASCVD, unless contraindicated. (I A)
                            </p>

                            <p>
                              In individuals with clinical ASCVD in whom
                              high-intensity statin therapy would otherwise be
                              used, when high-intensity statin therapy is
                              contraindicated or when characteristics
                              predisposing to statin-associated adverse
                              effects are present, moderate-intensity statin
                              should be used as the second option if
                              tolerated. (I A)
                            </p>

                            <p>
                              In individuals with clinical ASCVD &gt;75 years
                              of age, it is reasonable to evaluate the
                              potential for ASCVD risk-reduction benefits and
                              for adverse effects, drug-drug interactions and
                              to consider patient preferences, when initiating
                              a moderate- or high-intensity statin. It is
                              reasonable to continue statin therapy in those
                              who are tolerating it. (IIa B)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">2. Primary Prevention: </span>
                          <span class="sub-line">LDL-C &ge;190 mg/dL</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Individuals with LDL-C &ge;190 mg/dL or
                              triglycerides &ge;500 mg/dL should be evaluated
                              for secondary causes of hyperlipidemia. (I B)
                            </p>

                            <p>
                              Adults &ge;21 years of age with primary LDL-C
                              &ge;190 mg/dL should be treated with
                              high-intensity statin therapy unless
                              contraindicated. For individuals unable to
                              tolerate high-intensity statin therapy, use the
                              maximum tolerated statin intensity. (I B)
                            </p>

                            <p>
                              For individuals &ge;21 years of age with an
                              untreated primary LDL-C &ge;190 mg/dL, it is
                              reasonable to intensify statin therapy to
                              achieve at least a 50% LDL-C reduction. (IIa B)
                            </p>

                            <p>
                              For individuals &ge;21 years of age with an
                              untreated primary LDL-C &ge;190 mg/dL, after the
                              maximum intensity of statin therapy has been
                              achieved, addition of a nonstatin drug may be
                              considered to further lower LDL-C. Evaluate the
                              potential for ASCVD risk reduction benefits,
                              adverse effects, drug-drug interactions, and
                              consider patient preferences. (IIb C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">3. Primary Prevention:</span><span
                            class="sub-line">
                            Diabetes and aged 40 to 75 years with LDL-C
                            between 70 - 189 mg/dL</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Moderate-intensity statin therapy should be
                              initiated or continued for adults 40 to 75 years
                              of age with diabetes mellitus. (I A)
                            </p>

                            <p>
                              High-intensity statin therapy is reasonable for
                              adults 40 to 75 years of age with diabetes
                              mellitus with a &ge;7.5% estimated 10-year ASCVD
                              risk unless contraindicated. (IIa B)
                            </p>

                            <p>
                              In adults with diabetes mellitus, who are &lt;40
                              or &gt;75 years of age, it is reasonable to
                              evaluate the potential for ASCVD benefits and
                              for adverse effects, for drug-drug interactions,
                              and to consider patient preferences when
                              deciding to initiate, continue, or intensify
                              statin therapy. (IIa C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">4. Primary Prevention: </span><span
                            class="sub-line">No diabetes and estimated 10-year ASCVD risk of
                            &ge;7.5% who are between 40 to 75 years of age
                            with LDL-C between 70 - 189 mg/dL</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              The Pooled Cohort Equations should be used to
                              estimate 10-year ASCVD risk for individuals with
                              LDL-C 70 to 189 mg/dL without clinical ASCVD to
                              guide initiation of statin therapy for the
                              primary prevention of ASCVD. (I B)
                            </p>

                            <p>
                              Before initiating statin therapy for the primary
                              prevention of ASCVD in adults with LDL-C 70 -
                              189 mg/dL without clinical ASCVD or diabetes it
                              is reasonable for clinicians and patients to
                              engage in a discussion which considers the
                              potential for ASCVD risk reduction benefits and
                              for adverse effects, for drug-drug interactions,
                              and patient preferences for treatment. (IIa C)
                            </p>

                            <p>
                              Adults 40 to 75 years of age with LDL-C 70 to
                              189 mg/dL, without clinical ASCVD or diabetes
                              and an estimated 10-year ASCVD risk &ge;7.5%
                              should be treated with moderate- to
                              high-intensity statin therapy. (I A)
                            </p>

                            <p>
                              It is reasonable to offer treatment with a
                              moderate-intensity statin to adults 40 to 75
                              years of age, with LDL-C 70 to 189 mg/dL,
                              without clinical ASCVD or diabetes and an
                              estimated 10-year ASCVD risk of 5% to &lt;7.5%.
                              (IIa B)
                            </p>

                            <p>
                              In adults with LDL-C &lt;190 mg/dL who are not
                              otherwise identified in a statin benefit group,
                              or for whom after quantitative risk assessment a
                              risk-based treatment decision is uncertain,
                              additional factors may be considered to inform
                              treatment decision making. In these individuals,
                              statin therapy for primary prevention may be
                              considered after evaluating the potential for
                              ASCVD risk reduction benefits, adverse effects,
                              drug-drug interactions, and discussion of
                              patient preferences. (IIb C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>

                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Additional Factors</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p><strong>These factors may include:</strong></p>
                            <p>
                              Statin benefit may be less clear in other
                              groups; additional factors may be considered to
                              inform treatment decision making.
                            </p>
                            <ol>
                              <li>5 to &lt;7.5% 10-year ASCVD risk</li>
                              <li>
                                Primary LDL-C &ge;160 mg/dL or other evidence
                                of genetic hyperlipidemias
                              </li>
                              <li>Family history of premature ASCVD</li>
                              <li>
                                High sensitivity C-reactive protein &ge;2 mg/L
                              </li>
                              <li>
                                Coronary artery calcium score &ge;300 Agatston
                                units or &ge;75th percentile for age, sex, and
                                ethnicity
                              </li>
                              <li>Ankle-brachial index &lt;0.9</li>
                              <li>Lifetime risk of ASCVD</li>
                            </ol>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'summary_recommendations',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      General Populations Recommendation Summary
                    </h1>

                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Primary Prevention Recommendations for Adults
                            40-75 Years LDL 70-189 mg/dL (1.7 - 4.8 mmol/L)
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>COR</td>
                          <td>&nbsp;&nbsp;LOE&nbsp;&nbsp;</td>
                          <td class="text-center">Recommendations</td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. In adults at intermediate-risk, statin therapy
                            reduces risk of ASCVD and in the context of a risk
                            discussion, if a decision is made for statin
                            therapy, a moderate- intensity statin should be
                            recommended.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            2. In intermediate risk patients, LDL-C levels
                            should be reduced by ≥ 30%, and for optimal ASCVD
                            risk reduction, especially in high-risk patients,
                            achieve LDL-C reductions of ≥ 50%.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            3. For the primary prevention of clinical ASCVD*
                            in adults 40 to 75 years of age without diabetes
                            and with LDL-C 70 to 189 mg/dL (1.7 to 4.8
                            mmol/L), the 10-year ASCVD risk of a first "hard"
                            ASCVD event (fatal and non-fatal MI or stroke)
                            should be estimated using the race and
                            sex-specific Pooled Cohort Equations (PCE) and
                            adults should be categorized as low risk (<5%), borderline risk (5 to <7.5%),
                              intermediate-risk (≥7.5 to <20%), and high-risk (≥20%). </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            4. Clinicians and patients should engage in a risk
                            discussion that considers risk factors, adherence
                            to healthy lifestyle, the potential for ASCVD
                            risk-reduction benefits and the potential for
                            adverse effects and drug–drug interactions, as
                            well as patient preferences for an individualized
                            treatment decision.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            5. In intermediate-risk adults, risk-enhancing
                            factors favor initiation or intensification of
                            statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            6. In intermediate-risk or selected
                            borderline-risk adults, if the decision about
                            statin usage remains uncertain, it is reasonable
                            to use a coronary artery calcium (CAC) score in
                            the decision to withhold, postpone or initiate
                            statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            7. In intermediate-risk adults or selected
                            borderline-risk adults in whom a CAC score is
                            measured for the purpose of making a treatment
                            decision, AND
                            <ul>
                              <li>
                                If CAC=0, it lowers risk therefore it is
                                reasonable to withhold statin therapy and
                                reassess CAC score in 5-10 years;
                              </li>
                              <li>
                                If CAC= 1 to 99, it is reasonable to initiate
                                statin therapy for patients ≥ 55 years of age;
                              </li>
                              <li>
                                If CAC≥ 100 or CAC ≥ 75th percentile, it is
                                reasonable to initiate statin therapy.
                              </li>
                            </ul>
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            8. In intermediate-risk adults who would benefit
                            from more aggressive LDL-C lowering and in whom
                            high-intensity statins are advisable, but not
                            acceptable or tolerated, it may be reasonable to
                            add a non-statin drug (ezetimibe or bile acid
                            sequestrant) to a moderate-intensity statin.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            9. In patients at borderline risk, in risk
                            discussion, the presence of risk-enhancing factors
                            may justify initiation of moderate-intensity
                            statin therapy.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommenendations for Older Adults
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>COR</td>
                          <td>&nbsp;&nbsp;LOE&nbsp;&nbsp;</td>
                          <td class="text-center">Recommendations</td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            1. In adults > 75 years of age with LDL-C of 70 to
                            189 mg/dL (1.7 to 4.8 mmol/L), initiating a
                            moderate- intensity statin may be reasonable.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            2. In adults > 75 years of age, it may be
                            reasonable to stop statin therapy when functional
                            decline (physical or cognitive), multimorbidity,
                            frailty or reduced life expectancy limit the
                            potential benefits of statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In adults 76-80 years of age with LDL-C of 70
                            to 189 mg/dL (1.7 to 4.8 mmol/L), it may be
                            reasonable to measure coronary artery calcium
                            (CAC) to reclassify those with CAC = 0 to avoid
                            statin therapy.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommenendations for Patients with Diabetes
                            Mellitus
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>COR</td>
                          <td>&nbsp;&nbsp;LOE&nbsp;&nbsp;</td>
                          <td class="text-center">Recommendations</td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. In adults 40 to 75 years of age with diabetes,
                            regardless of estimated 10-year ASCVD risk,
                            moderate-intensity statin therapy is indicated.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-A">A</td>
                          <td>
                            2. In adults with diabetes who are 40 to 75 years
                            of age and have LDL-C 70 to 189 mg/dL (1.7 to 4.8
                            mmol/L), it is reasonable to assess the 10-year
                            risk of a first ASCVD event using the race and
                            sex-specific Pooled Cohort Equations (PCE) to help
                            stratify ASCVD risk.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            3. In adults with diabetes who have multiple ASCVD
                            risk factors, it is reasonable to prescribe
                            high-intensity statin therapy with the aim to
                            reduce LDL-C by ≥50%.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-NR</td>
                          <td>
                            4. In adults with diabetes older than 75 years of
                            age who are already on statin therapy, it is
                            reasonable to continue statin therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            5. In adults with diabetes and 10-year ASCVD risk
                            ≥20%, it may be reasonable to add ezetimibe to
                            maximum tolerated statin therapy to reduce LDL-C
                            by ≥50%.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            6. In adults with diabetes older than 75 years,
                            after a patient discussion of potential benefits
                            and risks, it may be reasonable to initiate statin
                            therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            7. In adults 20 to 39 years of age with diabetes
                            either of long duration (≥10 years of Type 2
                            diabetes, ≥20 years of Type 1), and/or albuminuria
                            (≥30 mcg albumin/mg creatinine), eGFR <60 ml/min/m², retinopathy, neuropathy, it may be
                              reasonable to initiate statin therapy. </td>
                        </tr>
                      </tbody>
                    </table>

                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommenendations for Primary Severe
                            Hypercholesterolemia (LDL-C ≥ 190 mg/dL (≥ 4.9
                            mmol/L))
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>COR</td>
                          <td>&nbsp;&nbsp;LOE&nbsp;&nbsp;</td>
                          <td class="text-center">Recommendations</td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            1. In patients 20 to 75 years of age with LDL-C
                            ≥190 mg/dL (≥4.9 mmol/L), maximally-tolerated
                            statin therapy is recommended.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            2. In patients 20 to 75 years of age with LDL-C ≥
                            190 mg/dL (≥4.9 mmol/L), who achieve less than 50%
                            reduction in LDL-C while receiving
                            maximally-tolerated statin therapy, and/or have an
                            LDL-C-≥100 mg/dL (≥2.6 mmol/L), ezetimibe therapy
                            is reasonable.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In patients 20 to 75 years of age with a
                            baseline LDL-C ≥190 mg/dL (≥4.9 mmol/L), who
                            achieve less than 50% reduction in LDL-C and have
                            fasting triglycerides >300 mg/dL (>3.4 mmol/L)
                            while taking maximally-tolerated statin and
                            ezetimibe therapy, the addition of a bile acid
                            sequestrant may be considered.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            4. In heterozygous familial hypercholesterolemia
                            patients 30 to 75 years of age with LDL-C ≥100
                            mg/dL (≥2.6 mmol/L) while taking
                            maximally-tolerated statin and ezetimibe therapy,
                            the addition of a PCSK9 inhibitor may be
                            considered.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            5. In patients 40 to 75 years of age with a
                            baseline LDL-C ≥220 mg/dL (≥5.7 mmol/L) who
                            achieve on treatment LDL-C ≥130 mg/dL (≥3.4
                            mmol/L), while receiving maximally-tolerated
                            statin and ezetimibe therapy, the addition of a
                            PCSK9 inhibitor may be considered.
                          </td>
                        </tr>
                        <tr>
                          <td colspan="2" class="text-center">
                            Value Statement: Uncertain Value (B-NR)
                          </td>
                          <td>
                            6. Among patients with familial
                            hypercholesterolemia without evidence of clinical
                            ASCVD taking maximally-tolerated statin and
                            ezetimibe therapy, PCSK9 inhibitors provide
                            uncertain value at 2018 US list prices.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    <table class="recommendationTable table">
                      <thead>
                        <tr class="recommendationLevel1">
                          <th colspan="3">
                            Recommenendations for Statin Therapy Use in
                            Patients with ASCVD
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>COR</td>
                          <td>&nbsp;&nbsp;LOE&nbsp;&nbsp;</td>
                          <td class="text-center">Recommendations</td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            1. In patients ≤75 years of age with clinical
                            ASCVD*, high-intensity statin therapy should be
                            initiated or continued with the aim of achieving a
                            ≥70% reduction in LDL-C.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORI">I</td>
                          <td class="LOE-A">A</td>
                          <td>
                            2. In patients with clinical ASCVD in whom
                            high-intensity statin therapy is contraindicated
                            or who experience statin-associated side effects,
                            moderate-intensity statin therapy should be
                            initiated or continued with the aim of achieving a
                            30-49% reduction in LDL-C.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            3. In patients with clinical ASCVD who are on
                            maximally tolerated statin therapy and are judged
                            to be at very high-risk, and have LDL-C ≥70 mg/dL
                            (≥1.8 mmol/L), it is reasonable to add ezetimibe
                            therapy.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">A <sup>SR</sup></td>
                          <td>
                            4. In patients with clinical ASCVD, who are judged
                            to be very high-risk and who are on maximally
                            tolerated statin therapy and ezetimibe and have
                            LDL-C ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100
                            mg/dL (≥2.6 mmol/L), it is reasonable to add a
                            PCSK9 inhibitor following a clinician-patient
                            discussion about the net benefit, safety, and
                            cost.
                          </td>
                        </tr>
                        <tr>
                          <td colspan="2" class="text-center">
                            Value Statement: Low Value (LOE: B-NR)
                          </td>
                          <td>
                            5. Among patients with clinical ASCVD at high-risk
                            and taking maximally tolerated statin and
                            ezetimibe therapy, PCSK9 inhibitors provide low
                            economic value at 2018 US list prices.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            6. In patients with clinical ASCVD older than 75
                            years, it is reasonable to initiate moderate or
                            high-intensity statin therapy after evaluating the
                            potential for ASCVD risk-reduction, adverse
                            effects, drug-drug interactions, frailty, and
                            patient preferences.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIa">IIa</td>
                          <td class="LOE-C">C-LD</td>
                          <td>
                            7. In patients with clinical ASCVD older than 75
                            years of age who are tolerating high-intensity
                            statin therapy, it is reasonable to continue
                            high-intensity statin therapy after evaluating the
                            potential for ASCVD risk-reduction, adverse
                            effects, drug-drug interactions, frailty, and
                            patient preferences.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            8. In patients with clinical ASCVD who are
                            receiving maximally tolerated statin therapy and
                            LDL-C remains ≥70 mg/dL (≥1.8 mmol/L), it may be
                            reasonable to add ezetimibe.
                          </td>
                        </tr>
                        <tr>
                          <td class="CORIIb">IIb</td>
                          <td class="LOE-B">B-R</td>
                          <td>
                            9. In patients with heart failure with reduced
                            ejection fraction due to ischemic heart disease
                            who have a reasonable life expectancy (3-5 years)
                            and are not already on a statin due to ASCVD,
                            clinicians may consider initiation of
                            moderate-intensity statin therapy to reduce the
                            occurrence of ASCVD events.
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <div data-bind="page: {id:'guideline_flowchart',afterShow: listchange, beforeShow: panzoom}"
                    class="group-section flow-chart">
                    <h1>Recommendations for Initiation of Statin Therapy</h1>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <img src="assets/img/squared_metal_@2X.png"
                            data-src="assets/graphics/statin-therapy-flowcharts.svg" alt="infographic on statin therapy"
                            style="width: 100%" />
                        </div>
                      </div>
                      <div class="button-group small panzoom-buttons expanded">
                        <button class="zoom-in button icon-only secondary" formnovalidate>
                          <i class="fa fa-plus-circle"></i>
                          <span class="text">Zoom In</span>
                        </button>
                        <button class="zoom-out button icon-only secondary" formnovalidate>
                          <i class="fa fa-minus-circle"></i>
                          <span class="text">Zoom Out</span>
                        </button>
                        <button class="reset ui-btn button icon-only secondary" formnovalidate>
                          <i class="fa fa-refresh"></i>
                          <span class="text">Reset</span>
                        </button>
                      </div>
                    </div>

                    <div class="page-wrapper">
                      <div class="content-padding">
                        <p class="quiet">
                          This flow diagram is intended to serve as an easy
                          reference guide summarizing recommendations for
                          ASCVD risk assessment and treatment. Assessment of
                          the potential for benefit and risk from statin
                          therapy for ASCVD prevention provides the framework
                          for clinical decision making incorporating patient
                          preferences.
                        </p>
                        <p class="quiet">
                          <strong>*</strong> Percent reduction in LDL&ndash;C
                          can be used as an indication of response and
                          adherence to therapy, but is not in itself a
                          treatment goal.
                        </p>
                        <p class="quiet">
                          <strong>&dagger;</strong> The Pooled Cohort
                          Equations can be used to estimate 10-year ASCVD risk
                          in individuals with and without diabetes. The
                          estimator within this application should be used to
                          inform decision making in primary prevention
                          patients not on a statin.
                        </p>
                        <p class="quiet">
                          <strong>&Dagger;</strong> Consider
                          moderate-intensity statin as more appropriate in
                          low-risk individuals.
                        </p>
                        <p class="quiet">
                          <strong>&sect;</strong> For those in whom a risk
                          assessment is uncertain, consider factors such as
                          primary LDL&ndash;C &ge;160 mg/dL or other evidence
                          of genetic hyperlipidemias, family history of
                          premature ASCVD with onset &lt;55 years of age in a
                          first-degree male relative or &lt;65 years of age in
                          a first-degree female relative, hs-CRP &gt;2 mg/L,
                          CAC score &ge;300 Agatston units, or &ge;75th
                          percentile for age, sex, and ethnicity (for
                          additional information, see
                          http://www.mesa-nhlbi.org/CACReference.aspx), ABI
                          &lt;0.9, or lifetime risk of ASCVD. Additional
                          factors that may aid in individual risk assessment
                          may be identified in the future.
                        </p>
                        <p class="quiet">
                          <strong>||</strong> Potential ASCVD risk-reduction
                          benefits. The absolute reduction in ASCVD events
                          from moderate- or high-intensity statin therapy can
                          be approximated by multiplying the estimated 10-year
                          ASCVD risk by the anticipated relative risk
                          reduction from the intensity of statin initiated
                          (~30% for moderate-intensity statin or ~45% for
                          high-intensity statin therapy). The net ASCVD risk
                          reduction benefit is estimated from the number of
                          potential ASCVD events prevented with a statin
                          compared to the number of potential excess adverse
                          events.
                        </p>
                        <p class="quiet">
                          <strong>&para;</strong> Potential adverse effects.
                          The excess risk of diabetes is the main
                          consideration in ~0.1 excess cases per 100
                          individuals treated with a moderate-intensity statin
                          for 1 year and ~0.3 excess cases per 100 individuals
                          treated with a high-intensity statin for 1 year. In
                          RCTs, both statin-treated and placebo-treated
                          participants experienced the same rate of muscle
                          symptoms. The actual rate of statin-related muscle
                          symptoms in the clinical population is unclear.
                          Muscle symptoms attributed to statin therapy should
                          be evaluated (see Statin Safety Recommendations).
                        </p>
                        <p class="quiet">
                          ABI indicates ankle-brachial index; ASCVD,
                          atherosclerotic cardiovascular disease; CAC,
                          coronary artery calcium; hs-CRP, high-sensitivity
                          C-reactive protein; LDL&ndash;C, low-density
                          lipoprotein cholesterol; MI, myocardial infarction;
                          RCT, randomized controlled trial.
                        </p>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'statin_dose',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Intensities of Statin Therapy
                    </h1>

                    <div class="row">
                      <div class="column large-4">
                        <h3>Low-Intensity</h3>
                        <p>
                          Daily dose lowers LDL-C, on average by approximately
                          &lt;30%
                        </p>
                        <table class="table">
                          <thead>
                            <tr>
                              <th></th>
                              <th>
                                <small> dose </small>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <!-- ko foreach: Statins() -->
                            <tr>
                              <!-- ko foreach: dose -->
                              <!-- ko if: type == 'doselow' -->
                              <!-- ko if: htmlText != '--' -->
                              <td data-bind="html:$parent.name"></td>
                              <td data-bind="html: htmlText" class="text-right"></td>
                              <!-- /ko -->
                              <!-- /ko -->
                              <!-- /ko -->
                            </tr>
                            <!-- /ko -->
                          </tbody>
                        </table>
                      </div>
                      <div class="column large-4">
                        <h3>Moderate-Intensity</h3>
                        <p>
                          Daily dose lowers LDL-C, on average by approximately
                          30% to &lt;50%
                        </p>
                        <table class="table">
                          <thead>
                            <tr>
                              <th></th>
                              <th>
                                <small> dose </small>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <!-- ko foreach: Statins() -->
                            <tr>
                              <!-- ko foreach: dose -->
                              <!-- ko if: type == 'dosemedium' -->
                              <!-- ko if: htmlText != '--' -->
                              <td data-bind="html:$parent.name"></td>
                              <td data-bind="html: htmlText" class="text-right"></td>
                              <!-- /ko -->
                              <!-- /ko -->
                              <!-- /ko -->
                            </tr>
                            <!-- /ko -->
                          </tbody>
                        </table>
                      </div>
                      <div class="column large-4">
                        <h3>High-Intensity</h3>
                        <p>
                          Daily dose lowers LDL-C, on average by approximately
                          &ge;50%
                        </p>
                        <table class="table">
                          <thead>
                            <tr>
                              <th></th>
                              <th>
                                <small> dose </small>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <!-- ko foreach: Statins() -->
                            <tr>
                              <!-- ko foreach: dose -->
                              <!-- ko if: type == 'dosehigh' -->
                              <!-- ko if: htmlText != '--' -->
                              <td data-bind="html:$parent.name"></td>
                              <td data-bind="html: htmlText" class="text-right"></td>
                              <!-- /ko -->
                              <!-- /ko -->
                              <!-- /ko -->
                            </tr>
                            <!-- /ko -->
                          </tbody>
                        </table>
                      </div>
                    </div>
                    <div class="row">
                      <p class="quiet">
                        Statins and doses that are approved by the U.S. FDA
                        but were not tested in the RCTs reviewed are listed in
                        parentheses
                      </p>
                      <p class="quiet">
                        <strong> * </strong>
                        Evidence from 1 RCT (down-titration if unable to
                        tolerate atorvastatin 80 mg)
                      </p>
                      <p class="quiet">
                        <strong> ** </strong>
                        Initiation of or titration to simvastatin 80 mg is not
                        recommended by the FDA due to increased risk of
                        myopathy, including rhabdomyolysis
                      </p>
                    </div>
                  </div>
                  <div data-bind="page: {id:'monitor_flowchart',afterShow: listchange, beforeShow: panzoom}"
                    class="group-section flow-chart">
                    <h1>
                      Recommendations to Monitor Response to Statin Therapy
                    </h1>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <img src="assets/img/squared_metal_@2X.png"
                            data-src="assets/graphics/statin-monitor-flowchart.svg" alt="infographic on statin therapy"
                            style="width: 100%" />
                        </div>
                      </div>
                      <div class="button-group small panzoom-buttons expanded">
                        <button class="zoom-in button icon-only secondary" formnovalidate>
                          <i class="fa fa-plus-circle"></i>
                          <span class="text">Zoom In</span>
                        </button>
                        <button class="zoom-out button icon-only secondary" formnovalidate>
                          <i class="fa fa-minus-circle"></i>
                          <span class="text">Zoom Out</span>
                        </button>
                        <button class="reset ui-btn button icon-only secondary" formnovalidate>
                          <i class="fa fa-refresh"></i>
                          <span class="text">Reset</span>
                        </button>
                      </div>
                    </div>
                    <p class="quiet">
                      <strong>*</strong>Fasting lipid panel preferred. In a
                      nonfasting individual, a non&ndash;HDL&ndash;C &ge; 220
                      mg/dL may indicate genetic hypercholesterolemia that
                      requires further evaluation or a secondary etiology. If
                      nonfasting triglycerides are &ge; 500 mg/dL, a fasting
                      lipid panel is required.
                    </p>
                    <p class="quiet">
                      <strong>&dagger;</strong>In those already on a statin,
                      in whom baseline LDL&ndash;C is unknown, an LDL&ndash;C
                      &lt;100 mg/dL was observed in most individuals receiving
                      high-intensity statin therapy in RCTs.
                    </p>
                    <p class="quiet">
                      <strong>&Dagger;</strong>Refer to Statin Safety
                      Recommendations
                    </p>
                  </div>
                  <div data-bind="page: {id:'clinical_reference_safety_recomendations',afterShow: listchange}"
                    class="group-section">
                    <h1 class="with-underline">
                      Statin Safety Recommendations
                    </h1>
                    <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Statin Selection</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              To maximize the safety of statins, selection of
                              the appropriate statin and dose in men and
                              nonpregnant/nonnursing women should be based on
                              patient characteristics, level of ASCVD risk,
                              and potential for adverse effects.
                            </p>
                            <p>
                              Moderate-intensity statin therapy should be used
                              in individuals in whom high-intensity statin
                              therapy would otherwise be recommended when
                              characteristics predisposing them to statin
                              associated adverse effects are present.
                            </p>
                            <p>
                              Characteristics predisposing individuals to
                              statin adverse effects include, but are not
                              limited to: (I B)
                            </p>
                            <ul>
                              <li>
                                Multiple or serious comorbidities, including
                                impaired renal or hepatic function.
                              </li>
                              <li>
                                History of previous statin intolerance or
                                muscle disorders.
                              </li>
                              <li>
                                Unexplained ALT elevations >3 times ULN.
                              </li>
                              <li>
                                Patient characteristics or concomitant use of
                                drugs affecting statin metabolism.
                              </li>
                              <li>&gt;75 years of age.</li>
                            </ul>
                            <p>
                              Additional characteristics that may modify the
                              decision to use higher statin intensities may
                              include, but are not limited to:
                            </p>
                            <ul>
                              <li>History of hemorrhagic stroke.</li>
                              <li>Asian ancestry.</li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Statin Dosage</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                Decreasing the statin dose may be considered
                                when 2 consecutive values of LDL-C levels are
                                &lt;40 mg/dL. (IIb C)
                              </li>
                              <li>
                                It may be harmful to initiate simvastatin at
                                80 mg daily or increase the dose of
                                simvastatin to 80 mg daily. (III A)
                              </li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Creatine Kinase (CK)</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                CK should not be routinely measured in
                                individuals receiving statin therapy. (III A)
                              </li>
                              <li>
                                Baseline measurement of CK is reasonable for
                                individuals believed to be at increased risk
                                for adverse muscle events based on a personal
                                or family history of statin intolerance or
                                muscle disease, clinical presentation, or
                                concomitant drug therapy that might increase
                                the risk for myopathy. (IIa C)
                              </li>
                              <li>
                                During statin therapy, it is reasonable to
                                measure CK in individuals with muscle
                                symptoms, including pain, tenderness,
                                stiffness, cramping, weakness, or generalized
                                fatigue. (II C)
                              </li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Muscle Symptoms</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              It is reasonable to evaluate and treat muscle
                              symptoms, including pain, tenderness, stiffness,
                              cramping, weakness, or fatigue, in
                              statin-treated patients according to the
                              following management algorithm: (IIa B)
                            </p>
                            <ul>
                              <li>
                                To avoid unnecessary discontinuation of
                                statins, obtain a history of prior or current
                                muscle symptoms to establish a baseline before
                                initiating statin therapy.
                              </li>
                              <li>
                                If unexplained severe muscle symptoms or
                                fatigue develop during statin therapy,
                                promptly discontinue the statin and address
                                the possibility of rhabdomyolysis by
                                evaluating CK, creatinine, and a urinalysis
                                for myoglobinuria.
                              </li>
                              <li>
                                If mild to moderate muscle symptoms develop
                                during statin therapy:
                                <ul>
                                  <li>
                                    Discontinue the statin until the symptoms
                                    can be evaluated.
                                  </li>
                                  <li>
                                    Evaluate the patient for other conditions
                                    that might increase the risk for muscle
                                    symptoms (e.g., hypothyroidism, reduced
                                    renal or hepatic function, rheumatologic
                                    disorders such as polymyalgia rheumatica,
                                    steroid myopathy, vitamin D deficiency, or
                                    primary muscle diseases).
                                  </li>
                                  <li>
                                    If muscle symptoms resolve, and if no
                                    contraindication exists, give the patient
                                    the original or a lower dose of the same
                                    statin to establish a causal relationship
                                    between the muscle symptoms and statin
                                    therapy.
                                  </li>
                                  <li>
                                    If a causal relationship exists,
                                    discontinue the original statin. Once
                                    muscle symptoms resolve, use a low dose of
                                    a different statin.
                                  </li>
                                  <li>
                                    Once a low dose of a statin is tolerated,
                                    gradually increase the dose as tolerated.
                                  </li>
                                  <li>
                                    If, after 2 months without statin
                                    treatment, muscle symptoms or elevated CK
                                    levels do not resolve completely, consider
                                    other causes of muscle symptoms listed
                                    above.
                                  </li>
                                  <li>
                                    If persistent muscle symptoms are
                                    determined to arise from a condition
                                    unrelated to statin therapy, or if the
                                    predisposing condition has been treated,
                                    resume statin therapy at the original
                                    dose.
                                  </li>
                                </ul>
                              </li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Hepatic Function</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <ul>
                              <li>
                                Baseline measurement of hepatic transaminase
                                levels (ALT) should be performed before
                                initiating statin therapy. (I B)
                              </li>
                              <li>
                                During statin therapy, it is reasonable to
                                measure hepatic function if symptoms
                                suggesting hepatotoxicity arise (e.g., unusual
                                fatigue or weakness, loss of appetite,
                                abdominal pain, dark colored urine or
                                yellowing of the skin or sclera). (IIa C)
                              </li>
                            </ul>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Diabetes</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              Individuals receiving statin therapy should be
                              evaluated for new-onset diabetes mellitus
                              according to the current diabetes screening
                              guidelines. Those who develop diabetes mellitus
                              during statin therapy should be encouraged to
                              adhere to a heart healthy dietary pattern,
                              engage in physical activity, achieve and
                              maintain a healthy body weight, cease tobacco
                              use, and continue statin therapy to reduce their
                              risk of ASCVD events. (I B)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Age and Drug Regimen Consideration</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              For individuals taking any dose of statins, it
                              is reasonable to use caution in individuals >75
                              years of age, as well as in individuals that are
                              taking concomitant medications that alter drug
                              metabolism, taking multiple drugs, or taking
                              drugs for conditions that require complex
                              medication regimens (e.g., those who have
                              undergone solid organ transplantation or are
                              receiving treatment for HIV). A review of the
                              manufacturer's prescribing information may be
                              useful before initiating any
                              cholesterol-lowering drug. (IIa C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                      <div>
                        <h2 class="toggle">
                          <i class="fa fa-holder"></i><span class="text">Cognitive Impairment</span>
                        </h2>
                        <div class="collapsable-panel">
                          <div class="bar close">
                            <a class="action-btn close" data-bind="click:panelHide">
                              <i class="fa fa-holder"></i>close</a>
                          </div>
                          <div class="content">
                            <p>
                              For individuals presenting with a confusional
                              state or memory impairment while on statin
                              therapy, it may be reasonable to evaluate the
                              patient for nonstatin causes, such as exposure
                              to other drugs, as well as for systemic and
                              neuropsychiatric causes, in addition to the
                              possibility of adverse effects associated with
                              statin drug therapy. (IIb C)
                            </p>
                          </div>
                          <div class="bar jumpToTop">
                            <a class="action-btn top" data-bind="click:panelScrollTop">
                              <i class="fa fa-holder"></i>top</a>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'reference_external_links',afterShow: listchange}" class="group-section">
                    <h1>External Links &amp; References</h1>
                    <nav class="nav nav-list small">
                      <ul>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S49.full.pdf">
                            <span class="text">2013 ACC/AHA Guideline on the Assessment of
                              Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S1.full.pdf">
                            <span class="text">2013 ACC/AHA Guideline on the Treatment of
                              Blood Cholesterol to Reduce Atherosclerotic
                              Cardiovascular Risk in Adults</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S102.full.pdf">
                            <span class="text">2013 AHA/ACC/TOS Guideline for the Management
                              of Overweight and Obesity in Adults</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S76.full.pdf">
                            <span class="text">2013 AHA/ACC Guideline on Lifestyle Management
                              to Reduce Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <li>
                          <a target="blank" href="http://www.ncbi.nlm.nih.gov/books/NBK63952/">
                            <span class="text">2008 AHRQ Guideline on Treating Tobacco Use and
                              Dependence</span><i class="fa fa-holder-dynamic"></i>
                          </a>
                        </li>
                        <!-- <li>
                            <a
                              target="blank"
                              href="http://ldl.cardiosource.org/"
                            >
                              <span class="text"
                                >ACC Dyslipidemia Clinical Community</span
                              ><i class="fa fa-holder-dynamic"></i>
                            </a>
                          </li>
                          <li>
                            <a
                              target="blank"
                              href="http://cardiometabolic.cardiosource.org/"
                            >
                              <span class="text"
                                >ACC Cardiometabolic Clinical Community</span
                              ><i class="fa fa-holder-dynamic"></i>
                            </a>
                          </li>
                          <li>
                            <a
                              target="blank"
                              href="http://www.cardiosource.org/~/media/Files/Science%20and%20Quality/Guidelines/Clinical_Documents/Prevention%20Guidelines%20Clinical%20Vignettes.pdf"
                            >
                              <span class="text">Clinical Vignettes</span
                              ><i class="fa fa-holder-dynamic"></i>
                            </a>
                          </li> -->
                      </ul>
                    </nav>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div class="page with-group-sections fill-page-height"
            data-bind="page: {id:'patient',  afterShow:tabchange ,beforeShow:pageScrollTop}">
            <div class="page-wrapper">
              <section class="section group-section">
                <h1>Patient Resources</h1>
                <nav class="nav-list">
                  <ul>
                    <li>
                      <a href="#!/content/patient-split-layout/patient_risk"><span class="text">Understanding My
                          Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_lifestyle"><span class="text">Diet and Physical
                          Activity</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_obesity"><span class="text">Weight Management
                          Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_cholesterol"><span class="text">Blood Cholesterol
                          Management Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>
                  </ul>
                </nav>
              </section>
            </div>
          </div>
          <div data-bind="page: {id:'patient-split-layout'}">
            <div class="medium split-layout fill-page-height">
              <div class="split-sidebar">
                <h3 class="content-padding">Patient Resources</h3>
                <nav class="nav-list small">
                  <ul>
                    <li>
                      <a href="#!/content/patient-split-layout/patient_risk"><span class="text">Understanding My
                          Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_lifestyle"><span class="text">Diet and Physical
                          Activity</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_obesity"><span class="text">Weight Management
                          Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>

                    <li>
                      <a href="#!/content/patient-split-layout/patient_cholesterol"><span class="text">Blood Cholesterol
                          Management Recommendations</span><i class="fa fa-holder-dynamic"></i></a>
                    </li>
                  </ul>
                </nav>
              </div>
              <div class="split-content page with-group-sections">
                <div class="section-nav back hide-for-medium">
                  <a data-bind="page-href: '../patient'">
                    <div class="circle">
                      <i class="fa fa-holder-dynamic"></i>
                    </div>
                    <div class="text">Back to Guidelines &amp; Resources</div>
                  </a>
                </div>
                <div class="page-wrapper">
                  <div data-bind="page: {id:'patient_risk',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Understanding My Cardiovascular Risk
                    </h1>
                    <p>
                      The "2013 ACC/AHA Guideline on the Assessment of
                      Cardiovascular Risk" provides clear recommendations for
                      estimating cardiovascular disease risk. Risk assessments
                      are extremely useful when it comes to reducing risk for
                      cardiovascular disease because they help determine
                      whether a patient is at high risk for cardiovascular
                      disease, and if so, what can be done to address any
                      cardiovascular risk factors a patient may have. Here are
                      the highlights of the guideline:
                    </p>
                    <ul>
                      <li>
                        <p>
                          Risk assessments are used to determine the
                          likelihood of a patient developing cardiovascular
                          disease, heart attack or stroke in the future. In
                          general, patients at higher risk for cardiovascular
                          disease require more intensive treatment to help
                          prevent the development of cardiovascular disease.
                        </p>
                      </li>
                      <li>
                        <p>
                          Risk assessments are calculated using a number of
                          factors including age, gender, race, cholesterol and
                          blood pressure levels, diabetes and smoking status,
                          and the use of blood pressure-lowering medications.
                          Typically, these factors are used to estimate a
                          patient's risk of developing cardiovascular disease
                          in the next 10 years. For example, someone who is
                          young with no risk factors for cardiovascular
                          disease would have a very low 10-year risk for
                          developing cardiovascular disease. However, someone
                          who is older with risk factors like diabetes and
                          high blood pressure will have a much higher risk of
                          developing cardiovascular disease in the next 10
                          years.
                        </p>
                      </li>
                      <li>
                        <p>
                          If a preventive treatment plan is unclear based on
                          the calculation of risk outlined above, care
                          providers should take into account other factors
                          such as family history and level of C-reactive
                          protein. Taking this additional information into
                          account should help inform a treatment plan to
                          reduce a patient's 10-year risk of developing
                          cardiovascular disease.
                        </p>
                      </li>
                      <li>
                        <p>
                          Calculating the 10-year risk for cardiovascular
                          disease using traditional risk factors is
                          recommended every 4-6 years in patients 20-79 years
                          old who are free from cardiovascular disease.
                          However, conducting a more detailed 10-year risk
                          assessment every 4-6 years is reasonable in adults
                          ages 40-79 who are free of cardiovascular disease.
                          Assessing a patient's 30-year risk of developing
                          cardiovascular disease can also be useful for
                          patients 20-59 years of age who are free of
                          cardiovascular disease and are not at high
                          short-term risk for cardiovascular disease.
                        </p>
                      </li>
                      <li>
                        <p>
                          Risk estimations vary drastically by gender and
                          race. Patients with the same traditional risk
                          factors for cardiovascular disease such as high
                          blood pressure can have a different 10-year risk for
                          cardiovascular disease as a result of their sex and
                          race.
                        </p>
                      </li>
                      <li>
                        <p>
                          After care providers and patients work together to
                          conduct a risk assessment, it's important that they
                          discuss the implications of their findings.
                          Together, patients and their care providers should
                          weigh the risks and benefits of various treatments
                          and lifestyle changes to help reduce the risk of
                          developing cardiovascular disease.
                        </p>
                      </li>
                    </ul>
                    <p class="quiet">
                      Source:
                      <a class="link" href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Risk-Assessment">
                        www.cardiosmart.org
                      </a>
                    </p>
                  </div>
                  <div data-bind="page: {id:'patient_lifestyle',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Diet and Physical Activity Recommendations
                    </h1>
                    <p>
                      The "2013 AHA/ACC Guideline on Lifestyle Management to
                      Reduce Cardiovascular Risk" provides recommendations for
                      heart-healthy lifestyle choices based on the latest
                      research and evidence. The guidelines focus on two
                      important lifestyle choices--diet and physical
                      activity--which can have a drastic impact on
                      cardiovascular health. Here's what every patient should
                      know about the latest recommendations for reducing
                      cardiovascular disease risk through diet and exercise.
                    </p>
                    <h3>Diet</h3>
                    <ul>
                      <li>
                        Diet is a vital tool for lowering cholesterol and
                        blood pressure levels, which are two major risk
                        factors for cardiovascular disease.
                      </li>
                      <li>
                        Patients with high cholesterol and high blood pressure
                        levels should eat plenty of vegetables, fruits and
                        whole grains and incorporate low-fat dairy products,
                        poultry, fish, legumes, non-tropical vegetable oils
                        and nuts into their diet. They should also limit
                        intake of sweets, sugar-sweetened beverages and red
                        meats.
                      </li>
                      <li>
                        There are many helpful strategies for heart-healthy
                        eating, including the DASH diet and the USDA's Choose
                        My Plate.
                      </li>
                      <li>
                        Patients who need to lower their cholesterol should
                        reduce saturated and trans fat intake. Ideally, only
                        5-6% of daily caloric intake should come from
                        saturated fat.
                      </li>
                      <li>
                        Patients with high blood pressure should consume no
                        more than 2,400 mg of sodium a day, ideally reducing
                        sodium intake to 1,500 mg a day. However, even
                        reducing sodium intake in one's current diet by 1,000
                        mg each day can help lower blood pressure.
                      </li>
                      <li>
                        It's important to adapt the recommendations
                        above, keeping in mind calorie requirements, as well
                        as, personal and cultural food preferences. Nutrition
                        therapy for other conditions like diabetes should also
                        be considered. Doing so helps create healthy eating
                        patterns that are realistic and sustainable.
                      </li>
                    </ul>
                    <h3>Physical Activity</h3>
                    <ul>
                      <li>
                        Regular physical activity helps lower cholesterol and
                        blood pressure, reducing the risk for cardiovascular
                        disease.
                      </li>
                      <li>
                        In general, adults should engage in aerobic physical
                        activity 3-4 times a week with each session lasting an
                        average of 40 minutes.
                      </li>
                      <li>
                        Moderate (brisk walking or jogging) to vigorous
                        (running or biking) physical activity is recommended
                        to reduce cholesterol levels.
                      </li>
                    </ul>
                    <p class="quiet">
                      Source:
                      <a class="link" href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Lifestyle">
                        www.cardiosmart.org
                      </a>
                    </p>
                  </div>
                  <div data-bind="page: {id:'patient_obesity',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Weight Management Recommendations
                    </h1>
                    <p>
                      The "2013 AHA/ACC/TOS Guideline for the Management of
                      Overweight and Obesity in Adults" was created to reflect
                      the latest research to outline best practices when it
                      comes to treating obesity--a condition that affects more
                      than one-third of American adults. These guidelines help
                      address questions like "What's the best way to lose
                      weight?" and "When is bariatric surgery appropriate?".
                      Here is what every patient should know about the
                      treatment of overweight and obesity:
                    </p>
                    <ul>
                      <li>
                        <p>
                          <strong> Definition of obesity: </strong>
                          Obesity is a medical condition in which excess body
                          fat has accumulated to the extent that it can have
                          an adverse effect on one's health. Obesity can be
                          diagnosed using body mass index (BMI), a measurement
                          of height and weight, as well as waist
                          circumference. Obesity is categorized as having a
                          BMI of 30 or greater. Abdominal obesity is defined
                          as having a waist circumference greater than 40
                          inches for a man or 35 inches for a woman.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Benefits of weight loss: </strong>
                          Obesity increases the risk for serious conditions
                          such as cardiovascular disease, diabetes and death,
                          but losing just a little bit of weight can result in
                          significant health benefits. For an adult who is
                          obese, losing just 3-5% of body weight can improve
                          blood pressure and cholesterol levels and reduce the
                          risk for cardiovascular disease and diabetes.
                          Ideally, care providers recommend 5-10% weight loss
                          for obese adults, which can produce even greater
                          health benefits.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Weight loss strategies: </strong>
                          There is no single diet or weight loss program that
                          works best for all patients. In general, reduced
                          caloric intake and a comprehensive lifestyle
                          intervention involving physical activity and
                          behavior modification tailored according to a
                          patient's preferences and health status is most
                          successful for sustained weight loss. Further,
                          weight loss interventions should include frequent
                          visits with health care providers and last more than
                          one year for sustained weight loss.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Bariatric Surgery: </strong>
                          Bariatric surgery may be a good option for severely
                          obese patients to reduce their risk of health
                          complications and improve overall health. However,
                          bariatric surgery should be reserved for only the
                          highest risk patients until more evidence is
                          available on this issue. Present guidelines advise
                          that weight loss surgery is only recommended for
                          patients with extreme obesity (BMI &ge;40) or in
                          patients that have a BMI &ge;35 in addition to a
                          chronic health condition.
                        </p>
                      </li>
                    </ul>
                    <p class="quiet">
                      Source:
                      <a class="link" href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Obesity">
                        www.cardiosmart.org
                      </a>
                    </p>
                  </div>
                  <div data-bind="page: {id:'patient_cholesterol',afterShow: listchange}" class="group-section">
                    <h1 class="with-underline">
                      Blood Cholesterol Management Recommendations
                    </h1>
                    <p>
                      The American College of Cardiology (ACC) and the
                      American Heart Association (AHA) recently developed new
                      standards for treating blood cholesterol. These
                      recommendations are based on a thorough and careful
                      review of the very latest, highest quality clinical
                      trial research. They help care providers deliver the
                      best care possible. This page provides some of the
                      highlights from the new practice guidelines. The
                      ultimate goal of the new cholesterol practice guidelines
                      is to reduce a person's risk of heart attack, stroke and
                      death. For this reason, the focus is not just on
                      measuring and treating cholesterol, but identifying
                      whether someone already has or is at risk for
                      atherosclerotic cardiovascular disease (ASCVD) and could
                      benefit from treatment.
                    </p>
                    <h3>What is ASCVD?</h3>
                    <p>
                      Heart attack and stroke are usually caused by
                      atherosclerotic cardiovascular disease (ASCVD). ASCVD
                      develops because of a build-up of sticky
                      cholesterol-rich plaque. Over time, this plaque can
                      harden and narrow the arteries.
                    </p>
                    <p>
                      These practice guidelines outline the most effective
                      treatments that lower blood cholesterol in those
                      individuals most likely to benefit. Most importantly,
                      they were selected as the best strategies to lower
                      cholesterol to help reduce future heart attack or stroke
                      risk. Share this information with your health care
                      provider so that you can ask questions and work together
                      to decide what is right for you.
                    </p>
                    <h3>Key Points</h3>
                    <p>
                      Based on the most up-to-date and complete look at
                      available clinical trial results:
                    </p>
                    <ul>
                      <li>
                        <p>
                          Health care providers should focus on identifying
                          those people who are most likely to have a heart
                          attack or stroke and make sure they are given
                          effective treatment to reduce their risk.
                        </p>
                      </li>
                      <li>
                        <p>
                          Cholesterol should be considered along with other
                          factors known to make a heart attack or stroke more
                          likely.
                        </p>
                      </li>
                      <li>
                        <p>
                          Knowing your risk of heart attack and stroke can
                          help you and your health care provider decide
                          whether you may need to take a medication&mdash;most
                          likely a statin&mdash;to lower that risk.
                        </p>
                      </li>
                      <li>
                        <p>
                          If a medication is needed, statins are recommended
                          as the first choice to lower heart attack and stroke
                          risk among certain higher-risk patients based on an
                          overwhelming amount of evidence. For those unable to
                          take a statin, there are other cholesterol-lowering
                          drugs; however, there is less research to support
                          their use.
                        </p>
                      </li>
                    </ul>
                    <h3>Evaluating Your Risk</h3>
                    <p>
                      Your health care provider will first want to assess your
                      risk of ASCVD (assuming you don't already have it). This
                      information will help determine if you are at high
                      enough risk of a heart attack or stroke to need
                      treatment.
                    </p>
                    <p>
                      To do this, your care provider will 1) review your
                      medical history and 2) gauge your overall risk for heart
                      attack or stroke. He/she will likely want to know:
                    </p>
                    <ul>
                      <li>
                        <p>
                          whether you have had a heart attack, stroke or
                          blockages in the arteries of your heart, neck, or
                          legs.
                        </p>
                      </li>
                      <li>
                        <p>
                          your risk factors. In addition to your total
                          cholesterol, LDL cholesterol, and HDL (so-called
                          "good") cholesterol, your health care provider will
                          consider your age, if you have diabetes, and whether
                          you smoke and/or have high blood pressure.
                        </p>
                      </li>
                      <li>
                        <p>
                          about your lifestyle habits, other medical
                          conditions, any previous drug treatments, and if
                          anyone in your family has high cholesterol or
                          suffered a heart attack or stroke at an early age.
                        </p>
                      </li>
                    </ul>
                    <p>
                      A lipid or blood cholesterol panel will be needed as
                      part of this evaluation. This blood test measures the
                      amount of fatty substances (called lipids) in your
                      blood. You may have to fast (not eat for a period of
                      time) before having your blood drawn.
                    </p>
                    <p>
                      If there is any question about your risk of ASCVD, or
                      whether you might benefit from drug therapy, your care
                      provider may make additional assessments or order
                      additional tests. The results of these tests can help
                      you and your health care team decide what might be the
                      best treatment for you. These tests may include:
                    </p>
                    <ul>
                      <li>
                        <p>
                          <strong> Lifetime risk estimates </strong>
                          &mdash;how likely you are to have a heart attack and
                          stroke during your lifetime
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong>
                            Coronary artery calcium (CAC) score
                          </strong>
                          &mdash;a test that shows the presence of plaque or
                          fatty build-up in the heart artery walls
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong>
                            High-sensitivity C-Reactive Protein (CRP)
                          </strong>
                          &mdash;a blood test that measures the amount of CRP,
                          a marker of inflammation or irritation in the body;
                          higher levels have been associated with heart attack
                          and stroke
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Ankle-brachial index (ABI) </strong>
                          &mdash;the ratio of the blood pressure in the ankle
                          compared to blood pressure in the arm, which can
                          predict peripheral artery disease (PAD)
                        </p>
                      </li>
                    </ul>
                    <p>
                      If you have very high levels of low-density lipoprotein
                      (LDL or "bad") cholesterol, your care provider may want
                      to find out if you have a genetic or familial form of
                      hypercholesterolemia. This condition can be passed on in
                      families.
                    </p>
                    <h3>Your Treatment Plan</h3>
                    <p>
                      Before coming up with a specific treatment plan, your
                      care provider will talk with you about options for
                      lowering your blood cholesterol and reducing your
                      personal risk of atherosclerotic disease. This will
                      likely include a discussion about heart-healthy living
                      and whether you might benefit from a
                      cholesterol-lowering medication.
                    </p>
                    <h3>Heart-Healthy Lifestyle</h3>
                    <p>
                      Adopting a heart-healthy lifestyle continues to be the
                      first and best way to lower your risk of problems. Doing
                      so can also help control or prevent other risk factors
                      (for example: high blood pressure or diabetes). Experts
                      suggest:
                    </p>
                    <ul>
                      <li>
                        <p>
                          <strong>
                            Eating a diet rich in vegetables, fruits, and
                            whole grains
                          </strong>
                          ; this also includes low-fat dairy products,
                          poultry, fish, legumes, and nuts; it limits intake
                          of sweets, sugar-sweetened beverages and red meats.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Getting regular exercise </strong>
                          ; check with your health care provider about how
                          often and how much is right for you.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Maintaining a healthy weight </strong>
                          .
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong>
                            Not smoking or getting help quitting
                          </strong>
                          .
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Staying on top of your health </strong>
                          , risk factors and medical appointments. For some
                          people, lifestyle changes alone may not be enough to
                          prevent a heart attack or stroke. In these cases,
                          taking a statin at the right dose will most likely
                          be necessary.
                        </p>
                      </li>
                    </ul>
                    <h3>Medications</h3>
                    <p>
                      There are two types of cholesterol-lowering medications:
                      statins and non-statins.
                    </p>
                    <h3>Statin Therapy</h3>
                    <p>
                      There is a large body of evidence that shows the use of
                      a statin provides the greatest benefit and fewest safety
                      issues. In particular, specific groups of patients
                      appear to benefit most from taking moderate or
                      high-intensity statin therapy. Based on this
                      information, your care provider will likely recommend a
                      statin if you have:
                    </p>
                    <ul>
                      <li>
                        <p>ASCVD</p>
                      </li>
                      <li>
                        <p>Very high LDL cholesterol (190 mg/dL or higher)</p>
                      </li>
                      <li>
                        <p>
                          Type 2 diabetes and are between 40 and 75 years of
                          age
                        </p>
                      </li>
                      <li>
                        <p>
                          Above a certain likelihood of having a heart attack
                          or stroke in the next 10 years (7.5% or higher) and
                          are between 40 and 75 years of age
                        </p>
                      </li>
                    </ul>
                    <p>
                      In certain cases, your care provider may still recommend
                      a statin even if you don't fit into one of the groups
                      above. He/she will consider your overall health and
                      other factors to help decide if you are at enough risk
                      to benefit from a statin. Based on the guidelines, these
                      may include:
                    </p>
                    <ul>
                      <li>
                        <p>
                          Family history of premature heart attack or stroke
                        </p>
                      </li>
                      <li>
                        <p>Your lifetime risk of ASCVD</p>
                      </li>
                      <li>
                        <p>LDL-cholesterol &ge;160 mg/dL</p>
                      </li>
                      <li>
                        <p>hs-CRP &ge;2 mg/L</p>
                      </li>
                      <li>
                        <p>
                          Results from other special testing (CAC scoring,
                          ABI)
                        </p>
                      </li>
                    </ul>
                    <h3>
                      If you are on a statin, your care provider will need to
                      find the dose that is right for you.
                    </h3>
                    <ul>
                      <li>
                        <p>
                          People who have had a heart attack, stroke or other
                          types of ASCVD tend to benefit the most from taking
                          the highest amount (dose) of statin therapy if they
                          tolerate it. This may be more appropriate than
                          taking multiple drugs to lower cholesterol.
                        </p>
                      </li>
                      <li>
                        <p>
                          A more moderate dose of statin may be appropriate
                          for some people with ASCVD, such as those over 75
                          years or those that might have problems taking the
                          highest dose of a statin (i.e., those with prior
                          organ transplantation).
                        </p>
                      </li>
                    </ul>
                    <p>
                      Sometimes more than one statin needs to be tried before
                      finding the one that works best.
                    </p>
                    <p>
                      If you are 75 years or older and have not already had a
                      heart attack, stroke or other types of ASCVD, your care
                      provider will discuss whether a statin is right for you.
                    </p>
                    <h3>Other cholesterol-lowering medications</h3>
                    <p>
                      Not all patients will be able to take the optimum dose
                      of statin. After attention to lifestyle changes and
                      statin therapy, non-statin drugs may be considered if
                      you have high-risk with known ASCVD, diabetes, or very
                      high LDL cholesterol values (&ge;190 mg/dL) and:
                    </p>
                    <ul>
                      <li>
                        <p>
                          Have side effects from statins that prevent you from
                          getting to the optimal dose or are not able to take
                          a statin at all.
                        </p>
                      </li>
                      <li>
                        <p>
                          Are limited from taking an optimal dose due to other
                          drugs that you are taking, including:
                        </p>
                        <ul>
                          <li>
                            <p>
                              Transplant drug regimens to prevent rejection
                            </p>
                          </li>
                          <li>
                            <p>Multiple drugs to treat HIV</p>
                          </li>
                          <li>
                            <p>
                              Some antibiotics like erythromycin and
                              clarithromycin or certain oral anti-fungal drugs
                            </p>
                          </li>
                        </ul>
                      </li>
                    </ul>
                    <p>
                      As always, it's important to talk with your health care
                      provider about which medication is right for you.
                    </p>
                    <h3>What About Having Goals of Treatment?</h3>
                    <p>
                      Although keeping LDL-cholesterol lower with an optimal
                      dose of statin is supported strongly by clinical trials,
                      getting to a specific goal level is not.
                    </p>
                    <h3>Staying on Top of Your Risk</h3>
                    <ul>
                      <li>
                        <p>
                          <strong>
                            Take steps to lower your risk factors for heart
                            attack, stroke and other problems
                          </strong>
                          &mdash;Make healthy choices (eating a healthy diet,
                          getting exercise, maintaining a healthy weight and
                          not smoking). Drug therapy, if needed, can help
                          control risk factors.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Report side effects </strong>
                          &mdash;Muscle aches are commonly reported and may or
                          may not be due to the statin. If you are having
                          problems, your care provider needs to know to help
                          manage any side effects and possibly switch you to a
                          different statin.
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong> Take your medications as directed </strong>
                          .
                        </p>
                      </li>
                      <li>
                        <p>
                          <strong>
                            Get blood cholesterol and other tests
                          </strong>
                          that are recommended by your health care team. These
                          can help assess whether statin therapy&mdash;and the
                          dose&mdash;is working for you.
                        </p>
                      </li>
                    </ul>
                    <h3>Questions to Ask</h3>
                    <ul>
                      <li>
                        <p>
                          What are my risk factors for heart attack and
                          stroke? Am I on the best prevention program to
                          minimize this risk?
                        </p>
                      </li>
                      <li>
                        <p>
                          Is my cholesterol high enough that it might be due
                          to a genetic condition?
                        </p>
                      </li>
                      <li>
                        <p>
                          What lifestyle changes can I make to stay healthy
                          and prevent problems?
                        </p>
                      </li>
                      <li>
                        <p>Do I need to be on a statin?</p>
                      </li>
                      <li>
                        <p>How do I monitor how I am doing?</p>
                      </li>
                      <li>
                        <p>
                          What should I do if I develop muscle aches or
                          weakness after starting the statin?
                        </p>
                      </li>
                      <li>
                        <p>
                          What do I do if I have other symptoms after starting
                          the statin?
                        </p>
                      </li>
                    </ul>
                    <p class="quiet">
                      Source:
                      <a class="link" href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Cholesterol">
                        www.cardiosmart.org
                      </a>
                    </p>
                  </div>
                  <div data-bind="page: {id:'statin_infographic',afterShow: listchange}" class="group-section">
                    <div class="row">
                      <h1>
                        Groups that Benefit from Statin Therapy Infographic
                      </h1>
                    </div>
                    <div class="holder" style="position: relative">
                      <div class="parent panzoom">
                        <div class="panzoom-element">
                          <img src="assets/img/squared_metal_@2X.png"
                            data-src="assets/graphics/Benifit-Group-Infographic.svg"
                            alt="Groups that benifit from Statins" style="width: 100%" />
                        </div>
                      </div>
                      <div class="button-group small panzoom-buttons expanded">
                        <button class="zoom-in button icon-only secondary" formnovalidate>
                          <i class="fa fa-plus-circle"></i>
                          <span class="text">Zoom In</span>
                        </button>
                        <button class="zoom-out button icon-only secondary" formnovalidate>
                          <i class="fa fa-minus-circle"></i>
                          <span class="text">Zoom Out</span>
                        </button>
                        <button class="reset ui-btn button icon-only secondary" formnovalidate>
                          <i class="fa fa-refresh"></i>
                          <span class="text">Reset</span>
                        </button>
                      </div>
                    </div>
                  </div>
                  <div data-bind="page: {id:'patient_reference_definition',afterShow: listchange}"
                    class="group-section">
                    <div class="content-padding">
                      <h1 class="with-underline">
                        Common Cardiovascular Terms
                        <span class="sub-line">Alphabetical Glossary</span>
                      </h1>
                      <input placeholder="Search" type="search"
                        data-bind="value: glossaryQuery, valueUpdate: 'keyup'" />
                      <ul class="no-bullet" data-bind="template: {name:'glossaryItem', foreach:$root.glossaryItems}">
                      </ul>
                      <script type="text/html" id="glossaryItem">
                          <li class="group-divide-auto">
                            <h4 data-bind="html: label"></h4>
                            <p data-bind="html: definition"></p>
                          </li>
                        </script>

                      <p class="quiet">
                        <a class="link" href="https://www.cardiosmart.org/AZ-Topics">For additional cardiovascular terms
                          visit
                          www.cardiosmart.org</a>
                      </p>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div data-close-on-click="false" data-close-on-esc="false" class="reveal" id="critical_notification"
          data-reveal="true" style="padding: 0">
          <div class="page with-group-sections">
            <div class="row collapse" data-bind="foreach: criticalNotification()">
              <div class="columns large-12 medium-12 small-12 text-center">
                <h2 class="highlighted colored-paper" style="color: white; padding: 1em; margin: 0">
                  <i class="fa fa-lock fa-2" aria-hidden="true"></i> Locked
                </h2>
              </div>
              <div class="columns large-12 medium-12 small-12 text-center">
                <h4 class="notification_text critical_text" data-bind="text: Title">
                  The system has been locked
                </h4>
                <p class="notification_text critical_text" data-bind="text: Text">
                  This version of the application has been <br />
                  locked because of need to ugrade the science.<br />
                  Please go to the store upgrade this application.
                </p>
                <br />
              </div>
            </div>
          </div>
        </div>
        <div class="reveal warning" id="requiredModal" data-reveal>
          <h1 class="with-underline">Cannot Calculate Risk</h1>
          <p class="lead">
            There is information that is either missing or outside acceptable
            limits. We cannot properly calculate risk and give you a
            recommendation until information is correct.
          </p>
          <p>
            Below is a list of information that is either missing or have
            errors
          </p>
          <ul class="inputList">
            <li data-bind="css: $root.sexValidation().status,text: $root.sexValidation().message"></li>
            <li data-bind="css: $root.ageValidation().status,text: $root.ageValidation().message">
              ">Age <span class="warning">Missing </span><span class="error">Error</span>
            </li>
            <li data-bind="css: $root.raceValidation().status,text: $root.raceValidation().message">
              "> Race
              <span class="warning"> Missing </span>
              <span class="error"> Error </span>
            </li>
            <li data-bind="css: $root.hdlValidation().status,text: $root.hdlValidation().message">
              ">HDL - Cholesterol <span class="warning">Missing </span><span class="error">Error</span>
            </li>
            <li
              data-bind="css: $root.totalCholesterolValidation().status,text: $root.totalCholesterolValidation().message">
              "> Total Cholesterol
              <span class="warning"> Missing </span>
              <span class="error"> Error </span>
            </li>
            <li data-bind="css: $root.bloodPresureValidation().status,text: $root.bloodPresureValidation().message">
              ">Systolic Blood Pressure <span class="warning">Missing </span><span class="error">Error</span>
            </li>
            <li data-bind="css: $root.diabeticValidation().status,text: $root.diabeticValidation().message"></li>
            <li data-bind="css: $root.smokerValidation().status,text: $root.smokerValidation().message"></li>
            <li data-bind="css: $root.hypertensionValidation().status,text: $root.hypertensionValidation().message">
            </li>
          </ul>
          <button class="button small expanded" data-close aria-label="Close reveal" type="button">
            Close</button><button class="close-button" data-close aria-label="Close reveal" type="button">
            <span aria-hidden="true">&times;</span>
          </button>
        </div>
        <footer class="footer page">
          <a href="#!/calulate/estimator/" class="logo">
            <img style="border: none 0" src="assets/img/logo-footer-medium.svg" alt="ACC Statin Intolerance Guidelines"
              class="show-medium" />
            <img style="border: none 0" src="assets/img/logo-footer.svg" alt="ACC Statin Intolerance Guidelines"
              class="show-small" />
          </a>
          <ul class="nav tabs tabs-primary reverse swappable">
            <li class="resources-Tab">
              <a href="#!/content/resources/"><span class="short-text btn-ga4">Resources</span>
                <span class="long-text btn-ga4">Resources</span></a>
            </li>
            <li class="disclaimer-Tab" class="">
              <a href="#!/content/disclaimer">
                <span class="short-text btn-ga4">Terms</span>
                <span class="long-text btn-ga4">Terms</span>
              </a>
            </li>
            <li class="about-Tab" class="">
              <a href="#!/content/about/about-index">
                <span class="short-text btn-ga4">About</span>
                <span class="long-text btn-ga4">About the App</span>
              </a>
            </li>
            <li id="notifications-Tab" class="">
              <a href="../index.html#!/content/notifications/">
                <span class="short-text btn-ga4">Notifications</span>
                <span class="long-text btn-ga4">Notifications</span>
              </a>
            </li>
          </ul>
        </footer>

        <script type="text/javascript" src="assets/js/vendor.min.js"></script>
        <script type="text/javascript" src="assets/js/jquery.panzoom.js"></script>

        <!-- If mobile device then add this script.
 This code cant be added to *.js file as it will be rejected by TestFlight as well as AppStore.
 Also we cannot insert this on document.ready, because it should be loaded before document loading.-->
        <!-- Start -->
        <script>
          if (
            document.URL.indexOf("http://") === -1 &&
            document.URL.indexOf("https://") === -1
          ) {
            //if mobile device detected
            //Load index.js dynamically
            var mobileScript = document.createElement("script");
            mobileScript.setAttribute("src", "js/index.js");
            document.body.appendChild(mobileScript);

            $("body").addClass("noselect");
          }
        </script>
        <!-- End -->

        <script type="text/javascript" src="assets/js/application.min.js"></script>
        <script type="text/javascript">
          getCookieBanner('https://www.acc.org');
        </script>
        <script>
          $(document).foundation();
        </script>
        <script>
          function init() {
            var imgDefer = document.getElementsByTagName("img");
            for (var i = 0; i < imgDefer.length; i++) {
              if (imgDefer[i].getAttribute("data-src")) {
                imgDefer[i].setAttribute(
                  "src",
                  imgDefer[i].getAttribute("data-src")
                );
              }
            }
          }
          window.onload = init;
        </script>
        <style>
          select {
            user-select: auto;
            -webkit-user-select: auto !important;
            -webkit-tap-highlight-color: rgba(0, 0, 0, 0);
            z-index: 1000 !important;
          }
        </style>
      </div>
    </div>
  </div>
</body>

</html>